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Abstract 
 
Introduction  
Despite the availability of efficacious drugs, cardiovascular disease (CVD) remains 
a leading cause of global mortality, and prevalence of CVD is higher in Scotland 
than in other developed countries. Better understanding of chronic disease 
management is important in closing the gap between outcomes found in general 
practice prescribing with clinical trial findings. A key component of disease 
management is drug adherence, consisting of initiation, implementation, and 
persistence, and Scotland has valuable nation-wide administrative databases 
which can be used to study aspects of adherence at a population level. With these 
datasets, it is possible to define different CVD patient groups, to compare 
adherence across a range of drug classes and risk-factors, and to assess the 
association between drug-persistence with subsequent mortality rates.  
 
Methods 
Using the Scottish Prescribing Information System (PIS), linked to hospital 
admissions data (SMR) and death certificates (NRS), we have defined four patient 
subgroups: primary prevention (n=1,659,566), treatment for symptomatic 
cardiovascular disease (n = 260,516), secondary prevention (n=25,283), and 
secondary-prevention-with-treatment (n=23,866).  
 
Within these patient groups, the Treatment Anniversary Model (TAM) and 
Proportion of Days Covered (PDC) were used to identify broad levels of 
persistence and implementation to ten different CVD drug-classes. Further 
multivariate analysis was conducted in four selected drug classes: ACE-inhibitors, 
antiplatelets, betablockers, and lipid-regulatory drugs. Risk factors considered 
include sex, age, socioeconomic status, and comorbidity.  
 
Cox-proportional hazards models were then used to investigate the association 
between drug-persistence with subsequent mortality. Some additional analyses 
were carried out to investigate possible sources of confounding.  
 
Results 
In the unadjusted analysis, adherence tends to be associated with traditional 
cardiovascular risk factors (male sex, older age, higher deprivation, etc.) across 
the drug-classes and patient groups studied. Implementation and persistence are 
lowest in the primary prevention group and highest in the secondary prevention 
group. In the multivariate analysis, higher levels of persistence were associated 
with male sex (OR range 1.16 – 1.40) and increased social deprivation (OR range 
1.07-1.18) across all drug-classes and patient-groups. Diabetes as a comorbidity 
was associated with higher persistence for the primary and treatment groups only 
(OR range 1.07-1.38). There was some inconsistency in the associations 
observed for age and for depression as a comorbidity.  
 
The relationship observed between persistence and mortality showed a protective 
association across the patient-groups and drug-classes studied. Adjusting for 
additional confounders, such as CVD polypharmacy, did not provide additional 
insights to these analyses and definitions of this may need refined for future study.  
 
Conclusion 
This is a longitudinal, Scotland-wide, retrospective study of adherence to 
cardiovascular drugs (namely, implementation and persistence), with near-
universal population coverage. This allows identification of population-level risk 
factors, and identification of patient groups who may require extra support. While 
much of these findings replicate those observed in literature review, this is the first 
study of its scale assessing implementation and persistence to cardiovascular 
medication in Scotland. It also proves as validation for Scottish administrative 
datasets in having the potential to assess medication adherence.  
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Definitions/Abbreviations 
ABC - Ascertaining Barriers to Compliance 
ACEi – Angiotensin-Converting-Enzyme inhibitors 
AMI/ MI – Acute Myocardial Infarction/ Myocardial Infarction 
ARB – Angiotensin-II-Receptor Blockers 
BB – Beta-blockers 
BNF – British National Formulary  
CCB – Calcium Chanel Blockers  
CHI – Community Health Index 
CMA – Continuous Measure of Medication Acquisition 
CMP - Continuous Multiple Interval Measure of Oversupply 
CVD – Cardiovascular Disease 
DCVP - Data Capture Validation and Pricing  
DDD – Defined Daily Doses 
DUR - Drug Utilisation Research 
eDRIS - Electronic Data Research and Innovation Service 
EHR - Electronic Health Records 
EMS – Electronic Monitoring System 
ESPACOMP - European society for patient adherence, compliance, and 
persistence  
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EMERGE - ESPACOMP Medication Adherence Reporting Guideline  
GTN – Glyceryl Trinitrate  
GBTM - Group based trajectory modelling 
HR – Hazard Ratio 
ICD – International Classification of Diseases 
MEMS - Medication Event Monitoring System 
MPR – Medication Possession Ratio 
NRS – National Records of Scotland 
NSS – National Services Scotland 
PBPP - Public Benefit and Privacy Panel 
PDCa – Proportion of Days Covered (all patients) 
PDCp – Proportion of Days Covered (persistent patients) 
PIS – Prescribing Information System 
SIGN - The Scottish Intercollegiate Guidelines Network 
SIMD – Scottish Index of Multiple Deprivation 
SMR – Scottish Morbidity Records  
TAM – Treatment Anniversary Model 
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1 Introduction 
This chapter provides a general background to the thesis and contextualises the 
basis for it. The following includes an overview of cardiovascular disease and 
pharmaceutical management of it, the problem of adherence to such 
medications and challenges in studying this, and a brief overview of 
pharmacoepidemiology as a means of study. 
1.1 Cardiovascular Disease and Public Health 
Cardiovascular disease (CVD) is a an established yet growing public health 
concern and is a leading cause of mortality worldwide[1], responsible for 
approximately 1 in 3 deaths[1, 2]. CVD is an umbrella term, covering a range of 
disorders such as coronary heart disease (angina, myocardial infarction (MI), 
heart failure), stroke, transient ischaemic attack (TIA), peripheral arterial 
disease, and aortic disease[3].  
The burden of CVD is likely to increase as the world’s population continues to 
age; as of 2017, the over-60 population was 962 million, and this is growing at a 
rate of 3% per year[4]. Other CVD risk-factors are also on the rise: rates of 
obesity and type-2 diabetes are increasing, and, while there has been a decline 
in smoking in the UK, there is an increase in smoking at a global level. The over-
60 population is projected to double to 2.1 billion by the year 2050[4]. 
Management of CVD and associated illnesses may therefore have a significant 
impact on global mortality rates and should continue to be a public health 
priority.  
In the UK, the highest prevalence of CVD is in Scotland, with the highest rate of 
CVD-related mortalities occurring within Scotland[5, 6]. In 2014, 15,016 deaths 
were caused by CVD[6], accounting for 27.7% of mortalities that year. The 2013 
age-standardised mortality rate for Scotland was 327 per 100,000, compared to 
268 per 100,00 in England, 304 per 100,000 in Wales, and 277 per 100,000 in 
Northern Ireland[6] (see Figure 1.1). Of the UK local authorities with the ten 
highest CVD mortality rates, five are located in Scotland[5]; with Glasgow City 
having the highest mortality rates for all ages (400 per 100,000) and for 
premature mortalities (i.e. under 75 years; 143 per 100,00). This indicates that, 
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despite a general decrease in CVD mortality in Scotland over recent decades, 
there is still a need to close the gap with the rest of the UK and reduce 
geographical health inequalities.   
CVD is not just a cause of significant mortality; it is also a cause of morbidity 
and significant costs to the National Health Service (NHS). The gross expenditure 
on all CVD prescriptions in Scotland for the financial year 2017-18 was 
£137,175,725[7], equating to approximately 11% of all prescription costs in 
Scotland per year[8]. In the year 2016-17, over 7,000 incidents involving heart 
problems were attended by the Scottish Ambulance service, of which 6,041 
resulted in conveyance to hospital[8]. Implications of CVD may have additional 
effects beyond this; for example, cardiometabolic disorders have been 
associated with a decrease in cognitive ability[9], so improvement of CVD 
prevention and management may have knock-on effects on rates of other 
diseases of ageing, such as Alzheimer’s and dementia. 
 
 
 
Figure 1.1: CVD age-standardised mortality rates across UK. Adapted from data in 
Townsend et al, 2015[6]. Graph designed using R package ggplot2. 
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Beyond the costs of routine CVD prescribing, the more significant healthcare 
costs come from CVD related hospitalisations. Costs of A&E admissions for CVD in 
the UK are approximately £47.64 million for a given year[10], while costs of 
hospital inpatient stays for CVD are in excess of £9,000 million[10]. A meta-
analysis by Chowdhury et al estimated that 9% of CVD events in Europe are 
directly related to medication nonadherence[11], meaning that patient inability 
to take medications as prescribed leads to adverse outcomes in some cases. 
Therefore, improving adherence may reduce CVD related hospital admissions and 
hence costs. It is important to note that while there may be an increased cost of 
prescriptions when people adhere to their medication, as they will collect drugs 
on a more regular basis, this cost is offset by the reduced risk of costly 
hospitalisation events.   
 
1.1.1 Cardiovascular Risk: Preventing and Managing Disease 
CVD is complex, though there are a variety of known risk factors. Clinical factors 
include hypertension, hyperlipidaemia, diabetes, family history/genetic factors; 
while behavioural factors include smoking, alcohol consumption, physical 
inactivity, unhealthy diet, and obesity[1, 3, 6, 12]. Assessment of such factors can 
be used to predict risk and determine disease prevention and/or treatment 
strategies. 
In Scotland, the ASSIGN score has been used to calculate CVD risk since 2007[13, 
14]. It is based on the Framingham risk score, though ASSIGN includes a measure 
of social deprivation and family history to better fit the Scottish population[15] 
and to address the impact of social inequalities on health. However, at present, 
the tool does not account for atrial fibrillation, specific high-risk ethnic groups 
or women with early menopause, whose risk will be elevated above the score 
calculated. The Scottish Intercollegiate Guidelines Network (SIGN) recommends 
that all adults over the age of 40 be offered risk score assessment every five 
years, though individuals with previously established CVD such as MI, stroke, or 
TIA, or those with other comorbidities, such as chronic kidney disease, familial 
hypercholesterolaemia, or diabetes, may not require assessment before being 
classified as high risk[13]. Once risk is assessed, appropriate intervention steps 
can be taken. 
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CVD has a range of interventions available for disease prevention, including 
lifestyle changes (smoking cessation, physical activity, healthy diet, reduced 
alcohol consumption)[1, 6], and cost-effective pharmacotherapies (e.g. aspirin). 
For disease management, there are surgical options such as coronary artery 
bypass grafting to prevent disease progression, and coronary angioplasty[16]. 
Pharmacotherapies may also be used in CVD management, such as glyceryl 
trinitrate (GTN) to control symptoms.  
CVD risk may be mediated at several levels of illness. An important aspect of this 
is disease prevention. Primary prevention of CVD is the prescription of drugs or 
recommendation of lifestyle changes in those with increased CVD risk (high 
blood pressure/ high cholesterol etc.) but with no history of CVD events or 
ongoing symptomatic disease. Secondary prevention of CVD is prescription of 
medication following a serious CVD event such as an MI in order to reduce future 
recurrence. The other aspect in disease management is treatment for patients 
with on-going symptomatic CVD, either in patients with no previous MI or for 
patients who are additionally undergoing secondary prevention measures.  
 
1.1.2 Pharmaceutical Prevention & Management of 
Cardiovascular Disease 
Drugs which mediate the cardiovascular system are listed in chapter 2 of the 
British national formulary (BNF)[17]. The main pharmacotherapies referenced in 
the SIGN guidelines are antiplatelets (e.g. aspirin, clopidogrel), lipid lowering 
drugs (e.g. atorvastatin, simvastatin), and antihypertensives (e.g. ace-inhibitors, 
angiotensin receptor blockers, calcium channel blockers)[13].  
These drugs have proven efficacy in trial settings. In particular, statins have 
been the subject of the West of Scotland Coronary Prevention Study 
(WOSCOPS)[18], a trial which initially lasted 5 years and has since been followed 
up for 20 years using routine data records. The initial study found that 
pravastatin reduced cholesterol by 20% (compared to the placebo which had no 
effect) in men, with an associated reduced risk of MI, CVD mortalities, and all-
cause mortalities of 31%, 28%, and 22% respectively[18]. Recent research from the 
study has found a long-standing benefit to those originally allocated to the  
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Table 1.1: CVD drugs classes and key characteristics. References: DI [19, 20], BB[21-23], AB[24, 
25], ACE[26, 27], ARB[27, 28], NI[29], CCB[27, 30], AP[31-33], LR[34]. 
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pravastatin group, with a 21% decrease in CVD mortalities over the 20 year 
follow-up[35]. As of yet, there is no equivalent study of this scale including 
women. 
The range of treatments available reflects the range of different CVD risk factors 
which have been identified and which can be targeted therapeutically. Lipid 
regulatory drugs reduce cholesterol, antiplatelet drugs reduce blood clotting, 
while antihypertensives control water balance and hence, blood pressure. Within 
these broad groups, there are multiple different drug formulations, and drugs 
with multiple different mechanisms of action, meaning that there are 
alternatives that may be suited to different people. For example, PCSK-9 
inhibitors would be the most suited lipid-regulatory drug for someone with 
familial hypercholesterolemia, while statins may be more suited for reducing 
circulatory LDL for those with high dietary cholesterol.   
Despite the introduction of cost-effective pharmacotherapies for CVD, related 
mortalities have steadily increased worldwide between 2007-2017[36] and CVD 
rates remain high. 
1.2 Adherence  
One factor that may contribute to preventable CVD morbidity and mortality 
rates is drug adherence[37-40]. Adherence is defined by the European society for 
patient adherence, compliance, and persistence (ESPACOMP) as “the process by 
which patients take their medications as prescribed, composed of initiation, 
implementation and  discontinuation”[41-43]. Literature which pre-dates the 
publication of the ESPACOMP definition may use the term ‘compliance’ or 
‘concordance’ to mean the same thing. The guidelines were introduced to avoid 
confusion, as terms have previously been used interchangeably despite not 
always being used to describe the same concepts. Importantly, this definition, 
known as ‘The ABC Taxonomy’, separates adherence into three phases: 
initiation, implementation, and discontinuation[41-44] and researchers should 
clarify which phase(s) their study focuses on.  
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The noted lack of consistency in studies of adherence[42, 45-48] has also led to the 
development of the ESPACOMP Medication Adherence Reporting Guideline 
(EMERGE)[41, 43], with a set of minimum reporting criteria for studies of 
adherence, and additional desirable items for reporting. In the interests of 
reproducibility and comparability, it is important for researchers to detail as 
many of the EMERGE criteria as is possible in their adherence reporting and 
consider the limitations where this is not possible. 
A 2001 report by the World Health Organisation (WHO) found that overall 
adherence to chronic medications was only 50%[49], and concluded that: 
“increasing the effectiveness of adherence interventions may have a far greater 
impact on the health of the population than any improvement in specific 
medical treatments”[49]. The same report found that only 25% of patients treated 
for hypertension reach their target BP[49]. This, along with previous studies which 
have identified an association between level of adherence with treatment 
outcomes in cardiovascular disease[11, 13, 38, 50, 51], highlights a huge gap for 
potential intervention.  
From previous adherence research, it is hypothesised that adherence may differ 
across some key patient characteristics; including disease severity, drug class 
prescribed, comorbidities, and polypharmacy. Understanding the epidemiology 
of drug adherence and identifying barriers to implementing treatment regimens 
are essential first steps toward implementing future interventions, and thus 
improving levels of adherence in the future. Identifying how adherence relates 
to patient health outcomes may also be important to consider, as it will inform 
on the scope that interventions may have in improving health outcomes for 
patients. 
 
1.3 Drug Utilization Research 
Drug utilisation research (DUR) is a branch of pharmacoepidemiology, which 
helps to facilitate “safe and effective use of medicines” at a population level[52],  
including adherence research. This is important because, despite the obvious 
benefits of modern medicines to life expectancy and reduced morbidities, there 
are still issues in drug management, as drugs cannot work as effectively in 
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patients who do not adhere. Furthermore, understanding factors influencing 
consumption of medicines is an important step in improving management of 
disease. 
DUR dates back to the 1960s and is useful in identifying issues with prescription 
drug use, such as: rare adverse drug reactions (ADR) which may not be identified 
in Phase Three trial; issues with prescribing, such as overprescribing of 
antibiotics; inappropriate polypharmacy, for example, prescribing of two drugs 
which contraindicate one another; and for identifying trends in drug-use habits, 
such as adherence and persistence[52]. Early DUR symposia helped to establish 
standard definitions to allow consistency between studies, such as the ATC drug 
classification system and the use of DDDs for comparing units[53] and, more 
recently, they have helped to define and standardise adherence research[42]. 
DUR is important in continued monitoring of drug use patterns, and can help to 
enhance understanding, implement policy changes around this in order to reduce 
morbidity and mortality, and save unnecessary expenditure[52]. Adherence 
research feeds into this, as one of the key founding goals of the European drug 
utilisation research group (EuroDURG) was “do patients take drugs 
correctly?”[52], and efforts to investigate this could have significant impacts for 
public health.    
Study designs in DUR are not dissimilar from traditional epidemiology and may 
broadly be grouped into qualitative or quantitative. Qualitative studies utilise 
non-numeric data, often relating to patient experience[54] and such studies help 
to enhance understanding of patient and/ or prescriber perspectives on drug 
utilization. Data for qualitative studies may be collected through various means 
including interviews, focus groups, and surveys[55], and can involve many hours in 
designing appropriate study questions and transcribing information for further 
analysis. In the late 1990s and early 2000s, the value of qualitative studies in 
medical and public health research began to be more clearly understood, and 
the BMJ published a series of papers to highlight the value of qualitative 
methods[56], to help researchers analyse these findings[57], and to quality assess 
qualitative work[58].  
Qualitative studies are important for understanding patient behaviours in the 
context of drug utilization; for example, a review of qualitative studies by 
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Kronish et al[59] identified confused perceptions of hypertension, and an 
assumption that high blood pressure only requires medication when accompanied 
by symptoms (e.g. stress, dizziness, headache), as a key barrier to 
cardiovascular drug adherence[60]. A more recent review by Rashidi et al also 
identified patient perception as having a key role in adherence, and further 
suggested that more support and guidance from healthcare professionals could 
facilitate this[61]. Qualitative studies are important when any policy changes are 
to be considered, as understanding the factors that influence healthcare 
providers and patients are vital to understanding how implementation may work. 
The other major study design in DUR is quantitative. Quantitative studies utilise 
numeric data, or data that can be ranked/ grouped[55]; information may be 
gathered through primary data collection or secondary data collected for 
purposes other than research e.g. hospitalisation records). Quantitative study 
designs can be grouped further into descriptive and analytical. While descriptive 
studies present information on patterns and trends[54, 55], analytical studies go 
further, by looking at explanatory factors, and attempt to identify associations 
by using appropriate statistical tests[55]. For an adherence project, both 
descriptive and analytical methods can have value, as descriptive methods are 
useful for hypothesis generating while analytical methods can be employed for 
hypothesis testing. 
To conduct a DUR study of adherence it is important to have a closed pharmacy 
system, detailing all prescriptions for the study population. This is particularly 
valuable for the study of chronic diseases, such as CVD, which are largely 
managed with prescription medications, as we expect patients to continue 
taking prescriptions for a prolonged time. This allows long-term follow-up using 
routine healthcare records.  
 
1.4 Using Scottish Routine Healthcare Data  
As health systems have moved toward digitised data storage and use of 
electronic health records (EHRs), the availability of large administrative and 
clinical datasets has increased. These can be highly valuable as a secondary data 
source for DUR study if there is an appropriate system in place for capturing 
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relevant data, linking it to other datasets, checking and maintaining the data 
quality, and ensuring appropriate data governance is in place.  
Scotland has good resources for accessing EHRs in secondary data analysis. The 
NHS provides GP coverage for Scotland’s 5 million residents, with less than 2% 
opting for additional private healthcare coverage[62], usually only for secondary 
care. It also has a relatively stable population[62], with low immigration and 
emigration, meaning longitudinal follow-up is fairly reliable. Furthermore, 
health records can be linked at an individual level by direct-matching methods, 
owing to the presence of a community health index (CHI) number automatically 
generated upon registering with a GP; and it has good coverage, with estimates 
ranging between 96.5-99.9% of the population in Scotland having a CHI 
number[62]. This unique CHI follows a patient through all NHS Scotland services as 
it is recorded on all interactions with the NHS in Scotland, even if they move 
between health boards, which also contributes to effective longitudinal study. 
Access to EHR data is managed through eDRIS, a branch of NHS Scotland’s 
information services teams, who perform data linkage and provide extracts for 
research. 
For adherence study, the prescribing information system (PIS) is particularly 
useful. It is a database of all community-dispensed prescriptions in Scotland, 
originally curated for the sole purpose of pharmacy reimbursement. It is CHI-
linked from 2009 onwards, meaning individual follow-up is possible as it includes 
dosage information as free-text dosage instructions and, crucially, an algorithm 
has been developed to pull out important information from this (i.e. how many 
units of a drug to take in a given time period). With this, along with the quantity 
of a drug dispensed, an estimation as to how long a prescription should last can 
be calculated and compared to true pharmacy dispensations for an individual, to 
estimate drug adherence and identify gaps in treatment. This can then be linked 
to hospital records and death records in order to consider possible related 
outcomes. 
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1.5 Thesis Overview 
1.5.1 Aims and Objectives 
Aim: Utilise national prescribing data to investigate the epidemiology of 
adherence to cardiovascular medications in Scotland, and its subsequent 
association with outcomes.   
Objectives: 
▫ To conduct literature reviews to understand current research of 
cardiovascular adherence and the methods used in adherence study.  
▫ To perform data cleaning and quality checks, understanding any 
potential issues with these data, and to develop methods for 
identifying adherence from the data utilised.   
▫ To determine various levels of adherence to CVD medication in 
Scotland, across different classes of CVD medication, by patient 
subgroup (primary prevention, treatment for symptomatic CVD, 
secondary prevention, and secondary-prevention-with-treatment), and 
across key risk factors (sex, age, social deprivation, and by 
comorbidities).   
▫ To describe outcomes associated with poor adherence, using linked 
prescription data and medical records.  
▫ To gain an understanding of the potential strengths and limitations of 
using administrative data to answer these research questions.  
 
1.5.2 Thesis Structure 
Chapters 2 and 3 provide further context to this thesis in the form of reviews; 
Chapter 2 is a systematic review of research on adherence in cardiovascular 
disease, updated from a paper published in May 2018 as part of this PhD[45]. 
Chapter 3 is a narrative review of methods used in measuring and assessing 
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adherence. This is followed by Chapter 4, the first methods chapter, focusing on 
data sources and the cleaning and management of these, while Chapter 5 details 
the methods used in determining adherence and for data analysis. Chapter 6 
provides descriptive baseline results, looking at the cohort across the key 
patient subgroups, as well as general prescribing of the CVD drugs of interest 
overtime. Chapter 7 shows results for adherence and persistence levels across 
patient subgroups and investigates different factors, while Chapter 8 considers 
the association between persistence with patient mortality. The thesis concludes 
with a discussion chapter which summarises the limitations and final conclusions. 
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2 Systematic Review: Adherence to 
Cardiovascular medication  
This chapter is an update on the paper published by Leslie et al, “Adherence to 
cardiovascular medication: a review of systematic reviews”[45] (see List of 
Publications). It identifies and critiques the existing literature on adherence to 
cardiovascular medicine and provides context to the research area of this thesis. 
The literature search to identify systematic reviews on adherence to 
cardiovascular medication is described, along with an update to include papers 
published between January 2017 and February 2020. It will be split into sections, 
first detailing the methods and results of the search strategy used, followed by a 
narrative review of risk-factors for cardiovascular non-adherence, and finally a 
description of clinical and economic outcomes of non-adherence identified by 
the current literature.  
2.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of global mortality[63], and so 
management of this is a pressing area of Public Health research. Drugs are 
commonly prescribed for disease management, as well as in primary or 
secondary prevention of CVD; the latter usually following hospitalisation due to 
myocardial infarction (MI). However, adherence to drugs for management of 
chronic conditions such as CVD, and for prophylaxis of MI, can be poor, 
particularly if not prescribed for symptom relief[64].  
Despite numerous attempts at research in this area to date, there are significant 
challenges in the study of adherence; many papers fail to define the term 
adherence and there is much methodological heterogeneity throughout the 
literature. A review of systematic reviews allows the existing literature to be 
collated and critically appraised[65] and was carried out here due to the high 
volume of papers in this subject area. The aim of this study was to review the 
existing published evidence of the factors and outcomes associated with 
adherence to CVD medications. 
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2.2 Methods 
For this review, the bibliographic databases Medline (1996-present), Embase 
(1996-present), CINAHL (1992-present), and PsycINFO were searched. As very 
few systematic reviews were written before the 1990s[65], it is unlikely that 
many papers would be missed by limiting to the 1996 version of the databases. 
Search terms for each database are listed throughout to allow replication, and 
any adjustments used to suit individual databases noted. All papers returned 
were considered against inclusion and exclusion criteria and quality assessment 
carried out as detailed below. A 10% sample of papers were independently 
reviewed by a member of the PhD supervisory team. Findings were compared, 
and any disagreements were discussed to reach a consensus.  
In February 2020, an update of this search was conducted, and papers published 
between the end of the previous search (Jan 2017) and the present date were 
added. 
2.2.1 Search Strategies 
The search strategy for this review was developed with assistance from a 
librarian. Earlier iterations of the search included MeSH terms, though these 
were ruled out due to a high volume of papers returned in Medline (n=40,904, 
limits “English language” and “humans”) and because the exact terms used 
covered the main scope of the MeSH terms. Limiting to systematic reviews was 
carried out as earlier Medline searches returned 7,042 papers, even after 
removal of MeSH terms and limiting to “humans” and “English language”. This 
also allowed an overview of systematic reviews to be performed, which can help 
to distil the high volume of literature into a more manageable and informative 
narrative.  
 
2.2.1.1 Medline  
Following earlier searches as detailed above, the final search strategy used for 
MEDLINE (1996 – present) was as follows: 
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1 (adherence or compliance or non?adherence or non?compliance or 
persistence or non?persistence).ti,ab. 
2 (hypertens* or antihypertens*).ti,ab. 
3 ((cardiovascular* or CVD) and prevention).ti,ab. 
4 2 or 3 
5 (patient or medication* or drug or treatment).ti,ab. 
6 1 and 4 and 5 
7 limit 6 to (english language and humans and systematic reviews) 
 
This returned 352 results which were added to EndNote X7 ahead of study 
selection. All papers returned from searches on each database were added to an 
EndNote library to allow removal of duplicates, before a manual search of 
remaining papers was carried out to remove any additional duplicates missed by 
the software. Following this, titles and abstracts were searched for immediate 
relevance, and then the remaining full-text articles were compared against 
inclusion and exclusion criteria as detailed below (Section 2.2.2). Within the 
352 papers found in Medline, 3 were removed as duplicates. 
The updated search in February 2020 replicated this, including a step limiting to 
papers published between January 2017-present. An additional 60 papers were 
identified in Medline, with 2 being removed as duplicates to the original search. 
 
2.2.1.2 Embase 
For Embase (1996-present), step 7 of the search strategy was edited to: 
limit 6 to (human and english language and "systematic review") 
 
This search returned 232 results. From this, 94 duplicates were removed using 
EndNote software, and a further 37 duplicates were removed manually as they 
had been missed by the software, leaving 101 titles and abstracts from Embase 
to be carried forward and reviewed for relevance, ahead of full-text review.  
In the updated search of February 2020, a further 151 papers were identified, of 
which 2 were removed as duplicates to the previous search; 1 was removed as it 
was the original version of this very study; and 51 were removed as duplicates to 
the updated Embase and/or the Medline search.  
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2.2.1.3 CINAHL 
   
S1 TI ( adherence or compliance or non#adherence 
or non#compliance or persistence or 
non#persistence ) OR AB ( adherence or 
compliance or non#adherence or 
non#compliance )  
Search modes - 
Boolean/Phrase 
S2 TI ( hypertens* or antihypertens* ) OR AB ( 
hypertens* or antihypertens* )  
Search modes - 
Boolean/Phrase 
S3 TI ( cardiovascular* or CVD ) OR AB ( 
cardiovascular* or CVD ) AND TI prevention OR 
AB prevention  
Search modes - 
Boolean/Phrase 
S4 S2 OR S3  Search modes - 
Boolean/Phrase 
S5 TI ( patient or medication* or drug or 
treatment ) OR AB ( patient or medication* or 
drug or treatment )  
Search modes - 
Boolean/Phrase 
S6 S1 AND S4 AND S5  Search modes - 
Boolean/Phrase 
S7 S1 AND S4 AND S5  Limiters - Publication 
Type: Systematic 
Review; Language: 
English; Human 
 
Search modes - 
Boolean/Phrase 
 
This search returned 151 papers on the CINHAL database, 24 of which were 
duplicates removed by software and a further 8 removed manually.  The 
updated search found an additional 34 papers, of which 11 were removed as 
they had been identified in the 2017-2020 Medline or Embase search.  
 
2.2.1.4 PsycINFO 
The final stage of the search strategy was adjusted for use in PsycINFO, 
according to database requirements: 
Limiters - Language: English; Population Group: Human; Methodology: -
Systematic Review 
 
This search returned 50 papers, consisting of 24 duplicates; 16 picked up by 
EndNote software, and 8 removed manually. The updated search identified a 
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further 27 papers published between Jan 2017 – Feb 2020, 10 of which were 
removed as duplicates.  
2.2.2 Eligibility criteria 
Papers were included if they studied factors impacting adherence or persistence 
in patients taking CVD medication, such as anti-anginal drugs, or medication for 
primary or secondary prevention of cardiovascular events. Papers were also 
included if they studied outcomes related to adherence or persistence, and 
papers using the term “compliance” were also accepted. As this is a narrative 
review of systematic reviews, only systematic reviews were included. Papers 
were excluded if they focused on interventions to improve adherence, 
adherence to non-medical interventions (e.g. lifestyle changes), guidelines on 
management of adherence, or if they did not study relevant drugs or conditions. 
However, papers were included if they studied cardiovascular adherence as well  
Table 2.1: Inclusion and exclusion criteria for literature review 
 
Inclusion Criteria 
Systematic Reviews of:   
Exclusion Criteria 
 
Factors associated with adherence 
to CVD medication (used for 
management of symptoms, 
primary or secondary prevention) 
Focused on interventions to improve 
adherence 
OR the association between 
adherence to CVD medication and 
health outcomes 
Adherence to non-medical interventions 
(such as behavioural change) 
Reviews that included other 
conditions, as well as CVD, were 
included 
Guidelines on the management of adherence 
 Not a systematic review 
 Reviews that focused exclusively on non-CVD conditions 
 Conference abstracts (with no paper associated that could be retrieved) 
 Papers could not be accessed  
 Papers that scored <=2 on quality assessment with AMSTAR tool 
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as other conditions, such as diabetes or HIV. Conference abstracts were also 
excluded if the relevant full paper could not be accessed. The search strategy 
was limited to English language, as the resources were not available to 
translate, and this limitation may result in important papers being missed out.  
2.2.3 Study Selection and Data Extraction 
Following removal of duplicates, study titles and abstracts were first assessed 
for relevance, before full-text reviews were interrogated against eligibility 
criteria, with further papers being excluded at this stage. Finally, a quality 
assessment was carried out using the AMSTAR tool (A MeaSurement Tool to 
Assess systematic Reviews)[66], with those scoring below the minimum 
requirement being rejected.  
During full-text interrogation of papers, study data were extracted, and study 
characteristics were compiled into an Excel spreadsheet (Office 2010). From 
full-text review, information on the aim and setting of each were included, as 
was information on the number of studies included in each review, the search 
strategies used, and quality assessment tools used. Adherence measurements 
used by the studies included in each review were also added, as was a summary 
of overall findings, and overall adherence if stated by the review. Papers were 
categorised into two tables (see Appendix A): studies which investigated factors 
impacting adherence or persistence (supplementary table 1), and studies 
looking at outcomes related to adherence or persistence (supplementary table 
2). 
 
2.2.4 Quality Assessment and Publication bias 
The AMSTAR tool [66] was used to assess quality of papers, and a score out of 11 
given to each. The AMSTAR tool is developed especially for assessing the quality 
of systematic reviews; it looks at whether researchers define an ‘a priori’ 
design, include details of a comprehensive search strategy and specify the 
inclusion and exclusion criteria used for paper selection. It also examines 
whether more than one reviewer was involved in paper selection and extraction 
of information, and if a table of summary characteristics for studies is included. 
It is also important that papers assess publication bias, heterogeneity, and 
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quality, and whether or not quality of papers is considered in drawing 
conclusions. Finally, AMSTAR asks whether papers state any conflicts of interest 
in their reporting. 
Based on the criteria, papers were assigned categories of either high quality (++: 
score of 9, 10, or 11), reasonable quality (+: score of 6, 7, or 8), poor quality (-: 
score of 3, 4, or 5) or rejected (score of 0, 1, or 2). 
2.3 Results 
2.3.1 Literature search 
The initial literature search resulted in 45 eligible systematic reviews, 34 of 
which dealt with factors associated with non-adherence and 11 which dealt with 
outcomes. The updated search between January 2017 and February 2020 added 
19 papers of factors and a further 3 outcomes papers, bringing this to a total of 
67 papers (see Figure 2.1, overleaf).  
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Figure 2.1: Flowchart: study selection process  
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2.3.2 Study characteristics 
Summary tables detailing the aims, setting, methods, search strategies and 
findings of included reviews are listed in Appendix A. Overall quality assessment 
led to removal of four studies after the initial and updated searches, though 
otherwise the majority of papers scored ‘very good’ (n=26, 39%), or ‘good’ 
(n=28, 42%) with the AMSTAR tool. However, while quality of systematic reviews 
was high, many noted that the primary studies included were of a variable 
standard.  
The vast majority of studies included in reviews focused on the USA, Europe, and 
generally economically developed countries, with only three systematic reviews 
focused on low or middle income countries (LMICS) [67-69].  
Just under half (47%) of the systematic reviews identified made an attempt to 
derive a pooled estimate of adherence, though these estimates often had a wide 
range, the most extreme example ranging from 20-88% [70]. Most systematic 
reviews included papers using a range of methods to study adherence, with self-
reporting being the most common method, followed by pharmacy claims, 
prescription refills, and pill counts. Electronic monitoring, such as the 
Medication Event Monitoring System (MEMS), were used in fewer reviews (n=15), 
though this may be due to the increased cost associated. Measures of adherence 
also varied, with many studies categorising adherence as ‘good’ if taken above a 
specified threshold (commonly 80%) and assessing the proportion of ‘good’ vs. 
‘bad’ adherers. Commonly, this was measured using the Medical Possession Ratio 
(MPR) i.e. the ‘number of days covered with medication in the refill gap, divided 
by the number of days in the refill gap’[71], or the Proportion of Days Covered 
(PDC), i.e. the ‘number of days with medication supplied divided by the length 
of follow-up’[71]. Others considered the relative change in adherence rates 
between groups, or the hazard ratio for non-adherence against a reference 
category, though most systematic reviews failed to specify which of these 
metrics was used in primary studies.  
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2.3.3 Factors affecting cardiovascular adherence 
There have been a number of factors identified as having an influence on 
adherence, which can be broadly categorised into disease factors, therapy 
factors, healthcare factors, patient factors, and social factors (Table 2.2). Here 
53 systematic reviews identified factors which could impact on medication 
adherence. However, due to the heterogeneity in study design, quality, and 
operational definitions of adherence, it was not possible to perform meta-
analysis in order to quantify the risk associated with any individual factor.  
 
Disease factors Therapy 
factors 
Healthcare 
Factors 
Patient 
Factors 
Social factors 
Disease treated 
[72] 
Side-effects 
[67, 73-75] 
Relationship/ 
communication 
with physician[76] 
[75, 77-79] 
Sex or gender 
[68, 80-85] 
Socioeconomic 
status[83] [70, 76, 
79, 81, 85-89] 
Primary vs 
Secondary 
disease 
prevention [71, 
81, 85, 88, 90, 91] 
Dosing 
Regimen/ 
frequency [67, 
72, 85, 90, 92-94] 
Self-monitoring 
[95] 
Age[69, 72, 81-84, 
91] 
Level of 
education/ 
Health literacy 
[68, 96, 97] 
Co-morbidity 
and/or disability 
[70, 82, 85] 
Drug class [59, 
70, 73, 74, 98] 
Cost/ Co-
payments [60, 67, 
75, 76, 82, 85, 88, 90, 94, 
99, 100] 
Making time 
for 
appointments 
[60, 76, 101] 
Ethnicity/ race 
[80, 83, 85] 
Depression [70, 
77, 85, 102] 
Combination 
Pill [103] [104-110] 
Routine place of 
care[76, 99] 
Stress/ anxiety 
[77] 
Minority status 
[70] 
Diabetes[70, 81, 85] Telemedicine 
[111] 
Routine 
physician [76, 78, 
99] 
Forgetfulness 
[76, 77] 
Social support 
[86, 112] 
Duration of 
treatment[85, 88, 
91] 
Pill-boxes[113] Practitioner 
disagreement 
with 
guidelines[77] 
Lack of 
understanding 
[60, 67, 77, 78, 101] 
Marital 
status[69] 
Perception of 
health at 
baseline[82] 
 Coronary Artery 
Calcium (CAC) 
screening [114] 
Alcohol 
consumption 
[115] or 
smoking[85] 
Cultural/ 
religious 
beliefs[97] 
Heart rate[83] or 
hypertension[85] 
  Patient 
beliefs/ 
Perception of 
drugs [67, 76-79, 
89, 97, 101, 116] 
 
Table 2.2: Factors found to impact adherence  
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Figure 2.2 Factors and their impact on adherence  
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2.3.4 Outcomes of Nonadherence 
14 papers were categorised as outcomes papers [11, 117-129], and all found an 
overall positive relationship between good adherence and clinical or economic 
outcomes, with the exception of the Jongstra et al review, which found no 
significant relationship between antihypertensive withdrawal and cognitive 
function [126] and the Murali et al review[128], which found an inconsistent 
relationship and, in some cases, a negative association between adherence and 
clinical outcomes. Once again, heterogeneity excluded the possibility of a meta-
analysis. Overall, the quality of these systematic reviews was lower than that of 
reviews identifying risk factors; 71% scoring good or very good compared to 89% 
for factors studies. 
Outcome References 
Blood Pressure Control [122, 125] 
Myocardial Infarction [123] 
Stroke risk [129] 
CVD risk [11, 120, 127, 128] 
CVD deaths [119, 128] 
All-cause mortality [11, 127] 
Healthcare costs [118] 
Cognitive function [126] 
Table 2.3: Outcomes related to non-adherence 
2.4 Discussion  
2.4.1 Disease Factors 
While this review is focused on adherence to CVD medications, it is worthwhile 
putting this into context, as the specific disease or condition treated [72] [76] is a 
crucial factor affecting adherence. For example, Assawasuwannakit et al 
compared adherence in HIV therapy to CVD, and found that adherence to HIV 
medications was 5% better than to antihypertensive medications [72]. Another key 
disease factor was duration of treatment, as adherence also tends to decline 
overtime [88, 91, 130]. In contrast to this, one study found new-users of statins were 
1.58 times more likely to be non-adherent[85] compared to prevalent users. This 
may indicate that initial uptake may be poor, but once people do initiate 
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treatment, implementation begins at a relatively high level, and then drops-off 
overtime. 
Chen et al found that adherence to cardiovascular medication was suboptimal in 
secondary prevention following acute coronary syndrome [71]. However, papers 
which compared secondary prevention to primary prevention found that 
adherence was suboptimal across the board, and secondary prevention was 
associated with considerably greater adherence [81, 85, 88, 90, 91]. Those who had 
been diagnosed with hypertension or those who had a history of MI or stroke 
were more likely to adhere [81, 85], and this may be related to a perception of 
poor cardiovascular health[82] and an enhanced desire to improve their wellbeing 
[81]. Diabetes was another co-morbidity associated with greater CVD 
adherence[70, 81, 85] though this was not consistent across all studies [81].  
Improved adherence with CVD drugs in diabetic patients may, again, be due to 
changes in patient perception and due to medication-taking behaviour being 
normalised into their daily routine. However, the specific nature of the co-
morbid condition alters the way it influences adherence. Depression is a common 
comorbidity with CVD, and has notably been found to negatively impact 
adherence[70, 77, 85, 102]; this may be due to lack of motivation or self-efficacy 
commonly reported alongside depression [102].  
 
2.4.2 Therapy factors 
An important therapeutic factor which negatively influences adherence is the 
occurrence of side-effects. In low-middle income countries (LMIC’s), ten of the 
fourteen studies investigating this found it to have a significant impact [67]. 
Patients on angiotensin converting enzyme inhibitors (ACEi’s) are 68% more 
likely to develop a cough than those on angiotensin-II receptor blockers (ARBs) 
[73]. Thiazides, beta-blockers (BB’s), and calcium channel blockers (CCB’s) are all 
associated with a higher percentage of patients suffering side-effects at a 
standard dose compared to ACEi’s [74], while ARB’s were not associated with any 
side-effects at this dose [74]. This ties closely to healthcare related risk factors 
and may in-part explain associations identified between drug class and 
adherence. 
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Factors Reviews Findings* 
Disease   
Primary vs Secondary Mann et al 2010; Lemstra et al 2012; Xu et al 2016; Chen et al 2015 
Secondary + 
Primary  - 
Comorbidity: diabetes 
Mann et al 
2010; Lemstra and Alsabbagh 2014; Ofori-
Asenso et al (2018)a 
Diabetes +  
Comorbidity: depression 
Khatib et al 
2014; Lemstra and Alsabbagh 2014; Eze-
Nliam et al 2010; Ofori-Asenso et al (2018)a 
Depression - 
Therapy   
Drug Class 
Matchar et al 2008; Powers et al 
2012; Lemstra and Alsabbagh 2014; Kronish et
al 2011; Bramlage et al 2009 
ARB’s +              ACEi’s +/- 
   CCB’s +/-           BB’s +/- 
Diuretics – 
Dosing frequency 
/Treatment Regimen 
Assawasuwannakit et al 2015; Bowry et al 
2011; Iskedjian et al 2002; Ingersoll et al 
2008; Schneider et al. (2018) 
High dosing freq. – 
High complexity +/- 
Healthcare   
Cost 
Bowry et al 2011; AlGhurair et al 
2012; Lemstra et al 2012; Xu et al 2016; 
Marshall et al 2012; Maimaris et al 2013, 
Mann et al 2014; Al-Noumani, et al. 
(2019); Cheen et al (2019); Ofori-Asenso et al 
(2018)a 
Higher costs - 
Patient   
Gender or sex 
Lewey et al 2013; Mann et al 2010; Nielsen et 
al 2017; Cheen et al (2019); Durand et al 
(2017); Ofori-Asenso et al (2018)a 
Female (vs.Male)  - (+) 
Age 
Assawasuwannakit et al 2015; Mann et al 
2010; Hope, et al (2019); Ofori-Asenso, R., et 
al. (2018)b; Cheen et al (2019); Durand et al 
(2017) 
Increasing age +/- 
Social   
SES 
AlGhurair et al 2012; Mann et al 
2010; Alsabbagh et al 2014; Lemstra et al 
2012; McKenzie et al 
2015; Lemstra and Alsabbagh 2014; Durand et 
al (2017); Kristina and Wulandari (2020) 
Higher SES + 
Lower SES - 
Table 2.4 Selected risk factors and their associations with adherence. *Associated with 
improved adherence (+), decreased adherence (-), or inconsistent (+/-) relationship with 
adherence    
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Drug class was consistently associated with differences in adherence levels [59, 70, 
73, 74, 98], despite heterogeneity in specific study settings and operational 
definitions of adherence [59]. Adherence and persistence were best with ARBs [59, 
70, 73, 74, 98], and in pooled results, those prescribed ARBs were 30-33% more likely 
to be adherent overall [59, 70]. Diuretics were associated with the lowest 
adherence rates of any drug class [59, 70] and they also had lower persistence 
rates, ranging from 16-38% across studies [98]. This could have important 
implications in prescribing CVD drugs. Combination drugs were also found to be 
associated with greater adherence, ranging from 12% in one meta-analysis by 
Sherrill et al,[103] to 29% better adherence in meta-analysis by Gupta et al [104]. 
Adherence reduced as the number of doses per day increased [72, 90, 92, 93], though 
this effect was diminished with increased age [72]. In resource limited settings, 
approximately half of the studies looking at dosing complexity found a 
significant relationship with >1 daily dosing and nonadherence, while the other 
half did not find any significant association [67]. However, it is worth noting that 
adherence to once-daily dosing may have a greater effect on health outcomes 
than twice or multiple daily dosing, as missing a single pill would mean an entire 
days’ treatment is missed [92]. 
 
2.4.3 Healthcare Factors 
The cost of medication or appointments was a commonly cited healthcare factor 
influencing non-adherence [60, 67, 75, 76, 82, 85, 88, 90, 94, 99, 100], largely in US settings, 
and in one systematic review cost or co-payment was the most commonly 
studied aspect of adherence  (29% of included studies) [90]. Patients who had to 
make a co-payment for their treatment were 28% less likely to be adherent to 
statins [88], and similar associations were found across cohort studies of 
adherence to antihypertensives [99], however the impact of co-payment on 
adherence varied from non-significant to a significant reduction of adherence, 
depending on the cost [100]. 
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Continuity of care, or having a routine physician and routine place of care, is a 
factor found to positively influence adherence[76, 78, 99]. This could be for a 
number of reasons; for example, some patients received conflicting information 
from different physicians [78], potentially damaging trust and meaning they could 
be less likely to take advice seriously. Contact with one routine physician 
minimises the likelihood of this occurring. These factors may also tie into the 
relationship patients have with their physician, another important risk factor[75-
79]. Short consultations and insufficient support or guidance from physicians has 
also been cited in self-reported studies [77], and likely contributes to a lack of 
patient understanding. The relationship between physician and patient is 
particularly important at the transition between primary and secondary care [78], 
as this can be a pivotal time in their treatment. 
An important factor cited by practitioners was disagreement with guidelines, or 
the perception that guidelines may not lead to improved outcomes[77]. Personal 
doubts about efficacy of drugs may also make them less likely to encourage their 
patients to adhere[77, 79]. 
Some practical elements of healthcare also had an important role in adherence. 
Self-monitoring of blood pressure was associated with greater adherence[95], and 
this may due to an increased awareness of blood pressure changes by the 
patient, making their need for blood pressure control more palpable. Coronary 
artery calcium (CAC) screening was also associated with improved adherence [114] 
and, once again, this may be because it creates a more tangible sense of their 
disease state and the need for prevention of CVD events.  
2.4.4 Patient factors 
Sex or gender was discussed in three reviews [68, 80-85]. A majority of studies 
identified a link between female sex and nonadherence, with an increased risk 
of 7-10%. However in LMICs, the opposite was true[68], and female sex was 
associated with improved adherence. It has been postulated that nonadherence 
in women may be partly caused by perceptions that women are at lower risk of 
CVD [80], and that lower adherence is associated with less severe disease, or 
maybe because women are generally more aware of potential side-effects of 
treatment [81], and not adhering as a result. However, this relationship did not 
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exist in any study conducted in Canada[80],  as male and female patients were 
found to be equally adherent across 11 studies [80]. It would be worthwhile 
identifying cultural, societal, or policy differences that may be influencing this. 
Sex and gender are complex factors, as it can be predictive of many other 
confounding factors. For example, it is more common for woman to assume a 
care-giving role than it is for men[80], and this has also been associated with 
poorer adherence[80]. Hence, better support for caregivers and social care 
infrastructures could potentially help contribute to better adherence in this 
subgroup.   
Age is another demographic factor indicated in adherence research[69, 72, 81-84, 91]. 
Pooled results by Assawasuwannakit et al found that there was a 9% 
improvement in adherence over a 13-year increase in age (from age 40-53) in 
hypertensive patients [72], however these findings are not representative in the 
very young, as paediatric patients will receive medication from caregivers, or 
the very old, who may have declining cognitive function and therefore may be 
more likely to forget [72] . Mann et al found a “u-shaped” relationship between 
nonadherence and age [81], with middle-aged patients having better adherence 
than those below 50 or above 70 [81]. Age is another complex demographic 
factor, as it will be influenced by different perceptions about health, increased 
co-morbidities, and lifestyle changes.  
Other patient-related barriers to adherence include stress or anxiety and 
difficulty in making time for appointments [60, 76, 77]. These are likely to be 
related to lifestyle, e.g. stress brought on by a fast-paced job and heavy 
workload, or perhaps difficulties with unemployment [77] and financial concern.  
Alcohol consumption has also been found to negatively affect adherence [77, 115] 
across various chronic diseases, though findings are somewhat inconsistent [115] 
and there is insufficient research on this in the case of hypertension [115]. 
Smoking is similarly associated with nonadherence[85] to statins in patients with 
hypertension. 
In self-reported studies, forgetfulness and lack of knowledge were some of the 
most commonly cited barriers to adherence [76, 77]. Patient perception is an 
important factor which ties into many of the other disease related and 
healthcare related factors also. As discussed previously, patients treated for 
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secondary prevention of cardiovascular disease, or with certain co-morbidities, 
may be more likely to adhere due to an increased sense of urgency around their 
healthcare needs. Equally, those with asymptomatic illnesses, such as 
hypertension, may perceive their health to be good and may not see the need 
for taking medication for preventative reasons. Some also discontinue treatment 
following a reduction of symptoms [77], as they believe they are “better” and do 
not understand the chronicity of their disease. Perceptions about the medication 
itself can also have a great impact; some self-reported studies have cited 
patient fears of reliance to cardiovascular drugs [77]. Many of these perceptions’ 
barriers come down to a lack of understanding, and so increasing patient 
awareness could help to reduce this.  
 
2.4.5 Social factors 
The literature on socioeconomic status (SES) is inconsistent. In the seven 
systematic reviews reporting SES, two found no significant link [87, 89] though did 
comment that the methodological heterogeneity throughout the literature may 
have impacted this [87]. High income status was associated with a minimum of 
11% better adherence and a maximum of 26% across reviews [70, 81, 87, 88] though 
there was considerable variation at the individual study level. For example, in 
the review by Alsabbagh et al, 77.5% of studies found a positive association 
between high SES and adherence, though one study found no association, while 
the remaining studies found that high SES actually had a negative impact on 
adherence [87].  
Social support is another social factor explored in two papers [76, 86]. While 
structural social support, i.e. married vs. unmarried/ family network etc., was 
found to significantly impact adherence in some studies, it appeared reliant on 
study design: those using pill-count methods were more likely to observe a 
tangible relationship than those using alternate measures [86]. However 
functional social support, such as informational support or operational support 
(e.g. help taking medications), was consistently found to be strongly associated 
with adherence[76, 86], with these patients being almost 4 times more likely to 
take their medications[76]. However when adjusted for ethnicity, the positive 
influence of social support was diminished [86]. This may be due to cultural 
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differences in family dynamics, or other social factors at play. Those of a 
minority ethnic group are 27% less likely to adhere compared to white 
patients[70] and it is worth investigating the potential causes of this as an 
important risk factor for health inequalities.  
Loke et al considered the relationship between health literacy and adherence to 
CVD or diabetes medications, however most studies were inconclusive, with only 
one cardiovascular study producing a significant association between poor health 
literacy and poor adherence [96].   
2.4.6 Outcomes associated with nonadherence 
Systematic reviews investigating outcomes generally found that good adherence 
was associated with improved clinical and economic consequences[11, 117-129], with 
one noting that all studies included found a positive relationship with adherence 
to secondary prevention following MI [123]. Chowdhury et al found that CVD risk 
was reduced by 20% and all-cause mortality reduced by 35% with good 
adherence[11]. However, some reviews found no discernible difference to 
outcomes overall [117, 122, 126, 128], though it was highlighted that there are gaps in 
the literature yet to be addressed [122, 123, 128] and this could have had an impact 
on these findings. There was much heterogeneity across all studies with regards 
to how adherence rates were accessed. For example, some studies reported on 
the percentage of good adherers while others report on an overall average 
percentage. One review noted that the different methods used to study 
adherence altered findings[86] and Cramer et al identified a stronger association 
between adherence and outcomes in studies assessing adherence using MEMS 
compared with alternative methods [117].  
Economic outcomes are another important consideration. Bramlage et al 
compared the cost-effect ratio across drug classes, and found newer drugs, 
ARB’s and ACEi’s, outperformed the others in spite of being more expensive per 
tablet [98]. This may be in part due to enhanced efficacy and also due to greater 
adherence to these drug classes [98], as it reduces later costs of CVD treatment 
and adverse events. Another study by  Bitton et al found that in secondary 
prevention of coronary artery disease, patients who took less than 80% of their 
prescribed medication cost up to US$868 more per patient[118]. Furthermore, 
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Shroufi et al found that improving adherence may reduce healthcare costs more 
than earlier prescribing of statins would do [124], highlighting this as a hugely 
important aspect of disease management.  
From these findings, it is apparent that poor adherence to CVD medications has 
important consequences, and it is a vital area of study in order to prevent 
unnecessary mortalities, adverse events, and healthcare expenses.  
2.4.7 Strengths and Limitations 
Performing a systematic review of reviews is a good way to collate and quality 
assess the numerous studies published in this field, however it is possible that 
important primary papers have been missed by focusing only on the reviews.  
This review is limited in that it is restricted to papers written in the English 
language, meaning there may be a bias against research from people with 
different ethnic backgrounds, where English is not the first language. The high 
levels of heterogeneity within the systematic reviews included, and between 
them, made meta-analysis impossible and it is a symptom of an area of research 
that has been largely unstandardized in its practice. Also, as this is an overview 
of systematic reviews, it would be impossible to perform meta-analysis without 
unpicking the individual studies to ensure none are over-represented. Another 
issue is that the study design and method used to collect adherence data has 
been found to alter the rates of adherence identified, and there is no clear gold 
standard within the literature for analysing this. Many systematic reviews also 
failed to summarise the operational definitions of adherence used by primary 
studies, i.e. whether studies looked at adherence as a continuous variable or 
used a cut-off value above which individuals were considered adherent. 
 
2.5 Chapter Summary 
To-date, there are a wide range of modifiable and non-modifiable risk factors 
associated with cardiovascular drug adherence. Studies are of variable quality 
and considerable heterogeneity and there is some inconsistency across the 
literature for the relationships identified for the different factors. Adopting the 
adherence taxonomy defined by Vrijens et al, and appropriate care given in 
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defining adherence measures used, will greatly enhance this field of research. 
While many of the systematic reviews included consider multiple factors, many 
of the primary studies look at risk factors in isolation, not accounting for the 
interplay between them, and because of the heterogeneity there was no 
opportunity to study this quantitatively. This gives clear scope to perform a 
national study of cardiovascular adherence, to answer these questions more 
fully.   
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3 Methods Review 
This chapter explores the literature describing data collection methods and 
analytical methods used in adherence studies, with a focus on those using 
pharmacy claims records such as the Prescribing Information System (PIS) 
database in Scotland, and some of the challenges associated with this in terms 
of data linkage, defining and quantifying adherence, and measuring outcomes.  
3.1 Introduction 
Robust methodologies are of utmost importance when carrying out any research 
project, and clear descriptions and definitions are necessary for reproducibility. 
Adherence is a complex variable to study and, as such, research to date has 
been largely unstandardized in its methods [131-134]. When studying adherence, 
whether at the initiation stage, implementation stage or discontinuation, it is 
important to provide an operational definition[46], and to define the metrics used 
to measure it, as there is no agreed consensus [48]. For example, adherence can 
be evaluated as either a dichotomous, categorical, or continuous variable, and 
can be calculated in a number of ways, such as the medication possession ratio 
(MPR) or the proportion of days covered (PDC). When assessing adherence as a 
categorical variable, many studies use 80% adherence as an arbitrary cut-off, 
above which adherence is considered “good” [48, 135]. However, when defining a 
cut-off there should be, where possible, some consideration of the underlying 
pharmacology, as adequate adherence depends somewhat on the half-life of the 
drug and the therapeutic index. It is also important to consider limitations in the 
methods of data collection and data linkage when it comes to analysing results 
and accounting for bias.  
3.2 Data collection: measurements of adherence 
There are a number of ways in which adherence data can be collected, however 
all methods have different pros and cons, and there is no gold standard [48]. 
Some key methods will be discussed here; administrative pharmacy records, 
patient self-reporting, electronic monitoring systems, and direct serum 
concentrations. However, it is important to note that this is not an extensive 
list.  
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3.2.1 Pharmacy records: prescription refill data 
Pharmacy records are a useful tool for adherence study, as they provide 
practical information in a community setting, are quantifiable [136], and offer a 
relatively cheap resource for evidence based medicine[137] when compared to 
studies involving primary data collection. Additionally, they allow for much 
larger sample sizes and longitudinal study over many years and, because they 
are non-selective, provide an insight to drug effectiveness in ‘real world’ 
settings [137, 138] compared with highly selected trial participants who may be 
more motivated and hence more likely to adhere to medication. Furthermore, 
direct contact with the patient is not required [138], and in many cases informed 
consent is not necessary as data privacy is tightly controlled and researchers 
cannot access un-anonymised patient information, thus reducing the risk of 
patients changing their behaviour due to observation. Claims records are often 
very complete datasets as the data comes directly from the dispensing pharmacy 
and filling out these records is necessary for reimbursement. It is also often 
subject to strict auditing [137].  
Yet, there are certain limitations with administrative pharmacy data. One 
important issue is the lack of data frequency [136, 139]; for example, if a drug is 
dispensed on an annual or six-month basis it can be difficult to gain enough 
insight to build a detailed picture of adherence [139]. Also, as these data are not 
collected for research purposes [48, 138], key information to the research question 
may not be routinely collected and therefore may not be available [138].  
Secondary analysis of existing databases may also present issues with missing or 
inaccurate information [138] and coding errors could introduce bias if they occur 
more frequently in certain subgroups, for instance in a particular pharmacy 
location, or if there is confusion coding for a specific drug type. Pharmacy claims 
often do not take into account over-the-counter medications or drugs prescribed 
and dispensed within the hospital setting [140], so this information cannot be 
captured. While pharmacy claims do tend to have a high level of accuracy, they 
are often linked to medical data for study [137, 141], and these datasets are also 
not specifically collected for research purposes. Additionally, hospital records 
will only account for severe cases where an event results in hospitalization[138]; 
for example, if studying ischaemic heart disease as an outcome, secondary data 
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may only inform on those who suffer an acute myocardial infarction while 
missing out those with milder symptoms of angina. Even if the data were 
perfect, this method can only indirectly inform on adherence, as we do not know 
what happens to the prescription once patients take it home: they may stock-
pile it, throw it away, take their medication at irregular intervals, or take “drug-
holidays”[48, 138, 142, 143], and this would not necessarily be picked up from refill 
records. Researchers can only be sure of drug availability or lack thereof, and 
must make assumptions; such as, if a patient routinely picks up prescriptions 
around the time their previous supply runs out, it is likely that they have taken 
it as directed. 
The Scottish Prescribing Information System (PIS) is a good example of a national 
prescriptions database, hosted by National Services Scotland (NSS) [140]. It can be 
linked to NHS data through individual community health index (CHI) numbers, at 
a capture rate at close to 100% [140]. CHI is a unique ID number allocated to all 
patients in Scotland when they first register, and it allows their health records 
to be linked longitudinally and across national health datasets, such as hospital 
admissions (SMR01, SMR04) [140], and death registrations (NRS), as well as 
external administrative datasets. In this way, PIS can be used to define cohorts 
within the population based on drug prescribing and dispensing, using pre-
defined BNF (British National Formulary) codes [140], or by other patient 
characteristics, such as age, social factors, or disease status. Many studies using 
PIS to-date are drug utilization studies and health economics studies[140].  
PIS shares similarities with the Nordic Prescribing databases, in that they have 
wide coverage due to universal, tax-funded healthcare systems [144], and unique 
individual patient identifiers [144], similar to CHI, allowing data linkage across 
medical and administrative national datasets. Furthermore, informed consent is 
not required from individual patients [144]. However, this level of information is 
only more recently available in PIS, with linkable, individual-level records dating 
back to 2009, and aggregate data dating back to 1993. As such, long-term 
follow-up studies are currently limited in comparison. Table 3.1 summarises 
some of the different prescribing databases available in different countries, 
along with their strengths and limitations. 
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Table 3.1: Summary of selected prescribing databases 
Country Database(s) Coverage Date Benefits Limitations Ref. 
USA 
TruvenHealth 
MarketScan 
Commercial 
Claims and 
Encounters 
Research 
Database 
Commercial 
Database. US 
wide though 
not full 
population, 
estimate 115 
million 
individuals 
included in 
database 
First study 
published 
1990 
Records from over 100 different 
insurance companies covered. 
Individual level data linkage, 
Medicaid prescribing claims, 
health and dental records etc. 
Incomplete capture rate 
may be subject to large 
amounts of missing data. 
[145, 146] 
Canada 
Ontario Drug 
Benefits (ODB) 
claims database 
Province of 
Ontario, Only 
covers patients 
on Ontario 
Health 
Insurance Plan 
(OHIP) -over 65 
years old or on 
social 
assistance 
April 1990 
to present. 
Updated 
monthly 
Complete coverage in over 65 
year olds, allows study in elderly 
patients with linkage to other 
healthcare and demographic 
records. Audited so high coding 
accuracy. Information on days 
supplied, dosage, and strength 
allows for drug exposure study, 
Data not representative of 
whole population of 
Ontario, only those on OHIP. 
[147-149] 
England 
The Clinical 
Practice Research 
Datalink (CPRD) 
11.3 million 
patients, 674 
GP practices 
Originates 
from 
General 
Practice 
Research 
Database 
(1993). 
Became 
CPRD in 
2012. 
Large database hence good 
statistical power for epidemiology 
research; long follow up (mean 
9.4 years at individual level). 
While it does not have full 
population coverage, sample is 
representative of UK population, 
as it maps closely to census 
records. Good data quality for 
certain data items covered by 
Quality and Outcomes Framework 
(QOF). 
Missing data ‘not at random’ 
e.g. BMI more likely to be 
recorded in those with 
related health issues. 
Prescribing data based on 
written prescription (rather 
than dispensed) so may not 
be accurate for drug 
exposure. Unstandardized 
definitions for diagnoses so 
individual studies may code 
differently and produce 
different results from same 
data source. 
[150] 
Scotland 
Prescribing 
Information 
System (PIS) – 
provided by 
National Services 
Scotland (data 
linkage via eDRIS) 
Whole Scottish 
population; 5.3 
million people 
2009 
onwards 
provides 
individual- 
level CHI-
linked data 
Linkage to Scottish administrative 
data, medical records, and death 
records. High capture rate. 
Longitudinal study possible; 
individual level follow up from 
2009 onwards. Data monitoring 
to ensure high quality. 
No data capture for over-
the-counter medication or 
drugs prescribed in hospital 
setting. Capture rate can 
vary based on prescriber 
and drug type. Some lags in 
processing of data. 
[140] 
Denmark 
Odense University 
PharmacoEpidemi
ological Database 
(OPED), Aarhus 
University 
Prescription 
Database (AUPD), 
Danish National 
Prescription 
Database (DNPD) 
OPED: 
Southern 
Denmark, 
AUPD: Central 
(1.2m) and 
Northern 
(0.6m) 
Denmark, 
DNPD: entire 
country (5.6m) 
1990 
OPED, 
1989 
AUPD, 
1995 DNPD 
Full population coverage, data for 
over 20 years allows longitudinal 
studies, linkage to other datasets 
and potentially to other Nordic 
countries. Based on prescriptions 
dispensed (rather than those 
written) – gives more accurate 
picture of usage. Also covers 
prescribing in nursing-home 
setting allowing more accurate 
drug-exposure studies in elderly 
population. 
Difficulty in assessing drug 
exposure; lack of 
information about intended 
duration of treatment and 
dosage. Lack of information 
on over-the-counter 
medications. 
[144, 151] 
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3.2.2 Self-reporting 
Patient self-reporting may take the form of interviews, questionnaires, patient 
diaries, or focus groups [152] and it is a straightforward and inexpensive method 
of collecting data on adherence [48]. As such, it is a very commonly used method 
and, in a review by Clifford et al., self-reporting was the most frequently used 
method of data collection in studies of adherence to diabetes medication[153]. 
These methods can be insightful, as diaries can give in-depth information on the 
drug-taking regimen [152], though it does risk two main types of error: random 
errors may arise from misinformation provided by patients; or systematic errors 
e.g. from patients consistently over-estimating their adherence. Interviews or 
focus groups allow patients to discuss issues or bring up barriers they feel are 
preventing them from adhering fully, which can be useful in developing future 
interventions to improve adherence. Questionnaires such as the 8-item Morisky 
Medication Adherence Scale (MMAS-8) are validated tools, and have been found 
to have high sensitivity [154]. However, all self-reported measures risk over-
predicting good adherence [48] as patients may feel embarrassed or do not wish 
to ‘let-down’ their doctor. One of the most commonly cited reasons for non-
adherence is forgetfulness [76, 155], and so it is likely that people can make errors 
in judgement when reporting on their own behaviours. Certain cognitive 
disorders can have a negative influence on adherence rates and may also create 
a barrier to the accuracy of self-reporting.  
3.2.3 Electronic monitoring system (EMS) 
Electronic monitoring systems, such as the Medication Event Monitoring System 
(MEMS) or unit dose monitor, use physical monitoring systems that record each 
time a pill-bottle or a blister pack is opened [136] as a measure of how often pills 
are removed and presumably taken. This is not a perfect system, as removal of 
the drug from its pack still does not ensure ingestion, and with pill-bottles there 
is no way to measure the number of pills removed at any one time, or indeed if 
any pills were removed at all. Though it does provide a more proximal picture of 
adherence patterns, and can add temporal measures to analysis, allowing a 
quantitative picture [136] of real-time drug-taking with a great level of detail. It 
is one of the most comprehensive measures available for adherence study, 
though previously, the technology has been expensive to provide on a large 
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scale[48] and would not be feasible for population studies. However, as the 
technology comes off-patent, costs will decline and make this a feasible option. 
Studies using EMS require patient consent and so participants who are willing to 
take part may not be representative of the patient population as a whole. Those 
who do consent may change their behaviour as they know their drug-taking is 
being monitored [136], potentially giving a less realistic picture compared with 
refill records. Once data has been collected, EMS can provide huge amounts of 
information which is rich in value, but which can preclude study of a large 
population given the volume of data produced for each individual.  
3.2.4 Direct methods: serum concentration  
Serological measures of adherence involve taking blood or urine samples in order 
to quantify the amount of medication or its metabolites present [48, 152]. Direct 
measures can quantitatively show the amount of medication in the body, and 
hence they are the only measures that concretely determine whether 
medications have been ingested. If serum concentrations are within the 
therapeutic range it is fair to assume that the patient has adhered adequately, 
and if it is outside of the range then it is likely that they have not. Nevertheless, 
this method has certain flaws attached. Similar to self-reported and EMS 
measures, this method requires consent and direct contact with patients, and as 
such, it may not always capture a representative population. Furthermore, it 
can be time-consuming and costly [48] and, depending on the half-life of the 
drug, it could be misrepresentative of the patient’s medication taking 
behaviours due to the ‘white-coat effect’ [48, 152]; if in the lead-up to a visit the 
patient adheres better than normal, the serum levels may not reflect their true 
day-to-day adherence. Where possible, holding observations at random intervals 
[152] or organising appointments with short notice may help to reduce this. 
Another issue is that variations in an individual’s metabolism [152] may lead some 
patients to appear unfairly more or less adherent than others, highlighting the 
complexity involved with pharmacokinetic measures. 
3.2.5 Direct methods: digital pill 
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A more recently developed alternative is the ‘digital pill’; a pill with a tracking 
sensor which communicates with a patch worn by the patient once it has been 
ingested. Data on ingestion can then be monitored using a mobile app. This 
would be the most direct method of measuring adherence as it can assess drug 
exposure on a daily basis, and it may be more accurate than serum 
concentrations as it is not dependent on metabolism of the drug. It is also less 
affected by ‘white-coat adherence’ as, with consent, doctors can monitor usage 
through the app without having to physically see the patient. However, it may 
inflate adherence compared to general usage due to the app’s ability to track 
adherence and patient awareness of being monitored. The drawbacks of this 
method, including the invasiveness of monitoring and discomfort from 
continually wearing a patch on the skin[46], are not thought to merit the use of 
these pills over EMS systems which can still give a detailed picture of adherence 
and which are thought to be as reliable as direct methods[46]. 
Table 3.2: Comparison of adherence measures 
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3.3 Using data collected from electronic prescription 
records 
3.3.1 Data linkage and handling linked data 
To make use of prescription data in adherence studies, it can be valuable to link 
refill records to medical records, such as hospital admissions or death registries, 
or to other administrative datasets such as education or social care records to 
gain additional information about the cohort. Data linkage is the “method to 
bring together information contained in two or more records” [156], such as 
hospital records with prescribing information. Linkage to healthcare data is 
often carried out by a separate party from the researcher who conducts the 
analysis, and no one party has access to all of the records in order to protect 
patient privacy [157]; for example, linkage is carried out by eDRIS in Scotland and 
SAIL in Wales [157] for public health research using national datasets. Linkage 
with a unique identifier present across multiple datasets is known as 
deterministic linkage, and is performed by exact matching[158], i.e. linking 
records across datasets that share the same identifier. However, the process of 
data linkage can be challenging in health systems which do not have a unique 
identifier across datasets, and instead data-linkers must rely on information such 
as patient name, date of birth, sex, and patient postcode [157]. This is known as 
probabilistic matching[158], and it valuable for making use of datasets which do 
not have a common identifier. This can be imperfect and may lead to false 
matches, where data is spuriously linked between different individuals [141, 157, 
159], or missed matches, where data which relate to one individual are not 
connected by the linkage algorithm. This can lead to loss of statistical power or 
may lead to bias if errors are over or under represented in different population 
subgroups [141, 157, 159].  
Linkage errors mainly arise in three ways: faults in the linkage method used; 
challenges in complying with data protection legislation, such as the need for 
acquiring consent[141]; and poor-quality or missing/inaccurate information in one 
or more of the datasets used [141]. Bias occurs when these errors appear more 
commonly in certain subgroups, such as different age-groups, sexes, specific 
hospitals or GP practices, or socioeconomic statuses [141]. An example of this 
would be when using names to link data, female participants are more likely to 
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be missed than male participants as they are more likely to change their name 
following marriage [141]. This particular problem is not an issue for datasets 
which use unique identification numbers such as CHI for linkage, as they use 
exact matching which does not rely on names. However, there may still be flaws 
with exact methods, for instance, if a CHI number is recorded incorrectly.  
Despite the benefits to patient confidentiality and research integrity by having 
data linkage carried out by a separate party to those conducting analysis, this 
can present challenges in accounting for uncertainty within the linked data 
during analysis [157, 159]. Errors arising from underlying data quality, such as 
inaccuracies with data collected by a specific hospital or GP practice [141] could 
be a difficult linkage error to account for, as analysts do not have access to 
information on the observed error-rates in different settings [141]. Access to 
information on the linkage methodologies used, e.g. use of probabilistic methods 
or deterministic methods, may also help researchers to adjust for bias [141]. 
3.3.2 Adherence measures 
3.3.2.1 Taxonomy 
Following data collection, there are a variety of methods that can be used to 
assess adherence, with one review identifying ten different terms describing this 
[42], and another review identifying eleven different calculations for 
comparison[143]. This lack of standardization can be problematic, as different 
terms can inhibit comparison of studies, while use of different criteria (e.g. 
different allowable gaps; different cut-off defined as an acceptable level of 
adherence) or calculations can result in different findings[142] from the same data 
source.  
Since Nichol et al.[132] identified the poor methodological rigour and lack of 
consistency in this field of research in the late 1990s, numerous efforts have 
been made to develop a standard taxonomy and methodological approach for 
adherence research [42, 133, 142, 143]. The ABC taxonomy, proposed by Vrijens et 
al.[42], considers adherence as encompassing three stages; initiation, 
implementation, and discontinuation. Initiation involves prescription of a drug 
and taking the first dose[42]. Some studies are flawed in that they do not 
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conceptually separate initiation from implementation, though this can be 
difficult to capture using refill records. One method that could be used is to 
identify initiators from non-initiators is by calculating implementation from the 
start of the second dose of the specified prescription, within a pre-determined 
time period. Those who only ever collect their first dose may or may not have 
initiated with their medication – it is not clear with the level of information 
available from refill records - while those who do collect a second dose are more 
likely to have completed their initial prescription and so can be considered as 
having initiated treatment in follow-up analysis. To determine between new 
users of a drug and continuous users, a ‘run-in’ period, i.e. a period of 
monitoring prior to initiation of drug use, in which there is no exposure to the 
drug, should be defined[160]. 6-months is a commonly used run-in period, though 
this may introduce bias by including people who are not truly naïve to the 
medication but who had instead just had a brief break in treatment; however 
having a longer run-in can reduce the size of the cohort[160]. The length of run-in 
depends on the study requirements (how important to the research question that 
incident and non-incident users are differentiated) and the drug itself; for 
example, drugs which are common in a population are more likely to have been 
used previously by those who appear to be new-users than drugs which are less 
common[161] , and so may require longer run-in times to eliminate bias. 
Implementation considers drug usage following initiation. This stage is 
conceptually what many previous studies would define as adherence – “the 
extent to which a patient’s actual dosing corresponds to the prescribed dosing 
regimen”[42]. Discontinuation is the end of the drug taking period – where the 
final prescription has been used up and no further prescriptions are collected[42]. 
Longer-term follow-up can help determine between “true” discontinuation and 
those who recommence treatment after a prolonged gap period.  
3.3.2.2 Components required to calculate adherence 
In adherence studies using medication records, there are clear guidelines on the 
minimum reporting[43, 142, 162], including operational definitions of adherence[43], 
and reporting of the assumptions made when preparing data[142, 163].  
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Generally, to calculate adherence, databases must have information on the drug 
name, strength e.g. milligrams per tablet, quantity e.g. the number of tablets 
within a packet, and dosage instructions[137] e.g. ‘take one tablet daily’. 
Alternatively, if this level of information is not available, the World Health 
Organization’s defined daily doses (DDD) can be used to estimate drug exposure. 
This is calculated by multiplying the strength of the drug by the quantity 
dispensed, and dividing by the DDD value [164], though there can be inaccuracies 
with this method as the DDD may not be reflected by the prescribing practice in 
the country of interest, or dosage may differ; for example, for different disease 
severities, for different indications[164], or due to interactions with concomitant 
drugs prescribed. One study by Rikala et al [165] found that compared to dosing 
instructions, DDD was subject to huge misclassification bias, leading to both 
under and over estimation of how long prescriptions should last. For adherence 
studies it is beneficial to have dosage instructions available; for instance, in the 
Scottish PIS dataset, dosage instructions are available for cardiovascular 
medications and are retrieved using a natural language processing (NLP) 
algorithm [166]. In this way, it is possible to work out the estimated length of 
time that the prescription should last and hence, when a new prescription ought 
to be picked up. This allows the possibility of greater accuracy in drug exposure 
and adherence studies. 
It is also important to define a grace period, or a gap of days allowable to be 
without a drug supply before a patient is considered non-adherent. When 
defining this, it is important to note that the length of time can alter the 
sensitivity of analysis[142] as a smaller gap will exclude a higher number of 
individuals from being classed as adherent. Generally a gap of 90 days is 
considered acceptable[142], as above this there is less variation in the number of 
people excluded[142], however it is important to consider the specifics of the 
medication, such as the half-life of the drug or the clinical effects of 
withdrawal, and the condition studied when defining a grace period[142]. 
3.3.2.3 Common measures: medication possession ratio and proportion of 
days covered 
There are a range of methods used to calculate the implementation phase of 
adherence using a closed pharmacy system (Table 3.3), with medication 
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possession ratio (MPR) and proportion of days covered (PDC) being most 
common. Using MPR, adherence is calculated by taking the number of days 
supplied with medication divided by the number of days in the refill or 
observation period, and multiplied by 100 to give a percentage value [131, 142, 162]. 
The modified MPR (MPRm) is similar, though it includes consideration of the final 
refill period[143]. MPR is often assessed as a binary variable, by applying a cut-off 
or threshold value above which adherence is considered good, and below which 
is described as non-adherence [135, 167]. Looking at adherence as a dichotomous 
variable can be a straightforward way to compare adherence within population 
groups, however it leads to a loss of information. For instance, someone who is 
classed at 50% adherent may take their medication every second day, or may 
have taken medication perfectly for the first half of the study period, and 
discontinued use for the second half[42].  
Studies which utilise MPR methods commonly use ≥80% as a cut-off value, though 
this is an arbitrary value and the exact threshold point used can influence the 
sensitivity and specificity of analysis [152, 167, 168]. Karve et al validated 80% as a 
cut-off value when investigating hospitalizations as an outcome of non-
adherence across five chronic disease areas; however the specific optimal value 
varied across diseases, from 58% in congestive heart failure to 85% in diabetes 
[167]. Hansen et al identified 80% as being a valid cut-off value in terms of 
sensitivity and specificity when studying hypertension and heart failure[168], 
though, while 80% may be acceptable as a cut-point for general study, it may be 
worth validating this for specific research areas[168]. Where it is not possible to 
study adherence as a truly continuous variable it may be preferable to group 
into categories, ranging from very high to very low adherence or discontinuation. 
PDC is the other commonly used measure for the implementation stage of 
adherence study, which is a measure of the number of days a drug is available, 
divided by the number of days in a given time period [162, 169]. Many of the 
considerations required when calculating MPR, such as assessment as a 
dichotomous or categorical variable and grace periods, also apply to it. 
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3.3.2.4 Alternative methods for estimating adherence:  
Usually PDC is studied as a ‘time-constant’ measure, meaning it is averaged over 
a fixed time period[170] and does not account for changes during that period. This 
could have clinical significance, as patients who take their medications stably 
over time could have different outcomes than those who take it irregularly[170]. 
Because of this, Bijlsma et al [170] proposed a time-varying method which takes 
into account changes in adherence overtime and is well-suited to longitudinal 
studies. With this model it is possible to account for drug-switching, assess 
exposure to polypharmacy more accurately, and to measure changes in 
adherence overtime [170]. 
Another way of utilising PDC is by developing a combined measure, using both 
PDC and the treatment anniversary method (TAM)[44]. TAM involves checking at 
an anniversary date (e.g. 6 months or 1 year after initial prescription) to identify 
patients who are still persistent with their medication at this point[44]. To 
calculate this, it is important to know the days-coverage for the prescription 
dispensed closest to the anniversary date [44] e.g. a drug dispensed as 28-tablets, 
to be taken once daily, would last 28 days. A patient prescribed this drug within 
28 days of their anniversary date (plus an allowable gap) would be considered 
persistent; whereas a patient prescribed 56 tablets on a once-daily regimen in 
the prescription closest to their anniversary date would have a window of 56 
days (plus allowable gap) in which they must have received a prescription in 
order to be considered persistent. Those classed as persistent could then have 
their PDC calculated to assess implementation during this period[44].  
Polypharmacy is a useful aspect to consider when studying adherence [142, 171]. 
Many studies take the adherence estimates for each drug individually and 
average this[171], though this does not account for the true complexity involved 
with taking multiple drugs, and can lead to overestimation of adherence[171] to 
their overall medication regimen. Because of this, Arnet et al proposed the daily 
polypharmacy possession ratio (DPPR) which takes into account the number of 
medications, switching, and assesses the number of days within the observed 
period in which a patient had access to all prescribed medications[171]. 
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Table 3.3: Summary of adherence calculation methods 
Method How calculated Pros Cons References 
Medication 
Possession Ratio 
(MPR) 
Number of days supplied 
during refill period/ Total 
number of days in study 
period x 100 (to give a 
percentage) 
 
Note that some studies use 
term MPR but describe 
different calculation 
Straightforward 
method, often data 
required for this is 
stored in 
administrative 
databases. Can access 
as dichotomous or 
continuous variable 
Can overestimate adherence, 
subject to bias (e.g. 
observation period, allowable 
gap between refills, overlaps 
can all influence sensitivity and 
specificity of results). Caution 
should be used when setting 
cut-off for dichotomous 
measure and this should be 
validated. 
[131, 162, 171] 
Modified 
Medication 
Possession 
Ration (MPRm) 
 
 
Total no. days’ supply/(last 
claim date – first claim date + 
last days’ supply)] × 100 
Attempts to define 
study period based on 
drug dispensing, rather 
than by arbitrary 
perimeters.  
Less reliable method; uses time 
between first and last refill as 
denominator which can 
overestimate adherence 
(assumes full adherence in final 
refill period). Does not account 
for premature discontinuation. 
[143, 172] 
Proportion of 
Days Covered 
(PDC) 
Total number of days 
“covered” with drug supply/ 
number of days in observation 
period. Often capped at 1.0. 
Less-likely to over-
estimate as surplus 
days capped. Good 
predictor of 
hospitalization as an 
outcome and intuitive 
to read.  
Requires accurate measure of 
days-supplied. Must be careful 
with grace periods/ defining 
point at which patient defined 
as ‘non-persistent’. 
[143, 162, 172] 
Treatment 
Anniversary 
Method (TAM) 
with PDC 
Persistence measured first 
with TAM – check if patient 
prescribed drug within a 
specified window around 
anniversary date. Those 
considered persistent then 
have PDC calculated for this 
period. 
Straightforward 
calculation; Can 
differentiate between 
those who implement 
treatment poorly but 
continue to persist 
from those who stop 
taking treatment early. 
Non-persistence outside TAM 
window may not be captured. 
As with PDC alone, decisions 
need to be made to account 
oversupply, switching, and 
polypharmacy.  
[44] 
Time-varying 
PDC 
Total days: no. pills 
dispensed/ no. pills per day 
Interval Length: time between 
prescription date (k) and date 
of second prescription after 
this (k+2) 
 
Adherence = total days/ 
interval length  
(excess carried over, 
assumption: drug stockpiling) 
Measures changes in 
adherence over-time; 
useful for time-to-
event analysis.  
Minimum of three refills 
required; cannot assess early 
non-adherence. Challenge in 
accurately estimating 
adherence for final interval. 
[170] 
Daily 
polypharmacy 
possession ratio 
(DPPR) 
Take each day of study period 
separately, for each set score 
between 0 (no meds available) 
and 1 (all meds available) and 
compare against the number 
of drugs that should be taken 
to give a score. Find the sum 
scores across all days and 
divide by no. days in 
observation period to find 
overall proportion.   
Provides standardized 
parameters so allows 
accurate comparison 
between studies. 
Accounts for 
polypharmacy; 
prevents 
overestimation as it 
reduces chance of 
duplication or 
overlapping 
Cannot identify over-supply of 
medications. If dosing 
instructions are variable (for 
example, “take as required”) 
then unable to calculate 
coverage. 
[171] 
Continuous 
measure of 
medication gaps 
(CMG)  
Total number of days without 
a supply (gaps) divided by 
number of days in observation 
period/ time between first 
and last refill date.  
Gives percentage of 
time without coverage, 
can highlight variability 
in refilling. Calculation 
with AdhereR. 
Complex and require more 
data to calculate.  
[143, 162] 
Group based 
Trajectory 
Modelling 
Using software, such as the 
SAS package ‘Proc Traj’, input 
monthly adherence estimates. 
Model runs multiple 
regressions and estimates 
groups using maximum 
likelihoods. 
Gives a clearer picture 
of the dynamics of 
adherence and 
categorises people 
based on their 
medication taking 
behaviour. Greater 
accuracy than PDC. 
Requires a significant amount 
of data cleaning prior to input 
to model, and computationally 
slow to run, especially with 
large amounts of data. 
[173] 
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The ‘gap methods’, continuous measure of medication availability/gaps (CMA or 
CMG) and continuous multiple interval measure of oversupply (CMOS), look at 
the level of non-adherence rather than the level of adherence[143]. While this can 
be useful, it requires translation into an adherence percentage value to allow 
comparison with other studies[143]. An assessment of adherence measures found 
that methods which use a defined study period, such as 365 days, were more 
reliable than those which used the time period between first and last refill as 
the denominator in calculations[143, 172], such as the MPRm method. 
The R package AdhereR can be used to calculate adherence using CMA 
methods[174] and this could prove a valuable tool as it could standardise 
adherence measurements if adopted widely. However, R can be challenging to 
use with large datasets due to memory restrictions[175] and alternative methods, 
such as using a relational database or Hadoop’s MapReduce algorithm, are 
required for processing[175]. This adds an extra layer of technical difficulty for an 
inexperienced programmer.  
Group based trajectory modelling (GBTM) is another potential method for 
estimating adherence. It illustrates the dynamics of adherence much more 
clearly when compared to summary measures such as MPR and PDC[15] and in one 
study was shown to have greater accuracy than PDC[173]. Based on the number of 
groups put into the model, usually no more than 5 or 6 is enough to show marked 
differences without over-complicating the analysis[173], it groups a population 
into clusters based on their major patterns of adherence overtime[15] and applies 
maximum likelihood to build trajectories and to estimate group sizes[15]. The 
groups produced by the model can then be compared for baseline characteristics 
that may predict inclusion into each group[173] and subsequent outcomes may be 
compared. One flaw with this method in adherence study at a population level is 
that it can take a very long time to compute within a large cohort.  
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Table 3.4 Comparison of main adherence calculations 
 
3.3.2.5 Persistence 
Persistence is also a component of adherence; it is defined as the time between 
initiation and discontinuation[42], and therefore does not encompass any time 
following discontinuation. For studies of persistence, there are also a variety of 
methods available, the main basis of which is to identify the ‘time to 
discontinuation’. In studies using pharmacy claims data, Caetano et al [169] 
identified five main methods used to measure persistence: the anniversary 
model, minimum refills model, refill sequence model, proportion of days 
covered, and the hybrid model. The anniversary model and the minimum refills 
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model do not take into account the amount of medication supplied or how long 
the prescribed drug should last[169], and in this respect are flawed, though could 
be used when available data are limited. As discussed previously, anniversary 
models can also be valuable when used as a combined measure[44]. More recent 
studies tend toward the use of proportion of days covered (PDC)[162] at specified 
time points (6 months, 12 months, 18 months etc.) and defining those as 
persistent if they have a PDC above a threshold value. The issue with using PDC 
as a persistence measure in this way is that people who implement drug use 
poorly may be classed as non-persistent, despite continuing to take the drug, 
which further confuses the conceptual difference between adherence 
implementation and persistence. Another possible persistence measure is the 
estimated level of persistence (ELPT) method, which evaluates the percentage 
of individuals considered persistent at any given time[162]. ELPT is useful for 
population level study, and can be used to create a ‘persistency curve’[162], 
similar in principle to a Kaplan-Meier plot[162].  
3.3.3 Outcomes 
When carrying out an adherence study, it may be of interest to relate this to 
clinical outcomes in order to identify the impact of non-adherence or non-
persistence[167]. This can commonly be identified through adverse events or 
hospitalisation, by looking for specific disease diagnosis codes for defined 
outcomes of interest[137]. Coding for outcomes is not always as accurate as 
coding in prescribing databases, especially if patient presentation is not clear 
cut[137]; for example, certain autoimmune conditions can present similarly or 
records may miss more minor events and outcomes which do not always result in 
hospital admissions[137]. Systems such as ICD coding work best for cases which are 
straightforward to diagnose, such as myocardial infarction or stroke, though it is 
important to also include death records in order to capture those who die 
without making it to hospital. The validity of such codes should be considered 
before use [176].  
Other outcomes of interest may be the change in a certain clinical marker, such 
as changes in blood pressure, or low-density lipoprotein tests for identifying 
cholesterol levels. However, the more specific information gained from 
laboratory tests may not be available to large-scale study, and often in 
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administrative datasets it is only recorded that a test has been ordered to allow 
for reimbursement[137], without the results themselves being included.  
3.4 Limitations in this field of study and future prospects 
Research in adherence must first define the term operationally, including how 
the data were collected and parameters used. Also necessary is a definition of 
the study population, the length of the observation period, the calculation used 
to find the defined daily dose or direct dosing instructions, a description of how 
missing information was handled[142], how confounders were accounted for and a 
definition of outcomes. All of this is required to provide a clear data handling 
and analysis plan, which is vital for studies to be transparent, reproducible, and 
comparable to other research.  
There are, as ever, issues with using secondary data. Steps in linkage, preparing, 
and analysing data can all be subject to selection bias or information bias and 
some specific information may not be captured. Using refill-records only 
accounts for drug availability and is not a direct measure of ingestion [48, 142, 177], 
however it is reasonable to assume that patients who consistently refill their 
prescription on time are more likely to be adherent, and that those who do not 
collect sufficient medication could not possibly be adherent to the prescribed 
regimen. Moreover, self-reporting, electronic measures, and prescription refills 
have all been found to have a fair level of agreement between them [168] and so 
despite there being no gold standard for measuring adherence, there are a range 
of valid methods to identify this, depending on resources available to the 
researcher and the study aims. Using secondary administrative data is indeed a 
viable way to study this, so long as the parameters, calculations used, and 
assumptions made are clearly stated. 
A challenge to adherence research as a whole is the wide variety of methods 
available for calculation of adherence, and the numerous decisions and 
assumptions that need to be made in the preparation of data. If these are not 
recorded accurately then it is impossible for research to be reproducible or 
comparable to other adherence studies. However, this flaw can also be a 
strength; the wide range of methods means that adherence can be estimated in 
line with specific requirements of a study, even if the data available is limited. 
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3.5 Chapter summary 
There are a breadth of methods available for collection of adherence data, 
though for population level study, pharmacy refill records are the most 
accessible. For adherence study, MPR and PDC are the most commonly used 
calculation methods, though it is important to justify parameters set, such as 
the grace period and cut-off points, and where possible it may be useful to study 
adherence as a continuous or categorical, rather than a dichotomous, variable. 
Comparison with newer methods such as the DPPR, time varying PDC, and GBTM 
could also be of value when conducting new research. Here, the combined TAM 
with PDC will be used, due to its relative ease of computability without 
compromising on validity. When using such data, it is important to acknowledge 
limitations in all stages, from data collection, linkage, analysis, and relating to 
outcomes. 
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4 Methods Chapter: Data Management  
4.1 Introduction 
This chapter covers the data management methods used to conduct this PhD 
project. It details the data sources and variables, assumptions made about the 
data, as well as steps in preparing and defining the cohort.  
4.2 Data Approvals and Access 
All data was provided by the electronic Data Research and Innovation Service 
(eDRIS), a division of NHS National Services Scotland (NSS). An application for 
data was made through the Public Benefit and Privacy Panel (PBPP) (application 
number 1617-0221). Once the application was approved, access to linked, 
anonymised records was provided through the National Safe Haven, hosted by 
NSS. Data exploration, cleaning and analysis was run on RStudio. The University 
of Glasgow MVLS Ethics Committee approved the project without the need of 
additional ethical review following acceptance of the PBPP (Date: 01/03/2017, 
See Appendix B). 
All study data were contained within the National Safe Haven hosted by NSS and 
accessed remotely via VPN. Data approval was achieved through PBPP 
application, with data linkage and data extract provided by eDRIS. All data 
cleaning and analysis work was carried out by the author in accordance with the 
terms agreed to by signing the written National Services Scotland eDRIS user 
agreement[178]. Any outputs were released following disclosure control and 
approvals.  
4.3 Linkage and Anonymization 
Data linkage was performed as part of the eDRIS extraction service using CHI 
numbers. CHI, or community health index, is a unique, ten-digit number[179] 
given to all Scottish patients upon registering with a GP. Patients accessing 
services within Scotland cannot opt-out of the CHI system[179], giving it universal 
coverage, and it is used to record healthcare encounters and usage across NHS 
services. This also allows CHI to be used to match a patients’ records across 
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these different services. Each individual CHI is made up of ten digits including a 
sex code, a 6-digit DOB, a unique code and a check digit [179] and thus includes 
identifying information[179]. Therefore, to protect patient anonymity, eDRIS 
removed the CHI following extraction of the data files and provided a unique 
study ID number (PatID), which has been generated for the purposes of this 
study. The CHI number is used for the linkage of records performed by eDRIS and 
is replaced by the unique PatID, which cannot be used to link to datasets outside 
of the extract provided for this specific study. As the researcher only has access 
to linked records indexed with this ID rather than original CHI numbers, this 
provides a higher level of data protection.  
To protect patient confidentiality, and to comply with the Data Protection Act, 
additional steps were taken to minimise identifying information provided in the 
data extract provided by eDRIS: for date of birth, the month and year were 
provided, though no day variable. Therefore, all dates of birth were set to the 
first date of the month, from which ages were derived.  
Other demographic information could also potentially lead to identification. Full 
UK postcodes pertain to an average of 15 addresses[180] and so people may be 
able to identify themselves or others in the data if this were provided alongside 
date of birth or prescription of certain medication. For example, the postcode 
‘G12 8RZ’ pertains to very few properties, whereas the postcode sector ‘G12 8’ 
contains 288 postcodes, and hundreds of residences. Hence, provision of 
postcode sector rather than full postcode helps to eliminate risk of a 
confidentiality breach.  
4.4 Data Sources  
For this study, Scottish administrative and routine health data records were 
used. The Prescribing Information System (PIS) for the period of 2009 – 2017 
inclusive was used, along with additional data on acute and psychiatric hospital 
admissions (Scottish Morbidity Records, SMR01/04) and deaths (NRS).  These 
databases are detailed in Table 4.1 and in the following sections: 
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4.4.1 Prescribing Information System 
A previous review highlighted that, in order to utilise prescribing or dispensing 
information to study adherence at a population level, a centralized, closed 
pharmacy system with consistent coding of information across all practices and 
pharmacies was the ideal organisational structure[184]. PIS is a closed, centralised 
database. It dates back to 1993, though prior to 2009 information is not linked 
Dataset Description Year of first 
available data 
Years 
included in 
this study 
References 
SMR01 Scottish Morbidity Record 01. 
Scotland-wide acute hospital 
episode data; includes inpatient 
stays and day-cases; excludes 
obstetric and psychiatric 
specialties; care for the elderly 
long-stay data included from 
2007 
1981 1999 - 2017 [181, 182] 
SMR04 Scottish Morbidity Record 04. 
Scotland-wide psychiatric 
facility episode data; includes 
inpatient stays and day case 
dataset; excludes community 
mental health care 
1981 1999 - 2017 [181] 
NRS 
deaths 
National Records of Scotland 
Deaths. Scotland-wide death 
registrations 
1974 2009 - 2017 [183] 
PIS Prescribing information system.  
Scotland-wide; medications 
dispensed by community 
pharmacies or primary care  
Aggregated data 
from 1993; 
individual level 
data from 2009 
2009 - 2017 [181] 
Table 4.1: Description of datasets from which extracts were provided for this study  
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and can only be analysed as aggregated data on use of medications rather than 
at an individual level. From 2009 onwards, the community health index (CHI) 
identifier was appended to the information held. This is a unique ID which 
relates to every patient registered with a GP in Scotland, giving it universal 
coverage and making it possible for patient records to be linked across NHS 
services. The CHI number enables medications dispensed to the same individual 
over time to be linked and allows PIS data to be linked, at an individual level, to 
other health datasets.  
To estimate adherence using a database it is important to have the date on 
when a drug was prescribed, the quantity, and dosage information. PIS contains 
three different date variables: prescribed date, dispensed date, and paid date. 
The prescribed date is the date on which the physician writes the prescription; 
the dispensed date is the date on which a patient fills (i.e. collects) the 
prescription; and the paid date is the date on which the pharmacy fills out pay 
claims for reimbursement of the costs, which falls on the last day of the relevant 
month. Ideally for an adherence study, it would be best to use the dispensed 
date as this is when a patient physically has access to a drug, however this often 
defaults to paid date, recorded at the end of month when pharmacies submit 
requests for bulk payments (55.23% of dispensations in our dataset fall on the 
end of the month, n = 102,419,655; see Figure 4.1) whereas with prescribed 
dates, this does not occur as often (11.73% prescriptions recorded as end of 
month, n = 21,757,669). This is still imperfect: in a year, 3.2% of days are ‘end 
of month’ days. However the level of systematic error is lower than with 
dispensing dates. This is important, as many prescriptions last for 28 days, so it 
would be very difficult to build an accurate picture of adherence with over half 
of the records skewed. The paid date variable would be the least suitable, as 
they are all recorded on the end of the month, when the pharmacies submit 
their records for reimbursement purposes. 
The variables relating to quantity in the dataset are the paid quantity (PQ) and 
dispensed quantity (DQ). The PQ variable was used to derive the quantity of the 
drug supplied as it was a complete record, while DQ had substantial records 
missing. Dosing information came from written instructions, which were 
provided in a structured format (more details Section 4.6.6.). 
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Figure 4.1: Frequency of prescribed, dispensed, and paid dates recorded on each calendar 
day of the month. 
4.4.2 Scottish Morbidity Records 
The Scottish Morbidity Record (SMR) records all inpatient and day-case 
hospitalisations in Scotland and is managed by the Information Services Division 
(ISD) of the NHS[182]. SMR01 covers all hospital specialities other than obstetric 
(SMR02) and psychiatric (SMR04) specialties, and the SMR is coded on completion 
of an episode of care due to discharge from hospital; transfer to another 
specialty, ward, or hospital; or death[182].  
Records have a continuous inpatient stay (CIS) marker, which allows transfer of a 
patient between clinicians, wards or hospitals to be linked and recorded as a 
single episode of care, with the final discharge date relating to the patient 
leaving hospital, either by returning home, or by death. This is important when 
conducting secondary analysis, as it is important not to incorrectly list 
movement from one ward to another as two separate incidents and overinflating 
incidence measures. For an adherence study, it is also important to accurately 
assess the date at which a patient leaves the hospital as apparent ‘gaps’ in 
treatment may be identified during a hospital stay. In Scotland, patients are 
encouraged to take their prescription medications from home for in-patient 
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hospital stays[185], meaning that significant gaps in medication coverage are less 
likely to appear in the prescribing data due to hospitalisations.  
The key variables of interest were the patient identifier (this is the study 
generated ID different from CHI, for reasons pertaining to patient anonymity), 
admission date, discharge date, CIS, main diagnosis, and the other diagnoses 
codes (1-5). In the SMR databases, diagnostic codes are recorded using the 
International Statistical Classification of Diseases and Related Health Problems 
(Tenth Revision) (ICD-10). Here, SMR records were used to identify the different 
patient subgroups based on presence of symptoms and past medical history. 
History of CVD was defined by presence of the following ICD10 codes: 
CVD: I20, I21, I22, I23 I24 I25, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69. 
MI: I21 
Stroke: I63 
4.4.3 National Records of Scotland Deaths 
National Records of Scotland are vital statistics recorded by the Scottish 
Government, such as deaths, births, marriages, divorces, and adoptions. From 
here on in this thesis, any mention of ‘NRS’ refers directly to the deaths records, 
as this is the only NRS database which was used.  
The full NRS database contains 156 variables[183], though for this study only 15 
variables were requested, of which 10 were ‘cause of death codes’ (see 
Appendix C: PBPP Application), however, the main/ underlying cause of death 
is the only code of interest when differentiating CVD-mortality from all-cause 
mortality. Cause of death is recorded using ICD-10 codes, which are added to the 
NRS database by software which reads the death certificate and allocates the 
appropriate code, before being checked by a human coder[186].  
The main variables of interest for this study were the unique patient ID (‘PatID’) 
for joining to PIS and SMR records (while the linkage had been performed by 
eDRIS, the datasets were provided in separate files; this study-generated PatID 
81 
 
was used to relate the information in each file together); the date of death 
(‘DOD’) variable was used in data cleaning stages, as well as identifying end-
points for inclusion in various patient subgroups; and cause of death was of 
interest in differentiating CVD-specific mortality when studying outcomes.  
4.5 Defining the Cohort 
The cohort was identified to include all adults aged 18 to 99 in Scotland, who 
had been prescribed an eligible CVD drug between the years of the study period 
(2009 – 2017). Drugs were specified using the British National Formulary (BNF) 
coding system. For any patient included, their entire prescribing histories for the 
dates of the study period were requested to allow assessment of co-morbid 
conditions and polypharmacy. Previous hospital admissions (SMR01) or 
psychiatric hospital admissions (SMR04) were requested for the study period, 
with additional records dating back to 1999 in order to apply a ten year ‘look-
back’ period, for identification of prior disease of interest. A fixed look-back 
period of ten-years was decided, as this was the maximum period available from 
the first date on which individual level, Scotland-wide PIS data were available.  
Those with a cohort entry date later than 2009 had their look-back period 
capped at 10 years, even if hospital records relating to a relevant episode of 
care older than this were available (e.g. those entering the cohort in 2015 would 
only have hospital records used from 2005 onwards) in order to avoid a bias 
whereby people entering the cohort later would be more likely to have had prior 
hospitalisations simply as a result of longer look-back.  
This study used a Scotland-wide cohort of individuals. Inclusion was restricted to 
patients prescribed at least one of the following cardiovascular drugs during the 
study period.  The list of appropriate drugs was produced with the assistance of 
a cardiologist:  
- lipid-regulating drugs (BNF 2.12) 
- diuretics (BNF 2.2) 
- alpha-blockers (BNF 2.5.4) 
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- beta-blockers (BNF 2.4) 
- ACE inhibitors (BNF 2.5.5.1) 
- angiotensin-2-receptor blockers (BNF 2.5.5.2) 
- nitrates (BNF 2.6.1) 
- calcium channel blockers (BNF 2.6.2) 
- other antianginal agents (2.6.3) 
- antiplatelet drugs (BNF 2.9) 
 
Subjects were excluded up until age 18 (n = 23,478 removed), as medications for 
paediatric patients are likely to be administered by parents or caregivers, 
influencing adherence for this group. Furthermore, these patients are less likely 
to have CVD, and congenital heart diseases were beyond the focus of this 
research. Subjects aged over 100 years were also excluded (n = 708). In 2015, 
there was an estimated 900 centenarians living in Scotland[187], accounting for 
just 2.3% of the over 90 population[187]. As this is a relatively small number of 
people, it was decided to remove those over the age of 100, in order to reduce 
the risk of information becoming identifiable. It is also likely that some of the 
birthdates provided for this group were inaccurate, as several patients had an 
age that exceeded records for the oldest known living person. By eliminating all 
centenarians from the dataset, the spurious results were removed with only a 
very small proportion of the “real” cohort being lost.  
PIS records relating to drugs of interest were used to estimate adherence and 
linkage to SMR01/04 and NRS deaths records was also used to identify outcomes 
related to non-adherence.  
4.5.1 Defining key subgroups 
A major hypothesis of this PhD is that patient adherence may be affected by the 
presence or absence of symptoms and whether the patient has undergone an 
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acute, life-threatening event, such as AMI. Therefore, PIS and SMR01/04 data 
were used to define four patient groups within the cohort. At any given 
timepoint, these groups are mutually exclusive; however, patients may move 
from one group to another overtime e.g. a patient in the primary group who is 
latterly prescribed GTN could move to treatment at this point. Patients were 
classified into prevention and treatment groups; each of which was further 
classified into two sub-groups: 
 prevention  
o primary prevention (drugs prescribed to prevent CVD) defined as no 
AMI within previous ten years and no anti-anginal glyceryl 
trinitrate, BNF 2.6.1 
o secondary prevention (drugs prescribed to improve prognosis 
following an AMI) defined as drugs commenced within 42 days of 
hospital discharge following an AMI, and no anti-anginal glyceryl 
trinitrate, BNF 2.6.1 
 treatment 
o treatment / no previous AMI (drugs prescribed to manage disease 
and control symptoms) defined as taking glyceryl trinitrate, BNF 
2.6.1 and no AMI within previous ten years 
o treatment / secondary prevention (drugs prescribed to manage 
disease and control symptoms) defined as fulfilling the criteria for 
secondary prevention group, plus prescribing of glyceryl trinitrate, 
BNF 2.6.1. 
More details of the inclusion and exclusion criteria for these groups and how 
they were determined can be found in Section 4.6.5. 
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4.6 Data Cleaning  
4.6.1 Data Quality Checks 
Checks were carried out to assess the quality of the data. In data quality checks, 
it is important to assess completeness (number of missing or incomplete 
records), correctness (extreme or implausible outliers, for example death 
records preceding hospitalisations or prescription records, or multiple deaths 
recorded for one individual), and consistency (does information that should 
remain the same over time stay that way? For example, date of birth and sex 
should not change for any given person).  
The initial cohort, derived from the listed drugs of interest during the period of 
2009-2017, resulted in almost 2 million subjects (n=1,948,198) (Figure 4.2). 
Following application of the age range inclusion criterion this fell to 1,906,110. 
These were then linked to death data and checked to determine if data errors 
were present: potential subjects were checked for multiple dates of death 
recorded, although none existed, or if their death was listed as having occurred 
prior to admission to hospital or drug prescription. Those who are recorded as 
having a hospital admission following their death date must either have an 
inaccuracy in their death records or in their SMR records, or an inaccuracy in the 
data linkage. Those who die before their first prescription could not feasibly be 
followed up, and some error in the date of death or an error in the date of 
prescription is likely for this issue to arise. Any subject with a prescription 
recorded more than 30 days before their death date were also excluded, with a 
window to allow for delays in processing by the pharmacy. This left a remaining 
1,901,693 subjects who were eligible to be checked for inclusion into the 
different patient sub-groups.  
4.6.2 Reformatting Data and Variable Selection 
All data were imported into R as a .csv file with the argument ‘stringsAsFactors = 
FALSE’. Variables were therefore imported as strings/character variables and 
had to be reformatted in order to be used in later analysis (i.e. factors, 
character, string, numeric). 
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Figure 4.2: Initial data quality checks: reasons for data removal and number of records 
removed. First set of checks carried out on PIS data, while second set of checks included 
information from NRS deaths data and SMR data. 
The default for missing data in R is not applicable (NA). Once a character 
variable is converted into dates, factors, or numerics, any missing records 
default to NA. This was used throughout for ease. 
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4.6.3 Demographic Data 
No demographic description was included in the data output, beyond the 
information contained in the PIS data capture validation and pricing (DCVP) files. 
Therefore, a demographic dataset was constructed by extracting this 
information from the datasets available. The PIS DCVP dataset was used to 
derive a single demographic record for each individual ID, with additional 
information from linked SMR and death records included where applicable. The 
resultant dataset included summary information pertaining to sex, DOB, 
postcode sector, date of entry to study, variables to indicate inclusion into sub-
groups (primary prevention, secondary prevention, treatment/no AMI, 
treatment/secondary prevention), and dates of entry and exit to each group 
(full list of headings and how these were derived in Appendix D: Demographic 
Dataset Assumptions Table). For variables such as DOB and sex, which would be 
expected to remain constant overtime, counts were added for the number of 
times details appeared together. The number of cases where DOB changed for an 
individual was (n<10) and no individuals were recorded as having changed sex 
(Figure 4.2). In the former cases, the most commonly occurring DOB was 
selected for inclusion in the demographic file, likely eliminating spurious data 
entries (for example, a mis-typed DOB). There were no ties, i.e. no one 
individual recorded as having two different DOBs with the same frequency. 
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4.6.3.1 Entry Dates 
Cohort entry dates for each subject were defined as the first prescription date 
recorded for an eligible drug. This was used to check against inclusion and 
exclusion criteria for each of the main patient groups; for example, in defining 
the primary group, the 10-year look-back period to check for previous history of 
CVD would range from the entry date to 10 years previously.  
Demographic Date Variable Definition 
Entry Date First date in study period (between April 2009 – March 2017) 
where drug of interest (as listed section 4.5 Defining the 
Cohort) was prescribed for individual patient. 
Primary Start Date Date of first prescription for all primary subjects. Same as 
entry date, as inclusion criteria for this group does not allow 
inclusion in any other group beforehand.  
Treatment Start Date Date of first GTN prescription within the study period. May be 
the same as the entry date if GTN happens to be the first drug 
of interest prescribed. 
Secondary Start Date Date of first prescription following MI during study period. 
Must be within 6 weeks of hospital discharge. 
Secondary with Treatment 
start date 
Date of first GTN prescription following inclusion in secondary 
group. 
Table 4.2: Describing the different start date variables. 
Records from January, February, and March 2009 were excluded (Figure 4.2) as 
all records in this timeframe had a prescribed date listed as the end of the 
month. This does not give a great enough level of granularity for estimating 
adherence, as it creates a four-week window of potential error.  
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4.6.3.2 Age at First Prescription 
From PIS, age at first prescription was evaluated by adding a dummy day column 
of ‘01’ to the DOB variable (given in the format mm/YYYY) and transforming into 
the format YYYY/mm/dd using the lubridate package. The interval between this 
date and the date at which each individual was first prescribed an eligible drug 
was then calculated to give an age variable and added as a column to the data 
frame.  Ages were also recalculated in a similar way when subjects entered a 
different sub-group (primary, secondary, etc.). 
4.6.3.3 Socioeconomic Status 
The measure of area-based socioeconomic status was provided by eDRIS. The full 
patient postcode held within PIS was used to derive the Scottish Index of 
Multiple Deprivation (SIMD) 2012, a metric derived from 38 indicators across 
seven distinct domains[188]: employment, income, health, education and skills 
training, crime, geographic access to services, and housing[188]. Each of the ten 
domains are given a standardized weighting and combined, which can be used to 
rank each postcode area in the country in terms of relative deprivation[188]. The 
advantage of using an index such as SIMD is that it is calculated using routinely 
collected administrative data, and hence can be updated more regularly than 
Townsend or Carstairs measures, which rely on census information[189]. However, 
as it is an area based measure, there is a possibility of misclassification at an 
individual level[190], particularly in rural or remote areas where data-zones may 
cover a larger and more variable population group[190]. 18% of Scotland’s 
population were classed as living in accessible rural or remote rural areas in 
2013, accounting for 97% of land, and so this may have an effect on SIMDs 
recorded[191].  
The information provided for this study grouped overall SIMD-2012 scores into 
deciles and quintiles, categorising each postcode sector between 1-10 or 1–5 
respectively, with 1 being most deprived and 10 or 5 being least deprived. SIMD 
information is based on weightings across the general population within Scotland 
and not limited solely to the study population. 
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SIMD information was taken from the details correct at the date of index 
prescription. Although SIMD may be subject to change, for example, if an 
individual moves to a new home which is in a different postcode sector, and 
hence a different data-zone which may be associated with a different SIMD-2012 
value, to study this as a factor we want to take the measure of socioeconomic 
status from a fixed point in time to allow comparability. Best practice is to use 
the index closest to time when the data is extracted[189]; although some within 
our cohort will have a cohort entry date closest to the SIMD-2009, and others 
will be closer to SIMD-2016, SIMD-2012 is more representative of the cohort as a 
whole. It is also important to take socioeconomic information from earliest 
possible time-point to prevent identifying cases of reverse causation[192], for 
example, if a patient becomes ill and is unable to work, this may impact their 
ability to pay rent, leading to reduced social mobility, which could in turn 
prompt a move to an area which is less affluent[192].  
4.6.4 Prescribing Information System Data 
The PIS data provided were given as two separate file types: data capture 
validation and pricing (DCVP) files, which contains prescribing, dispensing and 
paid dates, drug ID, BNF codes, drug formulations, drug strengths, and the 
quantity prescribed, dispensed, and paid. The other file type included dosage 
instruction information, which had been extracted from written messages 
provided on all ePrescribed items using a natural language processing (NLP) 
algorithm[166]. This was linkable to DCVP files through a dosage information key 
and a lookup-file.  
4.6.5 Primary, Treatment, Secondary, Secondary-with-Treatment:  
The key patient subgroups in this study were created as it was hypothesised that 
adherence differs by disease severity, and that the consequences of non-
adherence may also differ according to this. Conceptually, the primary 
prevention group are people with no history of myocardial infarction and no 
angina (defined by no concurrent prescription of GTN); the treatment group had 
symptomatic CVD (as evidenced by GTN prescription); the secondary prevention 
group had suffered an AMI and were recieveing follow-up prohylaxis to prevent 
future CVD events; and the secondary-with-treatment group included those who 
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had suffered an AMI and receieved prohylactic medication, but also had 
additional evidence of symptomatic CVD (as evidenced by GTN prescription).  
Patients could move group over time based on changes to their medical 
circumstances. Patients who fulfil criteria for the primary prevention group and 
who later receive a GTN prescription could move into the treatment group at 
this point. Similarly, those who suffer a subsequent MI could then be moved into 
the secondary group providing they receive a relevant prescription; and so on. 
Information from SMR01 was required prior to defining subgroups in order to 
identify previous CVD hospitalisations which affect inclusion within the different 
patient groups, and subsequent hospitalisation events that rule individuals out of 
each group. The following section describes how these groups were derived from 
the data. Figure 4.3 shows potential pathways through the different subgroups, 
while Figures 4.4, 4.5 and 4.6 depict the selection process into each of the 
subgroups. 
 
Figure 4.3: Possible pathways for an individual through the four main patient subgroups 
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4.6.5.1 Primary prevention 
Subjects were defined as being in the primary prevention group if they had been 
prescribed any of the drugs (listed) other than GTN during the study period and 
had no hospital record with a CVD disease code (listed) recorded in the main or 
any position, in the ten years preceding their index date. Subjects were 
excluded from the primary prevention group if they had a concurrent 
prescription of gylceryl trinitrate (GTN) with the BNF code starting with 
‘0206010FO’ as this indication is exclusively for management of angina and 
would be classed as a symptomatic disease (treatment group). The primary index 
date was the date of a subject’s first relevant CVD drug prescription within the 
study period. The primary end date was the date at which subjects left the 
group, either due to a change in status to secondary or treatment group, or 
exclusion from group due to hospitalisation with a CVD disease code (listed), 
death, reaching 100 years of age, or end of follow up.  
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Figure 4.4:  Flowchart of Inclusion and Exclusion for Primary Group  
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4.6.5.2 Treatment 
Subjects were included in the treatment group if they had a prescription of GTN 
during the study period. Those who had suffered an AMI in the 10 years prior to 
their first GTN prescription (listed under main condition in their associated SMR 
record) were excluded.  
Date of entry to the treatment group was classified as the date of first GTN 
prescription with the BNF code starting with ‘0206010FO’. As GTN is for 
management of an ongoing episode of angina, or prevention of an imminent 
attack, adherence to this drug could not be calculated, so subjects would also 
need to have a prescription of another drug of interest in order for adherence to 
be modelled.   
End points for inclusion in the treatment group are; hospitalisation with AMI, 
death, turning 100, or end of follow up (Figure 4.5).  
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Figure 4.5:  Flowchart of Inclusion and Exclusion for Treatment Group 
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4.6.5.3 Secondary 
Subjects were included in the secondary group if they suffered an AMI during the 
study period and had a subsequent prescription of a relevant CVD drug (other 
than GTN) within a specified timeframe. Of the group identified, those who had 
a concurrent prescription of GTN and those who had had a prior MI in the 10 
years preceding this (listed under main condition in their associated SMR record) 
were excluded.  
Secondary start date was calculated by identifying all MIs that occurred during 
the study period (2009-2017). For each subject, their first MI in this time frame 
was identified, and this was linked to PIS to identify those who received a 
prescription of a relevant drug within 6weeks (42 days) of discharge.  
End points for inclusion in the secondary group are; prescribed GTN, death, 
reach age 100, or end of follow up. Those prescribed GTN move into the 
‘Secondary-Treatment group’ (Figure 4.5).  
4.6.5.4 Secondary-Treatment 
The secondary-treatment group was conceptually separate from the secondary 
group, as it was hypothesised that patients who are high risk (following AMI) and 
have current symptomatic CHD may have different adherence behaviours to 
those who are simply high risk but with no symptomatic CHD. Therefore, all 
patients who had previously been sorted into the secondary group and then 
received a prescription of GTN moved to ‘secondary-treatment’.  
The start date for this group was the date of first GTN prescription following 
inclusion into the secondary group. End points for inclusion are; death, reach 
age 100, or final record relating to that individual (Figure 4.5). 
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Figure 4.6:  Flowchart of Inclusion and Exclusion for Secondary and Secondary-Treatment 
Groups. 
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4.6.6 Dosage instructions 
Information on dosage instructions was provided by eDRIS for the cardiovascular 
drugs specified, derived from free-text dosage instructions using a natural 
language processing (NLP) algorithm[193]. Dosage instruction data were held in a 
separate file from other PIS records, which could be linked via a barcode key. 
The NLP algorithm has a reported accuracy of 94.2%[193] and gives a structured 
output for 96.8% of cardiovascular drugs[193], giving it a very high capture rate 
for this therapeutic area. Here, only 90.4% of CVD records had a link to dosage 
instruction data, with a complete link (after cleaning) in only 88.8% of records. 
This discrepancy will be partly due to the fact that this dataset only has 
information on the specified CVD drugs of interest, and these may have a lower 
capture rate than the average across all CVD drugs. Also, due to the greater 
level of information required for this project, the dosage instruction information 
had to be of a high standard and so some which had a link to dosage information 
had to be rejected for other reasons, as detailed below.  
Due to the scale of the data (185,427,312 CVD prescription records), processing 
of dosage instruction data was split into drug categories: Diuretics (BNF 2.2), 
Beta-blockers (BNF 2.4), Alpha-blockers (BNF 2.5.4), ACE-inhibitors (BNF 
2.5.5.1), Angiotensin-2-receptor blockers (BNF 2.5.5.2), Nitrates (BNF 2.6.1), 
Calcium Channel Blockers (BNF 2.6.2), Other Anti-anginal agents (BNF 2.6.3), 
Antiplatelet drugs (BNF2.9), and Lipid-regulating drugs (BNF 2.12). Quality 
checks were carried out to ensure that the dosage units (e.g. mg, ml, spray, 
inject), were appropriate given the specific drug to which they related; for 
example ‘spray’ is an appropriate dosage unit for Glyceryl Trinitrate (GTN) as 
this drug is available in a spray formulation for common use, though it would not 
be appropriate for Amlodipine or Simvastatin as these are commonly prescribed 
as a capsule or tablet and do not come in a spray formulation. Equally, a dosage 
unit of “ml” would not make sense for a drug that is not available in a liquid 
formulation. Some such errors could arise from incorrect linkage to the dosage 
instructions or errors with the NLP algorithm identifying information from the 
free-text instructions. However, these errors were rare, accounting for 0.02% of 
all records (n = 44,793; of which, 25,957 are diuretics) (Table 4.3). A validity 
flag was created to highlight these erroneous records, as well as to highlight 
records which did not have any link to dosage instruction data, which made up  
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Table 4.3: Data cleaning for dosage instruction data – reasons for days coverage variable 
requiring imputation and counts across drug classes  
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9.6% of records (n = 17,803,761) (Table 4.3). Other data quality issues included 
incomplete dosage instructions, either due to missing dosage amount or having 
no timing or dosage interval given, respectively accounting for 1.34% and 0.25% 
of all records (Table 4.3).  
All records considered ‘valid’ at this stage were then processed to calculate a 
‘days-coverage’ (DC) variable (as detailed in Section 4.7.1). Records that had 
not been highlighted by previous quality checks but that also did not fulfil the 
criteria of any of the functions used to calculate DC accounted for 0.01% of 
records (n=17,057).  
Once the DC variable was calculated, further quality issues could be assessed as 
some records appeared to have either exceptionally high or low days coverage. 
This was often due to improbable paid-quantity values, for example, a drug 
which is usually dispensed in packets of 56 tabs having a paid quantity of 5,656. 
While a 56-tablet packet would last 2 months given a prescription of 1 tab per 
day, a packet of 5,656 would last 101 months, or 8.4 years. On the other 
extreme, paid quantities were sometimes given as 0.28 – an unlikely value given 
the challenge in providing this proportion of a tablet to a patient. These errors 
are likely to be mis-typed values. Furthermore, even if these values were 
accurate, they would be challenging to work with when estimating adherence 
overtime. Therefore, a cap of 168 days (6 months) was set as an upper limit for 
days covered, and 7 days (1 week) as a lower limit and any days-coverage values 
outside of this range were set as ‘NA’. These accounted for 0.05% of records (n = 
98,224). 
For the records identified as having an implausible days-coverage, and the 
remaining records which did not have a days-coverage value, either due to 
missing linkage to dosage instructions or data quality issues, imputations were 
carried out, as detailed in Section 4.8.1. 
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4.7 Drug utilization data 
4.7.1 Derivation of Days Coverage 
A vital piece of information for measuring adherence is the length of time that 
the prescription would be expected to last, or the day’s coverage (DC) value. 
The dataset provided included a defined daily dosage (DDD) variable which has 
previously been used in similar studies to calculate the drugs coverage; however, 
this is not always a reliable measure as the DDD is derived from the most 
common indication of a drug at a global level and therefore, may not be 
applicable in every instance. A robust method for calculating coverage is to use 
dosage instructions provided to the patient, along with the quantity of the drug 
prescribed (paid quantity, PQ). Table 4.4 details the variables provided by eDRIS 
which relate to dosage information. 
Table 4.4: Dose information variables provided in dataset 
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To estimate a DC value, the dosage instructions data was used, along with other 
variables from the PIS DCVP files: Patient ID (PatID), quantity (paid_quantity), 
and details about the specific drug (bnf_item_desc, bnf_item_code, and drug 
class – derived from BNF item code). Multiple functions were developed to 
extract a DC value for each record (Table 4.5), with variations in the code to 
allow for differences in the data available – most notably, calculating DC using a 
timing frequency differs from using an interval. For a simplified example, a 
prescription where a patient is prescribed 56 tablets with bi-daily dosing may 
have the instructions “take 1 tab twice a day” (timing frequency = 2; amount = 
1) or this could be written as “take 1 tab every 12 hrs” (interval = 12; amount 
=1). To derive DC, calculations would differ as so: 
 
Most records fulfilled the requirements for Method A (87.37%, n = 162,008,395), 
which included all records that did not have a specified amount unit (e.g. 1 per 
day), used timing frequency with either a non-specified timing unit or given as 
“day”, and which had passed initial data cleaning checks (as detailed in Section 
4.6.4). All other methods accounted for far fewer records, ranging from 0.001% 
(Method E) to 0.064% (Method D). 
  
Days coverage 
= paid quantity/(amount * timing frequency) 
= 56/(1*2) 
= 28 
Days coverage 
= paid quantity/(amount * 24/interval) 
= 56/(1 * 24/12) 
= 28 
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Table 4.5: Methods used to derive days-coverage and counts of records for which these 
applied, across drug groups.  
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After all 7 methods had been sequentially run, any remaining records without a 
DC, or those with a DC below 7 days or above 6 months, had to be imputed. 
Imputations were carried out sequentially (Table 4.6). First, by last-observation 
carried forward (LOCF) and then last-observation carried back (LOCB), Mean (for 
specific drug and paid-quantity for that patient), Mean (for specific drug and 
paid-quantity but across patients), Mean (for that specific drug for that patient 
but with any paid-quantity – thus accounting for records with suspicious paid-
quantities as detailed previously). The majority of imputed records (55.07%) 
were imputed by the method whereby the mean days-coverage was taken across 
records for a specified drug, strength, formulation, and paid-quantity. 
Table 4.6: Imputations for days coverage value  
4.7.2 Repeat Prescriptions  
Repeat prescriptions are commonly used, particularly for chronic conditions. To 
account for repeat prescriptions, records with the same patient ID, prescription 
date, dispensed date, drug approved name, drug formulation, drug strength, and 
paid quantity were grouped together and counted to create a new variable 
indicating the number of repeats (‘n_repeat’). For example, if there was only 
one record where the patient ID, prescription date, dispensed date, etc., were 
identical, then n_repeat would be equal to 1; if there were two records where 
all of these variables were identical, then n_repeat would be equal to 2; and so 
on.  
104 
 
Using the n-repeat variable, it was possible to cap the maximum number of 
identical repeat prescriptions that seemed likely to be correct. There are 
reasons that multiple prescriptions may be collected on the same date; if a 
patient is going on holiday, they may need to collect additional supplies to cover 
their time away, or they may collect extra to pre-emptively avoid repeat visits 
to the pharmacist. However, in some cases these identical records appeared to 
be spurious – e.g. 6 identical records, which would provide 6 months coverage, 
however, prescriptions still being routinely collected in each of the 6 months 
following. This could be a case where a 6 month repeat prescription is made but 
has erroneously been replicated as multiple records. For this reason, repeat 
prescriptions were capped at 2 when the initial adherence estimates were 
calculated, comparing across the different disease severity, drug class, and 
demographic groups.   
4.8 Chapter Summary 
Data cleaning is a long and arduous process, though it is important to record the 
details of this meticulously, particularly when using secondary data sources to 
ensure that work can be reproduced and held up to scrutiny. Here, the data 
sources and access has been described, along with a through explanation of the 
different patient sub-groups, as well as the steps taken to derive a key variable 
to adherence study, days-coverage, from the dosage instruction information. 
Further details on how adherence was defined and derived are included in the 
Chapter 5.  
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5 Methods Chapter: Analysis Methods 
 
This chapter will detail the different analysis methods used for this thesis, 
including methods of measuring adherence and persistence and the underlying 
assumptions made, and detail of data preparation and tools used for univariate 
and multivariate modelling.  
5.1 Defining variables for univariate analysis 
Sex: Sex was derived from the chi-number, as previously described in this thesis. 
In the dataset provided, 1 indicated male gender, while 2 indicated female 
gender. Reporting throughout will indicate male as ‘M’ and female as ‘F’.  
Age: Age was divided into three broad groups: below 55-years old, between 55 
and 65 years, and above 65 years. As prior exclusion criteria ruled out those 
below the age of 18 and above the age of 100, these ages form the lower and 
upper bounds of the below-55 and above-65 groups respectively. These narrow 
age groups were defined for ease of analyses, allowing comparison across 
categorical risk-factors. The specific age bands selected were based around 
expected relevance to CVD adherence following literature review, and the ‘n’ 
shaped relationship between age and adherence.  
SIMD: SIMD was derived from the SIMD-2012 deciles and divided into three broad 
groups: low (SIMD 1-3), mid (SIMD 4-7), and high (SIMD 8-10).  
Comorbidity status: Following on from the systematic review of cardiovascular 
adherence studies (Chapter 2), there were two main comorbidities associated 
with cardiovascular adherence: diabetes has been noted to have a positive 
association with adherence, while depression tends to be associated with a 
reduction in adherence. It was for this reason that these two specific 
comorbidities were chosen for further interrogation. Therefore, the specific 
groups compared in the analysis were: neither comorbidity, diabetes only, 
depression only, both (diabetes and depression). 
To define each of these comorbidities within the dataset, PIS data was used to 
identify relevant prescriptions for each. Some prescriptions led to exclusion from 
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the analysis, as patients with these could not confidently be classed as having or 
not having the relevant comorbidity. This criterion was defined with help from a 
clinician and built on definitions used in prior research involving PIS data[194]. 
Tables 5.1 and 5.2 show the inclusion and exclusion criteria for these.  
 
Table 5.1 Defining patients with diabetes using PIS data 
 
Include if prescription of any drug from BNF Chapter 4.3 ‘Antidepressant 
Drugs’ code: filter(grepl(“^0403”, PIBNFItemCode)) 
Include if Drug received within one year of start date/ date of 
inclusion into patient group. 
Exclude if Any of the ‘unknown’ drugs 
for depression are 
prescribed, without 
eligible antidepressant 
medications prescribed. 
These drugs have other 
indications as well, so 
prescription of this alone 
cannot indicate 
depression.  
‘Unknown’ drugs: 
Amitriptyline (if less than 
75mg), duloxetine, 
flupentixol, moclobemide, 
reboxetine, agomelatine, 
phenelzine, 
tranylcypromine, 
tryptophan. 
Table 5.2 Defining patients with depression using PIS data 
 
 
Include if prescription of any drug from BNF Chapter 6.1 ‘Drugs Used in 
Diabetes’ code: filter(grepl(“^0601”, PIBNFItemCode))  
Include if Drug received within one year of start date/ date 
of inclusion into patient group. 
Exclude if Any of the ‘unknown’ drugs for depression are 
prescribed (see Table 5.2) without eligible 
antidepressant medications also prescribed; cannot 
differentiate people with diabetes only from people 
with diabetes and depression on basis of these 
drugs alone.  
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5.2 Adherence measures: treatment anniversary model, 
proportion of days covered, and combined measure. 
5.2.1 Justification of adherence measures and assumptions used 
Chapter 3 details methods commonly used in adherence research and justifies 
the use of methods chosen for this study. A basic and technical definition of 
these is provided in Table 5.3. 
Adherence measure name, 
(acronym) 
Basic definition Technical definition and 
parameters set for study 
Treatment anniversary 
model (TAM) 
Is patient still taking any 
drug in class X at 12-month 
anniversary time point? 
 
Patients persistent at 12-
month anniversary for any 
drug within class, defined 
by a relevant drug 
prescription within 56 days 
before or after the 
treatment anniversary 
date. 
Combined measure: 
Proportion of days Covered 
for persistent patients 
(PDCp) 
Of patients who are still 
taking a drug in class X, is 
their drug supply/ coverage 
at least 80%? 
Of patients who were 
considered persistent at 12-
months with TAM: Patients 
classed as adherent if 
supply for drug class covers 
≥80% of the time in the 12-
months since first 
prescribed. 
Proportion of days Covered 
for all patients (PDCa) 
Of any patient initially 
prescribed a drug of class 
X, is their drug supply/ 
coverage at least 80%? i.e. 
includes patients who are 
not persistent as defined by 
TAM, as well as those who 
are. 
For all patients who are 
included; those classed as 
adherent if supply for drug 
class covers ≥80% of the 
time in the 12-months since 
first prescribed. 
Table 5.3 Adherence measures used; their basic and technical definitions 
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As has previously been highlighted in this thesis, adherence research has been 
plagued by a lack of standardisation. For this reason, it is important to select 
methods that closely fit the guidelines for adherence research, as laid out by 
Vrijens et al, while allowing for any limitations in the data available.  
When selecting a tool for adherence measurement, it is important to consider its 
computability, usability, validity, and comparability. The TAM and PDCp 
combined measure was used, as this method is considered valid, and it is 
described as such in ‘Drug Utilization Research Textbook’ – written in part by 
key adherence researchers. The combined measure is also used in some previous 
studies[195, 196]. This is also relatively straightforward computationally, which is 
important when using a large dataset.  
In estimating persistence with TAM, the gap used here is generous: 56 days 
either side of treatment anniversary date i.e. a four-month gap. This gap-length 
was chosen as 56 days is a common drug supply length in our dataset, so a 
shorter gap may have missed out lots of prescriptions. Also, some gap is 
permissible, as we do not want to erroneously classify people as nonpersistent if 
they have just taken a gap in treatment. Other studies use a similar method 
where they look to see if a prescription was filled in the last 90-days of a 365-
day period[197]. TAM is a good way of comparing adherence across a fixed time-
frame but may not take into account the fact that adherence declines over time. 
This is why adherence at one year is compared between groups, as the 
comparatively longer the follow-up times in the primary and treatment groups 
could otherwise bias results.  
For patients who were found to be persistent with TAM, implementation was 
estimated using the PDC method with an 80% cut-off. The number of days 
covered with a drug supply for the first year of treatment was summated, 
divided by 365 and multiplied by 100 to give a percentage of days across the 
year where a patient had access to the drug. Patients were classed as adherent 
if their drug supply was ≥80% for the year from their first prescription of any 
drug in a particular class. This measure was labelled PDCp, as it is a 
straightforward PDC calculation for the persistent group. 
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A standard PDC measure, PDCa, with no consideration of persistence, was also 
included for comparability to other studies. This was calculated in the same way 
as PDCp, though also included patients who had not been classed as persistent, 
and it is a commonly used metric. For all three measures of adherence, a 
number of underlying assumptions about the data needed to be made and 
maintained, as detailed in Table 5.4. 
 
Decision   Assumption made and limitation 
How to define start and end 
dates 
Start: first prescription of any drug in specific class, 
following inclusion in patient group (primary, 
secondary etc). Note an individual patient may have 
multiple start dates/ one for each group they meet 
the inclusion criteria for and one for each drug-class 
prescribed. End: Treatment anniversary date (1 
calendar year from start date). 
How to determine treatment 
initiated (note: 10% of all 
prescribed never filled) 
 
All records provided in the data output have been 
dispensed by the pharmacy, therefore assume 
patient has at least collected prescription/ has 
possession of drug. Assume initiation in all cases. 
How to handle people who 
fulfil an exclusion criterion 
before end of adherence 
measurement period 
Censor those who die/ turn 100/ have a subsequent 
CVD event that would lead to exclusion from the 
group. This is to reduce underestimation of 
adherence e.g. those who are dead cannot be 
expected to adhere to treatment 
How to handle stock-piling/ 
carry-over 
Cap 1-year PDC at 100%. Preferable to specify an 
allowed carry-forward of drug coverage for each 
individual prescription, rather than averaging across 
the whole year.  
How to handle switching Patients must adhere/ persist to any drug within 
that same class (of the ten classes defined for this 
study). May underestimate adherence where people 
switch between classes for the same indication or 
may overestimate adherence if two drugs of one 
class are prescribed concomitantly. 
 
How to consider regimens with 
multiple drugs 
Looking at adherence/ persistence on a class-by-
class basis. May overestimate adherence, especially 
in secondary group where SIGN guidelines indicate 
patients should be taking drugs of multiple classes in 
the year following an MI. Therefore, to be truly 
adherent to their regimen, adherence to multiple 
drug-classes may be important.  
 
Table 5.4 Assumptions made in defining adherence 
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5.3 Initiators vs non-initiators  
As the TAM and PDC were calculated within each of the patient groups for the 
first year that an individual patient used a particular class of drug, it was 
important to identify new/ incident users of a drug. For the primary and 
treatment groups, it is possible that patients would have been prescribed these 
drugs and would have been eligible for inclusion within this group prior to 2009, 
before data for this study was available. Therefore, a minimum drug-free period 
(a minimum amount of time without any prescription of a given drug-class prior 
to initiation) had to be set to determine new-users of a drug-class vs continuing 
users. This is important as adherence declines overtime (see Chapter 2 - 
systematic review) and so including continuing users in the year-one analysis 
could introduce bias. When deciding a minimum drug-free period, there must be 
a balance between using a shorter period, as many will be counted incident 
users even when it is not truly their first-use; and using a longer period, which 
may be more accurate, but which could reduce the size of the cohort and lead 
to loss of information. Here, any patient in the primary or treatment groups who 
had their first prescription in 2009 was excluded from the analysis. 
In the secondary and secondary-treatment group, all patients were classed as 
incident users due to their change of status, leading to inclusion into the group. 
People who could have been eligible for inclusion in secondary group prior to PIS 
data availability were removed by dint of the exclusion criteria, stating that 
those with history of an MI hospitalisation in the ten-years prior would be 
excluded, and so all in this group can be classed as new secondary-users (refer 
back to Chapter 4 for more information on inclusion and exclusion criteria for 
the four patient groups). The same is true of the secondary-treatment group, as 
patients must have had an MI during the study period and move through the 
secondary group in order to be included.  
 
5.4 Univariate analyses 
Initial analyses was carried out to identify levels of adherence across different 
patient groups (primary, treatment, secondary, and secondary-with-treatment) 
and for the different factors (age, sex, SIMD, and comorbidity), giving rise to 16 
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univariate tables (see Chapter 7), plus one last table comparing overall 
adherence levels between each of the patient groups.  
Within each group, patients were subdivided into the different factor levels (e.g. 
for sex, patients were divided into M and F) and into the 10 different drug-
classes of interest (alpha-blockers, ACEi’s, anti-anginals, etc). During the time in 
which a patient was eligible for inclusion in any given group, the date they were 
first prescribed a drug of any particular class was identified, and the treatment 
anniversary was calculated from this date plus 365 days. Therefore, any one 
individual patient could be represented numerous times within the data, 
depending on the number of different drug classes they were treated with while 
included in any one patient group, and depending on the number of groups they 
are included in over time; patients would have a different start date and 
anniversary date for each instance. 
Adherence was expressed as the percentage of patients in the group who started 
treatment with a given class of drug and who did not leave the group before the 
end of the treatment anniversary period. P-values were calculated using chi-
squared tests, or for groups where n<5, Fischer’s exact test was used instead.  
 
5.5 Multivariate analyses 
 
At the annual ESPACOMP 2020 meeting round table discussion, a room of experts 
in adherence research agreed that ‘persistence’ is the preferred metric of 
adherence to study[198], over and above the two other metrics of initiation and 
implementation. It is for this reason, and because sensitivity analysis found little 
difference in outputs between the measures, that the TAM was used in the 
subsequent multivariate analysis and survival analysis.  
For the multi-variate analysis, we also chose to refine focus to four key drug-
classes for clarity of information: ACE-inhibitors, antiplatelets, beta-blocker and 
lipid-regulatory drugs. These are the most commonly used drug-classes across 
the data.  
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To perform multivariate analysis the R-package finalfit was used. The function 
glmmulti() was used to perform a multivariate analysis, namely a logistic 
binomial regression, for each risk-factor(sex, age etc.) within each patient group 
and drug-class. The models from this were then run through the function 
fit2df(), along with the R-Markdown function kable(), to visualise outputs as a 
table. Here, a logistic binomial regression was chosen as the outcome variable 
was binary (persistence yes or no), while the predictors were the risk factors of 
interest. Logistic regression is common statistical technique used to identify 
relationships between variables and is particularly useful as it allows inclusion of 
multiple variables in one model. Addition of each predictor variable was 
considered incrementally, meaning that first the analysis was performed 
including sex and age only as predictors, then sex, age, and SIMD-group, then sex 
age, and comorbidity status; and finally, sex, age, SIMD-group, and comorbidity 
status. Only the final models are shown in Chapter 7, presented as forest-plots, 
with additional models presented in Appendix E. For each model, the ‘goodness-
of-fit’ was assessed by calculating the C-stat.  
5.6 Outcomes of Non-persistence   
To investigate the association between CVD drug adherence and clinical 
outcomes, Cox-proportional hazards models were performed for each patient 
subgroup (primary, treatment, secondary, secondary-treatment) and for each of 
the drug-classes (ACEi, antiplatelet, beta-blockers, lipid-regulatory) for all-cause 
mortality 5-years after the study-period (i.e. the first year of medication for 
which patient was determined persistent or nonpersistent). The function 
finalfit() from R-package finalfit was used to calculate Cox-proportional hazards. 
Results are presented to include univariate and multivariate hazard ratios for 
each of the risk factors included in the model.  
Survival plots were constructed using the function surv_plot(), also from the 
finalfit package, in order to test an underlying assumption of Cox-proportional 
hazards, that the hazards remain proportional overtime (i.e. that survival curves 
do not cross). Schoenfeld residuals were also performed (included in Appendix).  
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5.7 Investigating Potential Confounding 
Initial investigations of Cox-proportional hazards modelling produced some 
results that warranted further investigation (Results presented in Chapter 8). 
Inclusion of a ‘drug-count’ variable to account for cardiovascular polypharmacy 
was added to the analysis. All-cause mortality at 1-year after the study periods/ 
-year on from when patients were defined as persistent or non-persistent was 
also included to investigate the shorter-term association between adherence and 
outcomes, and to acknowledge that adherence levels may have changed over the 
time of follow-up. In two drug-classes, beta-blockers and antiplatelets, a 
comparison of persistence to individual drugs was performed. Additionally, to 
account for the potential that some patients were prescribed beta-blockers for 
anxiety rather than CVD, we repeated analysis in the primary prevention group 
excluding those who we could not confirm as having CVD. Using guidance from a 
clinician, we only included patients who had been prescribed a beta-blocker 
alongside CCBs or ACEi’s into the new analysis.   
5.8 Chapter Summary  
This chapter has provided an overview of the measures used to define adherence 
and persistence, as well as the statistical analyses performed, and the further 
investigations conducted to identify possible sources of confounding.  
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6 Results: Summary Statistics 
This chapter details descriptive statistics about the study data, including 
summaries of the four main patient subgroups, CVD drug prescribing during the 
study period, common causes of death, and common causes of hospitalisation. 
6.1 Summary Statistics: Patient Cohort 
Table 6.1a: Demographic summary statistics for full cohort  
Table 6.1a shows demographic information for the full patient cohort, including 
those who were excluded due to failure to fit criteria for any one patient group. 
This provides contextual background information, and somewhat suprisingly 
indicates a greater representation of female compared to male patients (54.8% 
vs 45.2%). The average age is ~60years, and there is a slightly lower 
represntation of people from SIMD 5 (affluent), incrementally increasing with 
each lower SIMD grouping.  
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Table 6.1b: Demographic summary statistics for primary prevention, secondary prevention, 
treatment, and secondary-treatment sub-groups 
There were differences in key characteristics across the four patient groups 
(Table 6.1b). The primary prevention group was over 6 times larger at 1,659,566 
patients, compared to the next largest group, the treatment-group, at 260,526. 
The secondary prevention group and secondary-with-treatment group were much 
smaller at 25,283 and 23,866 patients respectively.    
There were differences by sex between groups: in the primary group, 57% of 
patients are female, whereas in the other three groups, less than half of the 
patients are. In the treatment group there is a roughly 50:50 split, with 51% 
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male vs. 49% female, while in the secondary and secondary-treatment groups, 
~64% are male vs just ~36% female. 
Mean age of entry to each of the patient groups also differs substantially 
between the primary group and the three other patient groups. On average, age 
of entry to treatment, secondary, and secondary-treatment group is ~8 years 
older than that of the primary.  
Across the four groups the distribution of SIMD is largely similar, with the most 
affluent quintile (SIMD 5) being least represented, making up 14.6-17.4% of each 
of the groups. The most deprived quintile (SIMD 1) is also the most represented 
SIMD across the four patient groups, making up between 22.0-25.7%. 
6.2 Summary Statistics: Prescribing within patient 
groups 
The larger number of patients in the primary prevention group compared with 
the other three patient groups likely contributes to the total combined patient 
years being much larger (Table 6.2), 6.5x more than the total patient years of 
the next largest group, the treatment group. However, when patient follow-up is 
considered as a median per patient (i.e. how long people tended to stay in the 
group) this gap narrows somewhat, with patients being in the primary group for 
5 years and 5 months vs. 4 years and 10 months in the treatment group. In the 
secondary group, mean follow-up time is very limited, at just over 3 months. 
The main reason for patients leaving this group is prescription of GTN, so it is 
likely that this is due to patients moving to the secondary-treatment group. As 
well as this, patients who have suffered an MI are at a greater risk of subsequent 
MI, stroke, or death compared to the primary and treatment groups, possibly 
contributing to this also.  
Polypharmacy is much higher in the treatment, secondary, and secondary-with-
treatment groups compared to the primary, with over half of the patients in this 
group receiving more than five different drugs during their first year upon 
entering the study group, compared to just 19% of the primary group. Less than 
1% of patients in the more severe CVD groups receive just one drug, compared to 
18% of the primary group.   
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Table 6.2: Summary statistics for primary prevention, secondary prevention, treatment, and 
secondary-treatment sub-groups 
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The drugs most commonly prescribed also differ between groups. As GTN is an 
inclusion criterion for the treatment and secondary-treatment groups, 100% of 
these patients have a prescription for it, though as an exclusion criterion from 
the primary and secondary prevention groups, it does not feature for these 
patients. Aspirin is also one of the most common drugs prescribed in all patient 
groups and is prescribed in over two-thirds of patients in the treatment, 
secondary, and secondary-treatment groups. Statins are also common (Table 
6.2), with simvastatin and/or atorvastatin being in the five most common drugs 
for each of these groups. Ramipril is the most common ACEi drug represented 
across the four patient groups; amlodipine is the most common CCB; 
bendroflumethiazide is the most common diuretic drug; bisoprolol fumarate is 
the most common beta-blocker; and clopidogrel is the most common antiplatelet 
other than aspirin.  
6.3 CVD Drug Prescribing  
Overall, the most commonly prescribed CVD drug-class in the cohort was lipid-
regulating drugs (BNF 2.12), while the least commonly prescribed was the anti-
anginal drugs (BNF 2.6.3) – See Figure 6.1. Of the lipid-regulatory drugs, the 
most commonly prescribed therapeutic was simvastatin. During the years of the 
study period, prescribing of antiplatelets and diuretics showed a general decline 
(n= 3,015,090 patients prescribed with antiplatelets in 2010 vs. n= 2,649,786 in 
2016; n= 2,980,971 patients prescribed with diuretics in 2010 vs. n= 2,421,416 in 
2016), while prescribing of nitrates, alpha-blockers, and anti-anginal drugs 
showed a much more modest decline, remaining largely steady. Decline of use in 
these drug-classes, particularly for antiplatelets, may be due to the introduction 
of novel anticoagulant drugs; direct oral anticoagulants (DOACs). These drugs 
have an improved safety profile compared to older anticoagulants (e.g. 
warfarin). While adherence to these drugs has been studied previously with PIS 
data[199] it is a noted flaw of this study that this class has not been included. 
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Prescribing of lipid-regulating drugs, ACE-inhibitors, BBs, CCBs, and ARBs 
increased during the study period.  
Figure 6.1: Frequency counts of CVD prescribing by drug-class between 2010-2016.  
6.4 Deaths Data 
All-cause mortality across the study period (Figure 6.1) showed a seasonal 
trend, with peaks during the Winter months and dips in the Summer. There was 
a slight increase in average mortality over the period from 2009 to 2017.  
There were 338,140 deaths within the entire cohort during the years of the study 
(Table 6.3). The majority of these (63%) occurred within the largest primary 
group, while 19% occurred out-with inclusion within the patient groups. Deaths 
that occurred out-with inclusion in these groups could still be captured in follow-
up (Cox analyses, Chapter 8), as inclusion in these groups was only essential for  
defining adherence (Chapter 7). 
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Figure 6.2.1: All-cause mortality across the full patient cohort, July 2009 – Jan 2017 
 
Table 6.3: All-cause mortalities during inclusion in each patient group  
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In order, the five most common causes of death in the cohort are AMI (ICD-10 
code I219), lung cancer (C349), ischemic heart disease (I259), dementia (F03), 
and stroke (I64). It is notable that three of these causes are directly related to 
CVD. Dementia has also been associated with CVD in previous studies[9]. This is 
comparable with findings reported by ISD for the years of 2017 and 2018, which 
lists ischaemic heart diseases (ICD I20-I25) as the main cause of death reported 
in Scotland across all ages; followed by dementia and Alzheimer diseases (F01, 
F02, G30); trachea, bronchus and lung cancer (C33-C34); cerebrovascular disease 
(I60-I69); and chronic lower respiratory diseases (J40-J47)[200, 201].  
 
Figure 6.2.2: Main causes of death in patients prescribed any drug of interest between the 
years of 2009-2016 
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6.5 Common Causes of Hospitalisation 
 
Figure 6.3: Counts of common hospitalisations 
by four main patient groups – legend (right) 
details relevant ICD-10 codes and indicates if 
CVD   or related to CVD . 
Figure 6.3 shows the ten most common 
causes of hospitalisation, sorted by patient 
group. Notably, there are more 
hospitalisations overall in the primary and 
treatment groups, though these groups are far larger in comparison. Notably, 
the most common cause of hospitalisation differs in the primary group to the 
three groups with more severe CVD. The most common main diagnosis codes for 
hospitalisation in the primary groups are cataracts (unspecified, H269) and 
urinary tract infection (N390). In the other three patient groups, the most 
common ICD-10 codes relate to atherosclerotic heart disease (I251) and 
unspecified chest pain (R074). While unspecified chest pain cannot be directly 
attributed to CVD, it may be worth consideration in sensitivity analyses for 
studies using hospitalisation codes.   
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Other common causes of hospitalisation included atrial fibrillation and flutter 
(I48X), influenza and acute lower respiratory infections (J189, J22), chronic 
obstructive pulmonary disease (J440, J441), and syncope and collapse (R55x).  
6.6 Discussion  
Lipid-regulatory drugs are the most commonly prescribed class of CVD drug in 
our dataset, and simvastatin and atorvastatin both feature in the most 
commonly prescribed drugs across multiple patient groups (Figure 6.1).  
The primary group is a much larger group than the other three, as would be 
expected in a country where prophylactic CVD prescribing is recommended. The 
ASSIGN guidelines for assessing risk of CVD suggest that the majority of adults 
aged 65 or over are likely to be above the threshold for intervention, and that 
anyone over the age of 40 could be considered for risk-assessment[13]. For this 
reason, along with the increase in CVD risk and disease severity with older age, 
it is also in line with our expectations to see the primary group having a 
considerably younger mean age overall.  
On first glance, it may be unexpected that there is a slightly higher 
representation of female to male patients in the primary group, as male patients 
are known to be at higher risk of CVD[202, 203], and as the imbalance observed in 
this group exceeds the 51:49, female: male gender split observed across the 
background population, i.e. across the full population of Scotland[204]. However, 
as CVD disease severity increases in the treatment, secondary, and secondary-
treatment groups, this is reversed. This indicates that, as expected, male 
patients do suffer from more severe CVD. The higher representation in the 
primary group may be due to different health-seeking behaviours in women 
compared to men, or perhaps could be related to menopause: hormone 
replacement therapy (HRT) is not appropriate for women with uncontrolled high 
blood pressure. Therefore, a higher proportion of women compared to men will 
have their blood pressure checked by a doctor in this period of their lives as 
there is a direct clinical need. In turn, a higher proportion of women with 
hypertension may be identified and prescribed CVD prophylaxis in this way. 
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While there are not large differences in SIMD across the groups, it is notable that 
the highest representation of affluent patients is in the primary group (17%) 
compared to the other three groups (14%). This may be due to increased access 
to healthcare and these patients therefore having greater opportunity to access 
preventative CVD care. 
Increased CVD polypharmacy in the treatment, secondary, and secondary-with-
treatment groups compared to the primary is in line with our expectations: 
standard care following an MI involves multiple different drugs, including dual-
antiplatelet therapy, statins, beta-blockers, ACEi’s [205]. As the inclusion criteria 
for the treatment group requires a prescription of GTN, these patients are likely 
to be on additional CVD prophylaxis to manage angina. For example, in the SIGN 
guidelines for acute coronary syndrome, patients with unstable angina are 
recommended ACEi therapy[205]. Comparatively, it is quite likely for primary 
prevention patients to be prescribed just one drug in the first instance, such as 
statins in response to having clinically high cholesterol levels.  
6.7 Chapter Summary 
This chapter presented basic baseline information about the patient groups, 
alongside other information about prescribing, hospitalisations, and deaths. 
Understanding the data and differences between patient groups is important to 
consider before deeper analysis and comparisons of adherence and outcomes, as 
these may relate to confounders that must be considered. 
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7 Results: Epidemiology of Adherence  
This chapter concerns the epidemiology of adherence across the main patient 
subgroups of primary prevention, treatment, secondary prevention, and 
secondary prevention with treatment. Within these groups, levels of adherence 
are compared between men and women; age groups of below-55, 55-65, and 
above-65 years; socioeconomic groups derived from SIMD, of low (SIMD deciles 1-
3), mid (SIMD deciles 4-7), and high (SIMD deciles 8-10), with low deciles being 
the most-deprived and high being the most affluent; and between those with 
comorbid diabetes, comorbid depression, both or neither. In each instance, 
adherence measures are derived separately for the ten drug classes: diuretics 
(BNF 2.2), beta-blockers (BNF 2.4), alpha-blockers (BNF 2.5.4), ACE-inhibitors 
(BNF 2.5.5.1), angiotensin-2-receptor blockers (BNF 2.5.5.2), nitrates (BNF 
2.6.1), calcium channel blockers (BNF 2.6.2), other anti-anginal agents (BNF 
2.6.3), antiplatelet drugs (BNF2.9), and lipid-regulating drugs (BNF 2.12). 
Adherence is measured in a combined method: the treatment anniversary model 
(TAM) indicates the percentage of patients found to be persistent at 12 months; 
the proportion of day’s covered (PDCp) indicates the percentage of persistent 
patients (as identified with TAM) who received over 80% of their drug coverage 
in the first 12 months of treatment; and the proportion of days covered for the 
‘intention to treat’ group (PDCa) is the proportion of all patients within the 
group who started treatment of a particular drug class, and received over 80% of 
their drug coverage in the first 12 months of treatment (i.e. includes patients 
who were persistent with TAM, as well as those who were not). 
These three measures allow investigation of two key stages of adherence: 
implementation and persistence. PDCa is more comparable with the majority of 
adherence studies, which fail to use a mixed method of measuring adherence, 
while TAM and PDCp together give more insight, as it informs us whether people 
who are persistent are also adhering to their drugs.  
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7.1 Primary Prevention 
7.1.1 Sex 
 
Table 7.1.1 Adherence by sex in the primary prevention group at one year  
Overall, male patients have a higher level of adherence compared with female 
patients in the primary prevention group (Table 7.1.1). Across the ten drug-
Drug 
Class
Adherence 
measure n start n adhere 
% 
adherent n start n adhere
% 
adherent p-value
TAM 22,892 13,189 57.61 23,378 11,418 48.84 > 0.0001
PDCp 13,189 11,841 89.78 11,418 10,275 89.99 0.6004
PDCa 22,892 12,875 56.24 23,378 11,222 48.00 > 0.0001
TAM 121,059 83,063 68.61 121,281 72,540 59.81 0
PDCp 83,063 74,267 89.41 72,540 65,830 90.75 > 0.0001
PDCa 121,059 78,684 65.00 121,281 70,705 58.30 > 0.0001
TAM 1,188 646 54.38 1,584 749 47.29 0.0003
PDCp 646 561 86.84 749 660 88.12 0.5237
PDCa 1,188 592 49.83 1,584 722 45.58 0.0293
TAM 70,493 43,990 62.40 84,404 42,467 50.31 0
PDCp 43,990 34,944 79.44 42,467 34,595 81.46 > 0.0001
PDCa 70,493 36,817 52.23 84,404 36,661 43.44 > 0.0001
TAM 40,144 29,277 72.93 50,565 35,872 70.94 > 0.0001
PDCp 29,277 26,594 90.84 35,872 32,969 91.91 > 0.0001
PDCa 40,144 28,192 70.23 50,565 34,967 69.15 0.00049
TAM 100,560 46,351 46.09 172,120 64,079 37.23 0
PDCp 46,351 36,240 78.19 64,079 44,807 69.92 > 0.0001
PDCa 100,560 38,709 38.49 172,120 48,193 28.00 0
TAM 114,002 76,497 67.10 135,334 74,477 55.03 0
PDCp 76,497 67,185 87.83 74,477 64,874 87.11 > 0.0001
PDCa 114,002 71,148 62.41 135,334 69,480 51.34 0
TAM 83,220 48,193 57.91 120,080 62,161 51.77 > 0.0001
PDCp 48,193 40,262 83.54 62,161 49,967 80.38 > 0.0001
PDCa 83,220 43,040 51.72 120,080 53,146 44.26 > 0.0001
TAM 134,042 96,405 71.92 129,719 88,561 68.27 > 0.0001
PDCp 96,405 76,544 79.40 88,561 72,217 81.54 > 0.0001
PDCa 134,042 79,774 59.51 129,719 75,697 58.35 > 0.0001
TAM 1,827 914 50.03 2,285 1,008 44.11 0.0002
PDCp 914 797 87.20 1,008 882 87.50 0.8970
PDCa 1,827 851 46.58 2,285 940 41.14 0.0005
Min 38.49 28.00
Max 90.84 91.91
Range across all 
classes
Male Female
a-
blockers
ACEi
anti_ang
inal
lipid-
regs
nitrates
antiplate
lets
ARB
BBs
CCBs
diuretics
127 
 
classes and three different measures of adherence used, adherence ranged from 
38-91% for men and 28-92% for women. Looking at all combinations of drug and 
adherence indicator, adherence was only higher for women in 23% of cases, all 
of which were measured by PDCp. This indicates that while women may be less 
likely to persist with medication-taking, those who do persist display 
implementation to a higher level compared to male patients. It is also notable 
that for both male and female patients, PDCp is generally much higher than the 
other two measures. The median PDCp across all ten drug-classes is 87.02 for 
men while it is 87.30 for women. This compares to a median TAM of 60.16 for 
males and 51.04 for females; and a PDCa of 54.24 for males and 46.79 for 
females. This suggests that in persistent patients, implementation of CVD drug 
regimens is generally good, and there is little sex difference in implementation. 
However, when persistence is considered, stark differences between male and 
female sex emerge. 
Persistence (TAM) is highest for ARBs, lipid-regulatory drugs, and ACEi’s in both 
male and female patients. Implementation across all (i.e. including persistent 
and non-persistent) patients (PDCa) is highest in these same drug-classes for 
females, though differs for male patients: ARBs, ACEi’s, and CCBs. Compared 
with other drug classes, adherence to BBs is considerably lower – with only 37% 
of all female patients and 46% of all male patients persisting at 1-year. Nitrates 
and antianginals were the two drug-classes with the next-lowest persistence 
rates in both male and female patients: TAM of 50% and 54% respectively for 
males, and 44% and 47% respectively for females. 
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7.1.2 Age 
 
Table 7.1.2 Adherence by age in the primary prevention group at one year  
Adherence tends to be highest in the older age group (above 65-years) and 
lowest in the youngest age group (below 55-years) in the first year of CVD 
primary prevention (Table 7.1.2). Across the ten drug-classes and three 
adherence measures, adherence tends to increase with age: ranging from 20-88% 
in the below-55-year group, to 35-93% in the mid-group, to 49-94% in the oldest 
group. This is fairly consistent, as, when compared across the individual drug-
classes and adherence measures, all but two of the lowest adherence scores are 
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found in the youngest age group, and the highest adherence scores are found 
most often in the oldest age group. There are two drug-classes where adherence 
is highest in the middle (55-65-year) group, consistent across TAM, PDCp, and 
PDCa: alpha-blockers and diuretics; and four drug-classes where adherence is 
highest in the over 65-year group, consistent across all three measures: 
antianginals, antiplatelets, BBs, and nitrates. 
The drug-classes found to have highest or lowest persistence levels vary by age-
group; however, across all age-groups, persistence was high for ARBs, lipid-
regulatory drugs, and ACEi’s. Persistence to BBs varied by age: in the youngest 
age group, this is the class to which patients were least persistent, whereas in 
the over-65’s, this is one the drug-classes to which people were most persistent. 
This indicates that age may be associated with adherence in different ways, 
depending on the drug-class studied.  
Age may also partially explain the low adherence levels observed for BBs, as 
there is a higher proportion of BB prescriptions in younger patients. 30% of the 
prescriptions in the below-55-year group are for BBs (170,852 out of a total of 
569,467 prescriptions across all drug-classes), compared to approximately 10% 
representation in the 55-65 and over-65 years age groups.  
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7.1.3 Deprivation 
 
Table 7.1.3 Adherence by SIMD in the primary prevention group at one year  
Across the three SIMD categories, adherence is lowest in the most-deprived SIMD 
groups, as it is found to be lowest in this group in 23 out of the 30 measures 
studied. This is consistent for TAM, PDCp, and PDCa in four drug-classes: 
antiplatelets, ARBs, BBs, and diuretics. The reverse also holds true, in that the 
highest adherence levels tend to be observed in the more affluent (high) SIMD 
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groups, in 19 of the 30 measures. This was consistent in three drug-classes: 
ARBs, diuretics, and lipid-regulating drugs.  
Across all ten drug-classes and all 3 adherence measures, adherence for the low-
SIMD group was 28-90%, rising to 33-91% for the mid-SIMD group, and again to 44-
93% in the most affluent high-SIMD group.   
The drug-classes with the highest and lowest persistence rates are identical 
across the three different SIMD groups. The highest levels of persistence are 
observed in ARBs (72, 72, and 71% respectively across high, mid, and low-SIMD), 
lipid-regulatory drugs (71, 70, 70%), and ACEi’s (63, 64, 65%), while the lowest 
persistence rates are consistently observed across BBs (41, 41, 39%), nitrates 
(45, 47, 47%), and antianginals (46, 51, 51%). This suggests that, unlike age, 
deprivation does not appear to have different associations with adherence, 
dependent on the drug-class studied. 
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7.1.4 Comorbidity  
 
Table 7.1.4 Adherence by comorbidity in the primary prevention group at one year 
percentages are rounded where the number of nonadherent people is < 10 to protect anonymity 
(while the number of nonadherent patients is not provided, it could otherwise be inferred from 
percentages) 
When considering adherence rates by comorbidity status in the primary 
prevention group, the trend toward increased adherence in diabetic patients and 
reduced adherence in patients with depression (as observed in literature 
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review), tends to hold (Table 7.1.4). Across all ten drug-classes and all three 
measures, adherence ranged from 47-90% for patients with diabetes. Patients 
with depression as a comorbidity ranged from a minimum of 22-91%, though the 
minimum end of this range relates to beta-blockers and is somewhat of an 
outlier.  
Adherence to CVD medication is found to be highest in patients with diabetes for 
over half (57%) of the individual measures. This is consistent across TAM, PDCp, 
and PDCa in two different drug-classes: BBs and CCBs.  
Conversely, CVD adherence is found to be lowest in primary prevention patients 
who are concurrently being treated with anti-depressant drugs, compared to 
those with diabetes, diabetes and depression, or those with neither comorbidity. 
This was found to be the case across 18 of the 30 measures presented, and was 
consistent for TAM, PDCp, and PDCa for four drug classes: alpha-blockers, ARBs, 
BBs, and CCBs.  
The group of patients who were medicated for both diabetes and depression 
were found to be slightly more adherent overall when compared to those who 
had no evidence of either condition (found to be the most adherent of the four 
groups in 23% of instances vs 13%). Neither of these groups were associated with 
poorer adherence, with the exception of adherence to nitrates: this was lowest 
across all three adherence measures in the patients who had neither 
comorbidity.  
Whether diabetes comorbidity has a positive effect on medication taking 
behaviour (e.g. patients are ‘used-to’ daily medication taking behaviour) or if 
there is a skew toward older aged patients in this group, particularly those with 
type-2 diabetes, cannot be discerned from this table alone. Similarly, lower 
adherence in the group of patients with depression as a comorbidity could to due 
symptoms of this condition (low mood, hopelessness, little motivation), or due 
to younger average age. The potential confounding effect of age will be an 
important consideration in the multivariate analyses.  
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7.2 Treatment 
7.2.1 Sex 
 
Table 7.2.1 Adherence by sex in the treatment group at one year  
Like the primary prevention patients, adherence to CVD medications is 
consistently greater in male patients compared to female patients for the 
treatment group (Table 7.2.1). On a drug-by-drug basis, males generally tend to 
Drug 
Class
Adherence 
measure n start n adhere 
% 
adherent n start n adhere
% 
adherent p-value
TAM 6,333 3,927 62.01 5,973 3,345 56.00 > 0.0001
PDCp 3,927 3,561 90.68 3,345 2,966 88.67 0.0055
PDCa 6,333 3,824 60.38 5,973 3,225 53.99 > 0.0001
TAM 41,482 32,002 77.15 31,554 22,429 71.08 > 0.0001
PDCp 32,002 29,475 92.10 22,429 20,622 91.94 0.5072
PDCa 41,482 30,957 74.63 31,554 21,898 69.40 > 0.0001
TAM 15,080 9,481 62.87 12,875 7,997 62.11 0.1957
PDCp 9,481 8,501 89.66 7,997 7,084 88.58 0.0235
PDCa 15,080 9,174 60.84 12,875 7,592 58.97 0.0015
TAM 63,328 48,320 76.30 56,533 39,586 70.02 > 0.0001
PDCp 48,320 41,965 86.85 39,586 33,428 84.44 > 0.0001
PDCa 63,328 43,899 69.32 56,533 35,103 62.09 > 0.0001
TAM 14,268 10,953 76.77 15,951 12,216 76.58 0.7195
PDCp 10,953 10,211 93.23 12,216 11,353 92.94 0.3996
PDCa 14,268 10,747 75.32 15,951 11,986 75.14 0.7278
TAM 52,609 40,105 76.23 45,519 32,109 70.54 > 0.0001
PDCp 40,105 36,586 91.23 32,109 29,179 90.87 0.1033
PDCa 52,609 38,181 72.58 45,519 30,575 67.17 > 0.0001
TAM 35,719 25,163 70.45 36,285 23,431 64.57 > 0.0001
PDCp 25,163 22,748 90.40 23,431 20,759 88.60 > 0.0001
PDCa 35,719 23,990 67.16 36,285 22,043 60.75 > 0.0001
TAM 32,984 21,742 65.92 41,489 27,898 67.24 0.0001
PDCp 21,742 18,848 86.69 27,898 23,621 84.67 > 0.0001
PDCa 32,984 19,996 60.62 41,489 24,933 60.10 0.1456
TAM 64,888 53,428 82.34 56,204 43,404 77.23 > 0.0001
PDCp 53,428 46,264 86.59 43,404 36,904 85.02 > 0.0001
PDCa 64,888 47,886 73.80 56,204 38,461 68.43 > 0.0001
TAM 24,088 14,117 58.61 23,057 13,884 60.22 0.0004
PDCp 14,117 12,285 87.02 13,884 12,103 87.17 0.7223
PDCa 24,088 13,033 54.11 23,057 12,781 55.43 0.0039
Min 54.11 53.99
Max 93.23 92.94
Range across all 
classes
Male Female
a-
blockers
ACEi
anti_ang
inal
lipid-
regs
nitrates
antiplate
lets
ARB
BBs
CCBs
diuretics
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be more adherent, though across the ten drug-classes and three different 
measures of adherence used, both range from 54-93%. Adherence levels in the 
treatment group are notably higher than adherence for both sexes in the primary 
prevention group. There is an exception, as adherence to nitrates is higher for 
females compared to males, across TAM, PDCp, and PDCa. 
Persistence is greatest for lipid-regulatory drugs, at 82% for male and 77% for 
female patients. For male patients, there is a marked difference between this 
and the drug to which persistence is next-highest: 77% of male patients persist 
with ACEi’s. For female patients, there is less than a 1% gap to the next drug-
class, as 76.58% adhere to ARBs. Male patients are least persistent to nitrates 
(59%), -blockers (62%) and antianginals (63%), while female patients are least 
persistent to the same three classes of drug: alpha-blockers (56%), nitrates 
(60%), and antianginals (62%).  
Unlike the primary group, adherence to BBs is generally good.  
Again, PDCp is the adherence measure which scores highest, and shows the least 
variation between drug-classes. It ranges from 86 to 93% for males and from 84 
to 93% for females. TAM ranges from 58 to 82% for males and 56 to 77% for 
females, while PDCa ranges from 54 to 75% and 53 to 75% respectively. This 
indicates that, for either sex, patients who are persistent tend to have good 
implementation, whereas persistence is more variable. 
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7.2.2 Age 
 
Table 7.2.2 Adherence by age in the treatment group at one year  
In the treatment group, there is a clear association between age and level of 
adherence (Table 7.2.2). Across the ten drug classes, adherence ranges from 35-
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86% in the below-55 age group, rising to 47-92% for the 55-65-year group, and to 
59-95% for the over 65-year group. Comparing at the drug-class level, adherence 
is consistently highest for TAM, PDCp, and PDCa, in the over-65 age group for 
antianginals, antiplatelets, ARBs, BBs, CCBs, diuretics, lipid-regulatory drugs, 
and nitrates. Adherence is lowest in the below-55 age group, consistently for the 
three adherence measures for all of the same drug-classes, with the addition of 
ACEi’s. In fact, the only instance where adherence is not lowest for the youngest 
age group is persistence (TAM) for alpha-blockers. 
Similar to the primary prevention group, the drug-classes to which patients are 
most or least persistent after 1-year varies by age-group. For the under-55’s, 
more patients were persistent to ACEi’s (73%), ARBs (73%), and lipid-regs (72%), 
and least persistent to nitrates (41%), antianginals (55%), and diuretics (58%). 
The 55-65-year age group have greater levels of persistence observed in the 
same three drug-classes, though with the highest share of patients persisting to 
lipid-regulatory drugs (79%), followed by ARBs (76%) and ACEi’s (75%). The drug-
classes which showed lower persistence levels also included nitrates (52%) and 
antianginals (59%) but, unlike their younger counterparts, the drug-class with 
the next lowest persistence was alpha-blockers (59%). The oldest patient group, 
those aged over 65-years, also showed the highest level of persistence for lipid-
regulatory drugs (82%). Adherence was also high to antiplatelets (78%) and BBs 
(78%). Their lowest persistence levels were observed in alpha-blockers (59%), 
antianginals (66%) and nitrates (66%).  
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7.2.3 Deprivation 
 
Table 7.2.3: Adherence by SIMD in the treatment group at one year 
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In the treatment group, differences between SIMD categories are even more 
subtle than those observed in the primary prevention group (Table 7.2.3). 
Across the ten drug-classes, adherence ranges little between SIMD levels, with 
all groups having minimum level of adherence of 52-56% and a maximum of 92-
94%.  
The drug-classes which represent those that patients are most or least persistent 
to is consistent across the different SIMD levels. A higher proportion of patients 
are persistent to lipid-regulatory drugs (rounds to 80% across high, mid, and low 
SIMD-groups), ARBs (77% for high and mid SIMD, 76% for low SIMD group), and 
ACEi’s (74% for high and mid SIMD groups, 75% for the low SIMD group). The 
lowest levels of persistence were observed across nitrates (55%), alpha-blockers 
(57%) and antianginals (59%) in the high-SIMD group. The mid- and low-SIMD 
groups were also least persistent to the same three drug-classes: alpha-blockers 
(58% for mid-SIMD, 61% for low-SIMD), nitrates (59% and 62%), and antianginals 
(62% and 66%).   
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7.2.4 Comorbidity  
 
Table 7.2.4: Adherence by comorbidity in the treatment group at one year 
There is a similar association between adherence and comorbidity in the 
treatment group (Table 7.2.4) as was observed in the primary prevention group. 
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Adherence tended to be highest for those with diabetes as a comorbidity (61-
93%) and lowest in those with depression or neither comorbidity (53-91% and 53-
94% respectively).  
At a class-by-class level, adherence is lowest in patients with depression as a 
comorbidity, consistent across TAM, PDCp, and PDCa for six classes of drugs: 
ACEi’s, antiplatelets, BBs, CCBs, diuretics, and lipid-regulatory drugs. 
Antianginals notably differ, as they are consistently found to have the lowest 
adherence level in the group of patients who neither have diabetes nor 
depression as a comorbidity. Adherence is highest across TAM, PDCp, and PDCa 
in patients with diabetes as a comorbidity in three different drug-classes: 
antiplatelets, BBs, and CCBs. Patients with both diabetes and depression are 
associated with higher adherence when compared with those who have no 
evidence of either.  
Looking across the drug-classes, the class to which most patients are persistent 
(TAM) is lipid-regulatory drugs, regardless of comorbidity status (neither: 79%, 
diabetes: 84%, depression: 78%, diabetes and depression: 84%), followed by ARBs 
(neither: 77%, depression: 75%, diabetes and depression: 78%). For patients with 
diabetes, the drug-class to which persistence is second-highest is BBs (79%). The 
drug-classes to which a lower proportion of patients persist are alpha-blockers 
(neither: 57%, diabetes: 64%, depression: 58%, diabetes and depression: 65%), 
and nitrates (neither: 58%, diabetes: 65%, depression: 59%, diabetes and 
depression: 68%), consistent across the different comorbidity statuses. 
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7.3 Secondary Prevention 
7.3.1 Sex 
 
Table 7.3.1 Adherence by sex in the secondary prevention group at one year  
p-values derived from Fisher’s exact test where n < 5; In all other instances, p derived from chi-squared 
test. 
 
In the secondary prevention group, adherence is higher for male patients 
compared to female patients, though with a smaller sex difference compared 
Drug Class
Adherence 
measure n start n adhere 
% 
adherent n start n adhere
% 
adherent p-value
TAM 104 70 67.31 73 51 69.86 0.8449
PDCp 70 67 95.71 51 48 94.12 1.3919
PDCa 104 65 62.50 73 46 63.01 1.0000
TAM 3,182 2,612 82.09 1,616 1,181 73.08 > 0.0001
PDCp 2,612 2,539 97.21 1,181 1,153 97.63 0.5209
PDCa 3,182 2,552 80.20 1,616 1,175 72.71 > 0.0001
TAM 398 264 66.33 278 192 69.06 0.5074
PDCp 264 244 92.42 192 188 97.92 0.0173
PDCa 398 252 63.32 278 193 69.42 0.1175
TAM 3,842 3,411 88.78 2,180 1,875 86.01 0.0018
PDCp 3,411 3,363 98.59 1,875 1,846 98.45 0.7757
PDCa 3,842 3,474 90.42 2,180 1,926 88.35 0.0126
TAM 576 490 85.07 477 395 82.81 0.3615
PDCp 490 481 98.16 395 382 96.71 0.2443
PDCa 576 479 83.16 477 377 79.04 0.1033
TAM 3,355 2,916 86.92 1,819 1,556 85.54 0.1819
PDCp 2,916 2,849 97.70 1,556 1,526 98.07 0.4836
PDCa 3,355 2,866 85.42 1,819 1,540 84.66 0.4865
TAM 739 549 74.29 492 350 71.14 0.2482
PDCp 549 527 95.99 350 336 96.00 1.0000
PDCa 739 514 69.55 492 335 68.09 0.6305
TAM 1,045 779 74.55 897 692 77.15 0.2006
PDCp 779 743 95.38 692 659 95.23 0.9920
PDCa 1,045 733 70.14 897 647 72.13 0.3618
TAM 3,769 3,399 90.18 2,077 1,786 85.99 > 0.0001
PDCp 3,399 3,239 95.29 1,786 1,700 95.18 0.9163
PDCa 3,769 3,179 84.35 2,077 1,671 80.45 0.0002
TAM 467 304 65.10 369 266 72.09 0.0375
PDCp 304 285 93.75 266 261 98.12 0.0172
PDCa 467 283 60.60 369 253 68.56 0.0208
Min 60.60 63.01
Max 98.59 98.45Range across all classes
lipid-regs
nitrates
antiplatelets
ARB
BBs
CCBs
diuretics
Male Female
a-blockers
ACEi
anti_anginal
143 
 
with that observed for the primary prevention or treatment groups (average 
83.02% adherent for men across all ten drugs classes, vs average 82.89% for 
women) (Table 7.3.1). Generally, patients who are found to be persistent at the 
end of year 1 tend also to have very high levels of adherence, with the PDCp 
ranging from approximately 92-98% across male and female patients for any drug 
class.  
For antiplatelets, ARBs, and lipid-regulating drugs, male patients have higher 
implementation and persistence compared with female patients; for nitrates and 
antianginals the reverse is true, with women having higher levels of adherence 
across all measures. Alpha-blockers, ACEi’s, CCBs, BBs, and diuretics show a mix 
of male and female patients displaying higher rates of adherence, depending on 
the measure used. In all cases, the adherence in patients who were persistent 
(PDCp) is the value which contradicts the other two. For patients who do persist 
with treatment, there are very little differences in levels of implementation 
between the sexes.  
The drug-classes to which male patients are most persistent are lipid-regs (90%), 
antiplatelets (89%), and BBs (87%), while female patients are most adherent to 
antiplatelets (86%), closely followed by lipid-regulators and BBs (both of which 
round-up to 86%). The drugs to which males are least persistent are nitrates 
(65%), followed by antianginals (66%) and alpha-blockers (67%). For female 
patients, adherence to nitrates is comparatively higher, at 72%, while the drugs 
to which they are least persistent are antianginals (69%), alpha-blockers (70%), 
and CCBs (71%). 
In the secondary prevention group, we might expect people to be very adherent 
initially following their heart attack and for this to drop-off later; however it is 
difficult to study this accurately as very few people stay in this group for a long 
time, with a median follow-up time of just less than 4 months (see previous 
chapter, showing summary statistics for each of the patient groups). Comparing 
adherence over the first year of secondary prevention can only give us limited 
insight.  
 
144 
 
 
7.3.2 Age  
 
Table 7.3.2 Adherence by age in the secondary prevention group at one year  
p-values derived from Fisher’s exact test where n < 5; In all other instances, p derived from  
chi-squared test. 
 
 
For the secondary prevention group, average TAM across all drugs classes is 
lowest in the below-55 group (75%), highest in 55-65-year olds (79%), and slightly 
lower again in the over 65-year group (77%) (Table 7.3.2). This is consistent with 
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the ‘U-shaped’ association between age and nonadherence, as described by 
Mann et al (Chapter 2, literature review). However, this is not quite reflected in 
PDCp or PDCa measures, as adherence is lower in the below-55 age group (PDCp 
92%/ PDCa 68%) but remains constant between the 55-65 and above-65 age 
categories (PDCp 96%/PDCa 75%). This differs from primary prevention and 
treatment groups, where increased age seemed to have a clear positive trend 
with adherence. 
There is only one instance where the below-55 group have the highest 
adherence, and this is the TAM for ACEi’s. Adherence is consistently highest 
across TAM, PDCp, and PDCa in the 55-65 age group for five different drug-
classes: alpha-blockers, antiplatelets, ARBs, CCBs, and lipid-regs, while it is 
highest in the older (plus-65) group for diuretics, and nitrates. Lowest adherence 
levels were observed in the younger age-group in almost two-thirds of cases (19 
out of 30 measures), and this is consistent for the three adherence measures in 
alpha-blockers and CCBs. 
The drug-classes to which patients are most persistent differ slightly by age. 
Lipid-regulatory drugs were the class to which persistence was highest: at 90% 
for the below-55 group, 92% for the 55-65 group, and 87% for the above-65 
group. This is followed by antiplatelets (90%, 92%, 85% respectively), and then 
ARBs tied with ACEi for the younger age-group (both 84%) and BBs for the mid- 
and older groups (89 and 85%). Patients were least persistent to alpha-blockers, 
antianginals, and nitrates in all age-groups, though to varying degrees. For the 
below-55 group, persistence was lowest for nitrates (49%), alpha-blockers (62%), 
and then antianginals (64%); for the 55-65-year group, the lowest persistence 
level was to antianginals (62%), followed by nitrates (63%), and alpha-blockers 
(71%); in the above-65 group, persistence was lowest for alpha-blockers (68%), 
antianginals (69%), and nitrates (71%).   
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7.3.3 Deprivation 
 
Table 7.3.3 Adherence by SIMD in the secondary prevention group at one year  
p-values derived from Fisher’s exact test where n < 5; In all other instances, p derived from  
chi-squared test.  
 
Across all drug-classes, there is very little difference in adherence between the 
SIMD-groups for secondary prevention patients (Table 7.3.3).  
Dr
ug
 C
la
ss
Ad
he
re
nc
e 
m
ea
su
re
n 
st
ar
t
n 
ad
he
re
%
 
ad
he
re
nt
n 
st
ar
t
n 
ad
he
re
%
 
ad
he
re
nt
p-
va
lu
e
n 
st
ar
t
n 
ad
he
re
%
 
ad
he
re
nt
p-
va
lu
e
TA
M
52
32
61
.5
4
75
56
74
.6
7
0.
16
71
49
33
67
.3
5
0.
68
82
PD
Cp
32
31
96
.8
8
56
53
94
.6
4
1.
74
45
33
31
93
.9
4
1.
97
95
PD
Ca
52
33
63
.4
6
75
50
66
.6
7
0.
85
43
49
28
57
.1
4
0.
65
60
TA
M
1,
32
4
1,
04
1
78
.6
3
1,
98
5
1,
56
7
78
.9
4
0.
86
11
1,
48
0
1,
17
9
79
.6
6
0.
52
98
PD
Cp
1,
04
1
1,
01
8
97
.7
9
1,
56
7
1,
53
0
97
.6
4
0.
90
46
1,
17
9
1,
13
8
96
.5
2
0.
09
79
PD
Ca
1,
32
4
1,
02
3
77
.2
7
1,
98
5
1,
55
6
78
.3
9
0.
47
16
1,
48
0
1,
14
2
77
.1
6
0.
98
38
TA
M
17
6
10
9
61
.9
3
25
1
16
5
65
.7
4
0.
48
10
24
9
18
2
73
.0
9
0.
01
96
PD
Cp
10
9
10
5
96
.3
3
16
5
15
5
93
.9
4
1.
69
05
18
2
17
2
94
.5
1
1.
52
41
PD
Ca
17
6
11
3
64
.2
0
25
1
15
8
62
.9
5
0.
87
03
24
9
17
4
69
.8
8
0.
26
04
TA
M
1,
66
4
1,
45
6
87
.5
0
2,
51
2
2,
21
9
88
.3
4
0.
44
41
1,
83
7
1,
60
4
87
.3
2
0.
91
03
PD
Cp
1,
45
6
1,
43
0
98
.2
1
2,
21
9
2,
19
1
98
.7
4
0.
24
98
1,
60
4
1,
58
1
98
.5
7
0.
52
86
PD
Ca
1,
66
4
1,
49
8
90
.0
2
2,
51
2
2,
26
6
90
.2
1
0.
88
78
1,
83
7
1,
62
9
88
.6
8
0.
21
74
TA
M
32
5
27
0
83
.0
8
44
6
37
8
84
.7
5
0.
59
74
28
2
23
7
84
.0
4
0.
83
35
PD
Cp
27
0
26
3
97
.4
1
37
8
37
0
97
.8
8
0.
89
46
23
7
23
0
97
.0
5
1.
00
00
PD
Ca
32
5
25
9
79
.6
9
44
6
37
0
82
.9
6
0.
28
84
28
2
22
7
80
.5
0
0.
88
43
TA
M
1,
41
8
1,
22
9
86
.6
7
2,
17
0
1,
88
5
86
.8
7
0.
90
59
1,
57
9
1,
35
3
85
.6
9
0.
46
79
PD
Cp
1,
22
9
1,
20
6
98
.1
3
1,
88
5
1,
84
6
97
.9
3
0.
79
91
1,
35
3
1,
31
8
97
.4
1
0.
27
47
PD
Ca
1,
41
8
1,
21
6
85
.7
5
2,
17
0
1,
85
2
85
.3
5
0.
77
05
1,
57
9
1,
33
3
84
.4
2
0.
33
14
TA
M
33
1
23
9
72
.2
1
51
8
38
1
73
.5
5
0.
72
49
38
1
27
8
72
.9
7
0.
88
65
PD
Cp
23
9
22
8
95
.4
0
38
1
36
9
96
.8
5
0.
47
56
27
8
26
5
95
.3
2
1.
00
00
PD
Ca
33
1
22
6
68
.2
8
51
8
36
3
70
.0
8
0.
63
24
38
1
25
9
67
.9
8
0.
99
62
TA
M
51
7
39
0
75
.4
4
78
7
58
5
74
.3
3
0.
70
16
63
3
49
2
77
.7
3
0.
39
89
PD
Cp
39
0
37
3
95
.6
4
58
5
56
3
96
.2
4
0.
76
40
49
2
46
2
93
.9
0
0.
32
18
PD
Ca
51
7
37
2
71
.9
5
78
7
56
1
71
.2
8
0.
84
17
63
3
44
4
70
.1
4
0.
54
33
TA
M
1,
60
5
1,
43
8
89
.6
0
2,
43
6
2,
16
2
88
.7
5
0.
42
99
1,
79
5
1,
57
7
87
.8
6
0.
12
26
PD
Cp
1,
43
8
1,
37
6
95
.6
9
2,
16
2
2,
05
7
95
.1
4
0.
49
61
1,
57
7
1,
49
8
94
.9
9
0.
41
21
PD
Ca
1,
60
5
1,
36
6
85
.1
1
2,
43
6
2,
01
9
82
.8
8
0.
06
65
1,
79
5
1,
45
8
81
.2
3
0.
00
30
TA
M
20
0
13
1
65
.5
0
35
9
25
1
69
.9
2
0.
32
65
27
6
18
7
67
.7
5
0.
67
69
PD
Cp
13
1
12
5
95
.4
2
25
1
24
1
96
.0
2
0.
99
44
18
7
17
9
95
.7
2
1.
00
00
PD
Ca
20
0
13
1
65
.5
0
35
9
23
3
64
.9
0
0.
96
05
27
6
17
1
61
.9
6
0.
48
65
M
in
61
.5
4
62
.9
5
57
.1
4
M
ax
98
.2
1
98
.7
4
98
.5
7
Ra
ng
e 
ac
ro
ss
 a
ll 
cl
as
se
s
di
ur
et
ic
s
lip
id
-re
gs
ni
tra
te
s
an
ti_
an
gi
na
l
an
tip
la
te
le
ts
AR
B
BB
s
CC
Bs
Hi
gh
 (S
IM
D 
8-
10
)
M
id
 (S
IM
D 
4-
7)
Lo
w
 (S
IM
D 
1-
3)
a-
bl
oc
ke
rs
AC
Ei
147 
 
Adherence to antiplatelets, ARBs, and CCBs, is highest in the middle SIMD 
groups, consistent across all measures of adherence, while adherence to lipid-
regulatory drugs is greatest in the high SIMD groups across all measures. All other 
drug classes vary depending on which adherence measure is used. 
The drug-classes to which patients were most persistent was consistent across 
the SIMD-groups: it was highest for lipid-regulatory drugs (90%, 89%, 88% 
respectively for high-, mid-, and low-SIMD), followed by antiplatelets (87%, 88%, 
87%), and BBs (87% for high- and mid-SIMD, 86% for low-SIMD). 
Persistence was lowest overall to alpha-blockers, antianginals, and nitrates, 
though this did vary by SIMD group. For example, in both the high- and low-SIMD 
groups, adherence was lowest to alpha-blockers (62 and 67% respectively), 
however for the mid-SIMD group, persistence was 75% - roughly middle of the 
range of TAM values for this group, and 10 percentage points higher than the 
drug-class to which they were least adherent, antianginals. For the high-SIMD 
group, persistence was also lower for this drug class (62%), while the low-SIMD 
group was the outlier this time, with a much higher persistence of 73%. Instead, 
the class to which they were next associated with lower persistence levels was 
nitrates (68%), which was also poorly persisted to in the high- and mid- groups 
also (65% and 67% respectively). While there is some consistency here, there is 
not a clear pattern to the differences that can be observed. 
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7.3.4 Comorbidity  
 
Table 7.3.4 Adherence by comorbidity in the secondary prevention group at one year  
p-values derived from Fisher’s exact test where n < 5; In all other instances, p derived from chi-squared 
test. Percentages are rounded where the number of nonadherent people is < 10 to protect anonymity 
(while the number of nonadherent patients is not provided, it could otherwise be inferred from 
percentages). Note that N patients for PDCp is equivalent to the number of patients found to be 
persistent with TAM (PDCp = proportion of persistent patients who are adherent). Where percentages 
are rounded for TAM, the N patients for PDCp is expressed as the values equivalent to the range of 
percentages given for TAM, as the true value could otherwise be inferred.   
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Comparing adherence in the secondary prevention group is hindered by small 
group numbers, and reporting was subject to disclosure control. If these ranges 
are crudely rounded to the higher value (i.e. if the range is 95-100, take 100% as 
the value) in order to allow an overall average to be calculated, the pattern 
follows that observed in the primary prevention and treatment groups, in that 
adherence tends to be highest in those with diabetes.  
It is worth noting that most of the instances where rounding was necessary were 
in PDCp, as implementation rates were generally high, never dipping below 90%. 
This suggests that patients who do persist with a CVD treatment in the first year 
of secondary prevention therapy tend to implement this to a very high level.  
Comparing persistence across the groups, the drug-classes to which patients are 
most persistent are lipid-regulatory drugs for patients with neither comorbidity 
or with diabetes only (89% and 87% respectively), antiplatelets for those with 
depression only as a comorbidity (88%) and BBs for those with both diabetes and 
depression (90%). Persistence is also high to antiplatelets for those with neither 
comorbidity or those with diabetes only (88% and 86% respectively). For those 
with depression only, persistence was high to lipid-regulatory drugs (88%).  
The drugs to which patients were least persistent included alpha-blockers, 
antianginals, CCBs, and nitrates, though this varied across the groups.  
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7.4 Secondary Prevention with Treatment 
7.4.1 Sex 
 
Table 7.4.1 Adherence by sex in the secondary prevention with treatment group at one year  
As with the previous patient groups examined, for patients undergoing secondary 
prevention along with treatment for symptomatic CVD, male patients tend to be 
more adherent than female patients after 1 year (Table 7.4.1). Half of the 
instances in which females were found to be more adherent were measured by 
PDCp, suggesting that women tend to be less persistent, but where they are 
persistent, their implementation is to a high level. However, it is worth noting 
Drug 
Class 
Adherence 
Measure n patients n adhere % adherent n patients n adhere % adherent p-value
TAM 488 298 61.07 340 183 53.82 0.0448
PDCp 298 282 94.63 183 175 95.63 0.7855
PDCa 488 296 60.66 340 187 55.00 0.1206
TAM 10,886 8,572 78.74 5,012 3,718 74.18 > 0.0001
PDCp 8,572 8,329 97.17 3,718 3,624 97.47 0.3703
PDCa 10,886 8,497 78.05 5,012 3,765 75.12 > 0.0001
TAM 2,187 1,434 65.57 1,460 987 67.60 0.2157
PDCp 1,434 1,379 96.16 987 955 96.76 0.5095
PDCa 2,187 1,448 66.21 1,460 983 67.33 0.5050
TAM 13,544 11,146 82.29 7,133 5,731 80.34 0.0006
PDCp 11,146 10,898 97.77 5,731 5,593 97.59 0.4849
PDCa 13,544 11,547 85.26 7,133 5,890 82.57 > 0.0001
TAM 2,601 1,920 73.82 1,808 1,351 74.72 0.5216
PDCp 1,920 1,877 97.76 1,351 1,310 96.97 0.1924
PDCa 2,601 1,957 75.24 1,808 1,354 74.89 0.8184
TAM 11,966 9,690 80.98 6,126 4,871 79.51 0.0196
PDCp 9,690 9,460 97.63 4,871 4,761 97.74 0.7065
PDCa 11,966 9,612 80.33 6,126 4,850 79.17 0.0689
TAM 3,397 2,274 66.94 2,213 1,381 62.40 0.0005
PDCp 2,274 2,197 96.61 1,381 1,321 95.66 0.1647
PDCa 3,397 2,267 66.74 2,213 1,367 61.77 0.0002
TAM 4,361 2,941 67.44 3,537 2,411 68.17 0.5075
PDCp 2,941 2,809 95.51 2,411 2,272 94.23 0.0397
PDCa 4,361 2,903 66.57 3,537 2,296 64.91 0.1293
TAM 13,552 11,138 82.19 6,914 5,548 80.24 0.0007
PDCp 11,138 10,639 95.52 5,548 5,311 95.73 0.5636
PDCa 13,552 10,595 78.18 6,914 5,316 76.89 0.0370
TAM 2,951 1,808 61.27 2,105 1,395 66.27 0.0003
PDCp 1,808 1,733 95.85 1,395 1,344 96.34 0.5359
PDCa 2,951 1,763 59.74 2,105 1,344 63.85 0.0034
Min 59.74 53.82
Max 97.77 97.74
Range across all 
classes
nitrates
Male Female
a-
blockers
ACEi
anti_ang
inal
antiplate
lets
ARB
BBs
CCBs
diuretics
lipid-
regs
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that the PDCp measure is rarely statistically significant. Antianginals and nitrates 
were the only drug classes where women were found to be more adherent across 
all three adherence measures. The drug-classes to which patients in the 
secondary-treatment group were most persistent are antiplatelets (82.29% for 
males and 80.34% for females), closely followed by lipid-regulating drugs (M: 
82.19%, F: 80.24%) and BBs (M: 80.98%, F: 79.51%). Patients in this group were 
least persistent to alpha-blockers (M: 61.07%, F: 53.82%). 
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7.4.2 Age 
 
Table 7.4.2 Adherence by age in the secondary prevention with treatment group at one year  
For the patients who are in secondary prevention with treatment group, 
adherence tends to be highest in the over-65’s group overall (Table 7.4.2), 
ranking highest across 16 of the 30 measures. This was consistent across TAM, 
PDCp, and PDCa for antianginals, diuretics, and nitrates.  
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Adherence is lowest in the below-55 age group in 50% of instances, and this was 
consistent across all three measures for antianginals and diuretics. However, 
overall differences in adherence between the groups were subtle; across the ten 
drug classes and three adherence measures, average adherence was 78% for the 
below-55 age group, 79% for the 55-65 age group, and 80% for the above 65’s. 
Looking at persistence only (TAM) this flips, with the youngest group being the 
most persistent (72%) and the over-65 group being the least persistent (71%). 
This may indicate that older patients who do persist are comparatively better at 
implementing regimens. Across the ten drug-classes, the range from maximum to 
minimum persistence level is wider in the younger patient group (ranges from 
51-87%; i.e. 36% difference), compared with the group aged over 65 (ranges 
from 58 – 79%, i.e. 21% difference). 
The drugs classes to which patients in the below-55 and 55-65 groups are most 
persistent are antiplatelets (87 and 84%), followed by lipid regulatory drugs (85% 
and 83%), and then BBs (84% and 83%). The over 65’s are most persistent to the 
same three drug-classes, but they are most persistent to lipid regulatory drugs 
(79%) followed by antiplatelets (78%) and BBs (78%). The classes to which 
persistence is lowest varies by age group: for the under-55’s, it is lowest for 
nitrates (51%), antianginals (61%), and diuretics (62%); for the 55-65-year group, 
persistence is lowest to alpha-blockers (57%), nitrates (60%), and antianginals 
(64%); and for the over-65’s, adherence is again lowest to alpha-blockers (58%), 
followed by CCBs (63%) and then nitrates (67%). 
 
 
 
  
154 
 
7.4.3 Deprivation 
 
Table 7.4.3 Adherence by SIMD in the secondary prevention with treatment group at one 
year  
Across SIMD groups, adherence tends to be highest in the more affluent groups 
and lowest in the most deprived groups (Table 7.4.3). However, this is not so 
clear cut, as there is much variation by drug-class and measure used. 7 of the 14 
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instances where adherence is lowest in the most deprived patients, PDCp is the 
measure used. PDCp is possibly less informative when compared with TAM and 
PDCa, as there is very little difference between the maximum and minimum 
values (ranges from 94.44 – 98.42%) and it only reaches a significant p-value for 
one out of the ten drug-classes when comparing the low to mid-SIMD groups, and 
in five of the ten drug-classes when comparing the low to high-SIMD groups. This 
could also indicate that differences are only significant when comparing 
extremes. 
For both age and SIMD, the middle groups (age 55-65 years; SIMD 4-7) are least 
likely to have the highest or lowest adherence levels. This is to be expected if 
there is a linear correlation i.e. as age increases, adherence increases; as 
affluence increases, adherence increase – at the univariate level.  
Regardless of SIMD status, persistence is highest for antiplatelets, followed by 
lipid-regulatory drugs, and BBs. Persistence to all three classes is very high, 
reaching 80-82% in each SIMD group. However, the classes to which patients are 
least persistent does vary slightly by SIMD status. The affluent, high-SIMD, group 
are least adherent to nitrates (62%), CCBs (63%), and alpha-blockers (65%). The 
mid-SIMD group are least persistent to alpha-blockers (57%), nitrates (63%) and 
CCBs (65%), while the most deprived group are least persistent to alpha-blockers 
(54%), nitrates (65%), and antianginals (67%). 
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7.4.4 Comorbidity 
 
Table 7.4.4 Adherence by comorbidity in the secondary prevention with treatment group at 
one year  
p-values derived from Fisher’s exact test where n < 5; In all other instances, p derived from chi-
squared test. Percentages are rounded where the number of nonadherent people is < 10 to protect 
anonymity (while the number of nonadherent patients is not provided, it could otherwise be 
inferred from percentages).  
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Patients with neither diabetes nor depression as a comorbidity were found to be 
the most adherent group overall. They were the most adherent in 11 of the 30 
instances studied, whereas they were only found to be the least adherent group 
in 3 cases: PDCa for anti-anginals, PDCa for CCBs, and PDCp for diuretics.  
For the group of patients who presented with both diabetes and depression, 
there is some conflict in the findings. In 9 out of 30 instances, they were found 
to be most adherent of all four groups, however in 10 cases they were the least 
adherent group. Similarly, there was some inconsistency in the diabetes 
patients, as they were most adherent in 5 cases and least adherent in 5 cases.  
Like the findings for the secondary-prevention group, adherence is never found 
to be highest in the patients who have depression as a comorbidity, for any drug-
class or adherence measure. This matches our expectations following the 
literature review (Chapter 2) and the findings in the primary prevention and 
treatment groups. 
On a class-by-class level there is general agreement in which drug-classes 
patients are most persistent to. For patients with neither comorbidity, diabetes 
only, or those with depression only, persistence was greatest for antiplatelets 
(82, 78, 82% respectively), lipid-regulators (again, rounds up to 82, 78, and 82% 
respectively), and BBS (81, 78, 80%). Similarly, patients who have both diabetes 
and depression, were most persistent to lipid-regulators (80%), ARBs (79%), and 
antiplatelets (79%). Notably in all cases, the differences between the drug-
classes are marginal for each comorbidity group – within a range of 2% for the 
top three classes.  
Persistence is markedly lower in alpha-blockers compared to other drug-classes, 
across all comorbidity sub-groups, ranging from 54-59%. Persistence is also low 
for; nitrates in patients with neither comorbidity and those with depression only 
(63% and 62% respectively); CCBs for those with diabetes only (64%); and 
antianginals for those with both diabetes and depression. 
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7.5 Comparison of Primary Prevention, Treatment, 
Secondary Prevention, and Secondary Prevention 
with Treatment  
 
Table 7.5 Adherence levels between different prevention and treatment groups at one year 
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Across the ten drug-classes and three adherence measures, adherence ranges 
from 32-91% for the primary prevention group, 55-93% for the treatment group, 
63-97% for the secondary prevention group, and 58-96% for the secondary-
treatment group. Consistently, adherence is higher in the secondary prevention 
group compared with the others and is consistently lowest in the primary 
prevention group. Broadly, we can infer that adherence is higher overall for 
those who have previously suffered an MI (secondary prevention, secondary 
prevention with treatment) compared to those who have not (primary 
prevention, treatment).   
The drug-classes to which patients are most or least persistent differ by patient 
group, however there are some consistencies. Lipid-regulatory drugs are one of 
the classes to which patients are most persistent (primary: 70%, treatment: 80%, 
secondary: 89%, secondary-treatment: 82%) and nitrates are a class to which 
they are all least persistent (p: 47%, t: 59%, s: 68%, s-t: 63%). Two other drug-
classes that generally have low-persistence across all four groups are alpha-
blockers (p: 53%, t: 59%, s: 68%, s-t: 58%) and antianginals (p: 50%, t: 63%, s: 
68%, s-t: 66%). The secondary-treatment group also has comparatively lower 
persistence to CCBs (65%).  
BBs are the class to which primary prevention patients are least persistent (40%); 
however, for patients who have suffered an MI (secondary prevention, secondary 
prevention with treatment), BBs are the class to which they are third-most 
persistent (s: 86%, s-t: 80%). Persistence to BBs is therefore in some way 
associated to the different CVD disease severities.   
Persistence also differs by disease severity for some of the drugs to which 
patients are most persistent. Those in the primary prevention and treatment 
groups are, alongside lipid-regulatory drugs, most persistent to ARBs 
(respectively 72% and 77% for primary and treatment) and ACEi’s (65% and 75%). 
Besides lipid-regs and BBs, the secondary and secondary-treatment group are 
most persistent to antiplatelets after 1 year of treatment (respectively 88% and 
82%).   
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7.6 Discussion of adherence epidemiology 
7.6.1 Sex and Age  
Across all four patient groups, male sex is associated with greater adherence. 
There is a notable exception to this, as women tend to be more adherent to 
nitrate drugs compared with men. This fits-in with findings from the systematic 
review of reviews (Chapter 2).   
The strong association between age and adherence observed in the primary 
group may be worth further consideration in the subsequent multi-variate 
analysis. The primary prevention group has a mean age approximately 8 years 
younger than the three other groups (treatment, secondary prevention, etc.) 
and so may impact differences between the groups. Equally, there is a higher 
representation of women in the younger primary prevention group compared 
with the other three groups (Table 7.6), so this may also have a confounding 
effect.  
Table 7.6: Age-Sex distributions  
This could also explain lower adherence to BBs in the primary prevention group 
as, in fact, it is one of the drug classes with the highest levels of adherence in 
the treatment, secondary prevention, and secondary prevention with treatment 
groups. This may be due to prescriptions for anxiety which have not been 
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identified and removed during data-cleaning steps, despite attempts to account 
for this (see Chapter 4). 
Young people may be more likely to be prescribed BBs for anxiety rather than 
CVD, which means it may be taken to manage anxiety symptoms as they occur 
rather than as a daily CVD prophylactic. This could also impact lower adherence 
to BBs in those with depression as a comorbidity (see Table 7.1.4) as it may be 
more likely that this is due to prescriptions with an anxiety indication, rather 
than for CVD. As depression and anxiety often present together, this could 
confound results for this class of medication. As the treatment, secondary 
prevention, and combined groups have evidence of symptomatic CVD, it may be 
more likely that BB prescriptions observed here are for a CVD indication, rather 
than anxiety.  
7.6.2 Deprivation 
SIMD does not have a strong association with adherence at the univariate level, 
though for all patient groups there is a trend toward more-affluent (high SIMD) 
groups being associated with higher adherence, and for the primary prevention, 
secondary prevention, and secondary prevention with treatment groups, it 
appears to be a dose-dependent association. Notably, compared to the other 
characteristics studied (i.e. age, sex, etc) SIMD did not have a differential effect 
on adherence between the drug-classes, in that for all levels of SIMD, patients 
were generally found to be most or least persistent to the same drug-classes. It 
is possible that there is less of an effect than we may expect, as people from 
low-SIMD areas and who are taking medications in the first place have already 
accessed health services and may be more motivated, compared to those in low-
SIMD areas who have been unable to access services in the first instance, and 
who therefore could not be observed in this study.  
It is also important to note that in Scotland, there is universal, free-at-the-
point-of-access healthcare. This could mean that socioeconomic factors have a 
lesser impact on drug adherence compared to that observed in other settings 
(e.g. in the US). A 2017 study found that initiation of DOACs is roughly 
equivalent between the different SIMD groups in Scotland[206], suggesting that 
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this observation may be replicated across other measures of adherence and CVD 
drug-classes too. 
7.6.3 Comorbidities 
Across the different comorbidities, findings were somewhat inconsistent. From 
the literature review, diabetes was associated with higher adherence to CVD 
medications, while depression was associated with lower adherence. This finding 
was replicated in the primary prevention and treatment groups and, on balance, 
the positive effect on adherence that diabetes was associated with seemed to 
cancel out the negative effect of depression, as those with both conditions were 
found to be slightly more adherent than those with neither condition. In the 
secondary prevention group, adherence was again highest for those with 
diabetes as a comorbidity, but those with neither comorbidity were this time 
more adherent than those with both. In this instance, those with depression 
were in fact more adherent than those with both diabetes and depression, a 
finding that was also replicated in the secondary prevention with treatment 
group.    
This variation between patient groups could be due to interactions with 
polypharmacy. Patients with more severe CVD may be on many more 
medications to manage their condition. There is evidence in the literature that 
polypharmacy can have a negative impact on adherence[207], and may make for 
an interesting follow-up to this study in order to investigate this interaction.  
 
7.6.4 Drug-classes 
Adherence is generally low for nitrates, antianginals, and alpha-blockers. 
Compared with the other drug classes, adherence is particularly low for nitrates 
for all patient groups, despite excluding records labelled with ‘as-required’ from 
the analysis. This could be due to missing information, as the NLP algorithm may 
have missed records where the free-text dosage instructions used alternate 
phrasing or if there was insufficient information in the free-text instructions in 
the first place.  
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It is notable that there are 4,112 people in the primary prevention group 
investigated for adherence to nitrates, and 836 in the secondary prevention 
group (Tables 7.1.1, 7.3.2). Had classification of patients into non-symptomatic 
(primary and secondary prevention) and symptomatic (treatment and secondary-
with-treatment) carried out in Chapter 4 been accurate, there would be no 
prescriptions of nitrates or anti-anginals in these groups, as these drugs are only 
prescribed for angina or heart failure. This indicates possible misclassification of 
the patient groups, as only GTN was used to differentiate these patients, while 
other drugs such as isosorbide dinitrate, isosorbide mononitrate, and ivabradine 
may also have been considered. It is also possible that some of these patients 
are truly primary or secondary prevention patients who have been prescribed 
GTN for a non-CVD indication, namely in treating anal fissures; however, these 
should have been removed in data-cleaning steps as prescriptions for topical 
formulations of GTN were removed.  
Consistently, adherence is found to be high for lipid-regulatory drugs, ACEi’s, 
and ARBs. BBs and antiplatelets are also frequently associated with high 
adherence, with notable exceptions in the primary prevention group for BBs and 
in younger (below-55) patients for antiplatelets.   
Notably, adherence to antiplatelets for the first year following an MI is higher 
compared to those in the primary prevention or treatment groups. This is, in a 
way, reassuring as clopidogrel and ticagrelor are two important antiplatelet 
medications, which are a key component of secondary prevention therapies. 
Aspirin as a prophylactic for the primary prevention and treatment groups may 
have lower adherence or may only appear to have lower adherence as it can be 
purchased readily over-the-counter and would not be picked up by PIS.  
7.6.5 Adherence-measures 
Overall trends show very high implementation in patients who are persistent 
(PDCp) suggesting that generally, patients who persist with treatment tend to 
implement their regimens quite well. This means that efforts to understand 
barriers to persistence may be more important than considering implementation.  
Going forward for the multi-variate analysis, TAM will be the measure used.  
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7.6.6 Limitations 
There are some limitations to this analysis: adherence may appear higher than it 
truly is because this analysis excludes people who leave the patient group early; 
this is an issue for the secondary prevention group, as the median time spent in 
this group is very short - only about 4 months. As this study is comparing across 
10 drug classes, it also has quite a generous definition of adherence compared to 
other studies that look at drugs individually. Here, people are identified as 
adherent if they have any prescription of that class, compared to other studies 
which may have more strict definitions of drug switching. 
7.7 Multivariate Analysis 
 Primary Treatment Secondary Secondary-Treat 
  OR (CI)  
p 
value   OR (CI)  
p 
value   OR (CI)  
p 
value   OR (CI)  
p 
value  
ACEi                 
sex female 0.7 (0.68-0.71) 
 
p<0.00
1 
0.72 (0.70-
0.75) 
 
p<0.00
1 
0.62 (0.53-
0.72) 
 
p<0.00
1 
0.84 (0.77-
0.91) 
 
p<0.00
1 
age 55 to 65 0.98 (0.96-1.00) 
 
p=0.07
6 
1.11 (1.04-
1.17) 
 
p=0.00
1 
0.87 (0.69-
1.09) 
 
p=0.23
0 
0.86 (0.77-
0.96) 
 
p=0.00
9 
age above 65 0.87 (0.85-0.89) 
 
p<0.00
1 
1.12 (1.06-
1.18) 
 
p<0.00
1 
0.67 (0.55-
0.82) 
 
p<0.00
1 
0.63 (0.57-
0.70) 
 
p<0.00
1 
diabetes 1.16 (1.12-1.19) 
 
p<0.00
1 
1.21 (1.14-
1.27) 
 
p<0.00
1 
1.01 (0.80-
1.28) 
 
p=0.94
0 
0.87 (0.78-
0.98) 
 
p=0.02
3 
depression 0.93 (0.91-0.96) 
 
p<0.00
1 
0.98 (0.94-
1.04) 
 
p=0.55
0 
0.8 (0.65-
0.99) 
 
p=0.03
4 
0.9 (0.81-
1.01) 
 
p=0.06
2 
diabetes and 
depression 
1.11 (1.05-
1.18) 
 
p=0.00
1 
1.15 (1.06-
1.26) 
 
p=0.00
1 
1.05 (0.68-
1.68) 
 
p=0.82
6 
0.84 (0.68-
1.05) 
 
p=0.11
2 
SIMD mid 1.04 (1.02-1.06) 
 
p<0.00
1 
1.04 (1.00-
1.09) 
 
p=0.06
2 
1.01 (0.84-
1.20) 
 
p=0.94
3 
1.04 (0.94-
1.15) 
 
p=0.44
9 
SIMD low  1.08 (1.06-1.11) 
 
p<0.00
1 
1.1 (1.05-
1.15) 
 
p<0.00
1 
1.07 (0.88-
1.29) 
 
p=0.51
3 
1.05 (0.94-
1.16) 
 
p=0.39
1 
Model fit (c-
stat) 5.60E-01 5.52E-01 0.5911754 5.67E-01 
Antiplatelet                 
sex female 0.6 (0.59-0.62) 
 
p<0.00
1 
0.68 (0.67-
0.70) 
 
p<0.00
1 
0.84 (0.71-
1.00) 
 
p=0.04
7 
0.96 (0.88-
1.03) 
 
p=0.25
2 
age 55 to 65 2.39 (2.32-2.46) 
 
p<0.00
1 
1.73 (1.66-
1.80) 
 
p<0.00
1 
1.19 (0.91-
1.57) 
 
p=0.20
5 
0.83 (0.74-
0.93) 
 
p=0.00
2 
age above 65 3.15 (3.07-3.24) 
 
p<0.00
1 
2.69 (2.59-
2.79) 
 
p<0.00
1 
0.66 (0.52-
0.83) 
 
p<0.00
1 
0.57 (0.52-
0.64) 
 
p<0.00
1 
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diabetes 1.07 (1.02-1.11) 
 
p=0.00
2 
1.24 (1.18-
1.30) 
 
p<0.00
1 
0.82 (0.65-
1.04) 
 
p=0.09
1 
0.81 (0.73-
0.91) 
 
p<0.00
1 
depression 1.22 (1.18-1.25) 
 
p<0.00
1 
1.01 (0.98-
1.05) 
 
p=0.51
8 
1 (0.79-
1.28) 
 
p=0.99
6 
0.92 (0.83-
1.02) 
 
p=0.12
4 
diabetes and 
depression 
1.42 (1.31-
1.54) 
 
p<0.00
1 
1.46 (1.35-
1.57) 
 
p<0.00
1 
1.09 (0.69-
1.84) 
 
p=0.72
2 
0.76 (0.63-
0.92) 
 
p=0.00
5 
SIMD mid 1.07 (1.04-1.10) 
 
p<0.00
1 
1.07 (1.03-
1.11) 
 
p<0.00
1 
1.05 (0.86-
1.28) 
 
p=0.63
7 
1.06 (0.96-
1.16) 
 
p=0.23
5 
SIMD low  1.16 (1.12-1.19) 
 
p<0.00
1 
1.18 (1.14-
1.22) 
 
p<0.00
1 
0.93 (0.75-
1.14) 
 
p=0.47
7 
1.08 (0.98-
1.19) 
 
p=0.13
1 
Model fit  6.36E-01 6.07E-01 0.5838904 5.69E-01 
BBs                 
sex female 0.73 (0.72-0.74)  p<0.001 
0.73 (0.71-
0.75)  p<0.001 
0.92 (0.78-
1.10)  p=0.372 1 (0.92-1.08)  p=0.918 
age 55 to 65 2.12 (2.08-2.17)  p<0.001 
1.64 (1.57-
1.71)  p<0.001 
1.23 (0.95-
1.59)  p=0.111 
0.88 (0.78-
0.99)  p=0.037 
age above 65 3.42 (3.35-3.50)  p<0.001 
2.28 (2.19-
2.37)  p<0.001 
0.88 (0.70-
1.10)  p=0.277 
0.65 (0.59-
0.73)  p<0.001 
diabetes 1.38 (1.32-1.44)  p<0.001 
1.26 (1.20-
1.33)  p<0.001 
0.88 (0.69-
1.12)  p=0.285 
0.85 (0.76-
0.95)  p=0.005 
depression 0.93 (0.91-0.95)  p<0.001 
0.88 (0.84-
0.91)  p<0.001 
0.9 (0.71-
1.16)  p=0.419 
0.85 (0.76-
0.95)  p=0.004 
diabetes and 
depression 
1.32 (1.23-
1.42)  p<0.001 
1.2 (1.10-
1.30)  p<0.001 
1.49 (0.87-
2.80)  p=0.176 
0.76 (0.62-
0.94)  p=0.011 
SIMD mid 1.07 (1.05-1.09)  p<0.001 
1.05 (1.01-
1.09)  p=0.009 
1.02 (0.83-
1.24)  p=0.875 
1.02 (0.93-
1.13)  p=0.646 
SIMD low  1.1 (1.07-1.12)  p<0.001 
1.17 (1.13-
1.22)  p<0.001 
0.91 (0.73-
1.13)  p=0.403 
1.03 (0.93-
1.14)  p=0.593 
Model fit  6.47E-01 5.95E-01 5.48E-01 5.55E-01 
Lipid-regs                 
sex female 0.82 (0.81-0.84) 
 
p<0.00
1 
0.7 (0.68-
0.72) 
 
p<0.00
1 
0.69 (0.58-
0.82) 
 
p<0.00
1 
0.94 (0.87-
1.02) 
 
p=0.13
3 
age 55 to 65 1.37 (1.34-1.40) 
 
p<0.00
1 
1.5 (1.43-
1.57) 
 
p<0.00
1 
1.23 (0.93-
1.62) 
 
p=0.15
1 
0.85 (0.76-
0.96) 
 
p=0.00
7 
age above 65 1.39 (1.36-1.42) 
 
p<0.00
1 
1.91 (1.83-
1.99) 
 
p<0.00
1 
0.76 (0.60-
0.96) 
 
p=0.02
5 
0.66 (0.60-
0.73) 
 
p<0.00
1 
diabetes 1.38 (1.34-1.43) 
 
p<0.00
1 
1.35 (1.29-
1.42) 
 
p<0.00
1 
0.84 (0.66-
1.09) 
 
p=0.19
1 
0.8 (0.72-
0.89) 
 
p<0.00
1 
depression 1.05 (1.02-1.07) 
 
p<0.00
1 
1.09 (1.05-
1.13) 
 
p<0.00
1 
0.89 (0.70-
1.15) 
 
p=0.38
0 
0.92 (0.83-
1.03) 
 
p=0.14
6 
diabetes and 
depression 
1.66 (1.56-
1.76) 
 
p<0.00
1 
1.6 (1.47-
1.73) 
 
p<0.00
1 
1 (0.63-
1.69) 
 
p=0.98
8 
0.83 (0.69-
1.02) 
 
p=0.07
5 
SIMD mid 0.96 (0.94-0.99) 
 
p=0.00
1 
1 (0.97-
1.04) 
 
p=0.90
5 
0.89 (0.71-
1.10) 
 
p=0.26
5 
1.07 (0.97-
1.17) 
 
p=0.17
3 
SIMD low  1 (0.97-1.02) 
 
p=0.70
3 
1.07 (1.03-
1.11) 
 
p=0.00
1 
0.83 (0.66-
1.04) 
 
p=0.10
7 
1.09 (0.99-
1.20) 
 
p=0.09
0 
Model fit  5.53E-01 5.83E-01 0.5878772 5.55E-01 
Table 7.7: Multivariate analysis in each of the patient groups for selected drug-classes.  
166 
 
Table 7.7 shows the results of the multivariate analysis, and Figure 7.1 depicts 
these as a forest plot. The odds-ratio here relates to the ‘risk of persistence’ i.e. 
an OR below 1 indicates that the risk factor is associated with lower levels of 
persistence, while an OR above 1 indicates an association with increased levels 
of persistence. 
In all patient groups, female sex is associated with poorer persistence compared 
to the referent group (male). In the primary prevention and treatment groups, 
this is significant for all four drug-classes studied. In the secondary prevention 
group, this is significant for all drug-classes other than BBs, and for the 
secondary prevention with treatment group, this is only significant for ACEi’s.  
The clearest positive association between older age and higher persistence is in 
the treatment group. Compared to the referent (below-55 years), persistence 
tends to increase with increased age, as the over-65-year group has an even 
stronger association than that observed in the 55-65-year group. ACEi’s are the 
one exception to this, where the positive association slightly decreases between 
the 55-65 and over-65-year groups. In the primary prevention group, antiplatelet 
drugs and BBs also show an increased association with persistence as age 
increases; as do lipid-regulatory drugs, but to a lesser extent. ACEi’s are again 
an exception, where there is a non-significant difference in the association with 
persistence observed between the referent group and the 55-65-year group, and 
a reduced association with persistence observed in the over-65s compared to the 
below-55s.  
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Figure 7.1: Multivariate odds-ratios of persistence to CVD drugs: blue = ACEi, red = 
antiplatelet, green = betablockers, purple = lipid-regulatory  
Secondary Prevention         Secondary-with-treatment 
Primary Prevention       Treatment 
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In the secondary prevention group, none of the drug-classes show a significant 
difference between the referent (below-55) and 55-65-year group. For the group 
aged over-65, there is an association with reduced persistence, significant in all 
drug-classes other than BBs. The secondary prevention with treatment group 
shows almost the exact inverse of the relationship observed in the primary 
prevention group: all drug-classes are associated with reduced levels of 
persistence, and this is ‘dose-dependent’, with the oldest age group showing the 
poorest persistence.  
In the primary prevention and treatment groups, diabetes as a comorbidity is 
associated with higher levels of persistence compared to the referent group. 
This is significant in all drug classes and is also true of the patients who have 
both diabetes and depression as comorbidities, compared to the referent group 
who have neither. The association between depression and persistence is less 
clear. In the primary prevention group, depression is associated with lower 
levels of persistence for ACEi’s and BBs, but higher persistence for antiplatelet 
drugs and lipid-regulatory drugs. This is also true of the treatment group, though 
ACEi’s and antiplatelets show non-significant differences between the 
persistence predicted in the referent group with the depressed group.   
For secondary prevention there are no significant associations between the 
comorbidities studied and persistence, except for depression, which is 
associated with poorer persistence to ACEi’s. For the secondary prevention with 
treatment patients, the presence of either diabetes, depression, or both 
diabetes and depression as a comorbidity tends to be associated with decreased 
persistence levels, though this is only significant for diabetes across all four 
drug-classes. Persistence to BBs is significantly associated with decreased 
persistence in those with depression and those with both depression and 
diabetes, while persistence to antiplatelets is significantly associated with 
decreased persistence only in patients with both comorbidities.  
Across the four patient groups and drug-classes, there are no clear patterns 
between SIMD and persistence. In the primary prevention and treatment groups, 
there is an association with lower SIMD (i.e. most deprived) and increased 
persistence, for ACEi’s, antiplatelet drugs and BBs. For lipid-regulatory drugs, 
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this is only significant in the treatment group. In the secondary prevention and 
secondary prevention with treatment groups, there are no significant 
interactions  
7.8 Discussion of Multivariate Analysis 
Observations of decreased persistence being associated with female sex 
replicates results observed in literature review (Chapter 2). This could be 
mediated through disease severity, as it is well-established that women tend to 
suffer less severely from CVD compared to men[202, 203]. If it follows that male 
patients tend to have higher blood-pressure or higher cholesterol at baseline, or 
that they have suffered a much more severe MI, the urgency for CVD prophylaxis 
may be more substantial. Furthermore, as men are generally at higher risk of 
CVD, and this risk is communicated to them, it could contribute to different 
health perceptions and an increased motivation to persist with therapy. This 
theory could be backed up by the fact that there is a non—significant difference 
between the sexes in the most severe CVD group, the secondary prevention with 
treatment group, indicating that patients who have both suffered an MI and have 
symptomatic CVD persist regardless of sex. Specifically, there is not a sex-
difference for BBs and antiplatelets, which are key drug-classes recommended 
for use following an MI.  
The relationship with age and persistence seems to flip between patients who 
have not suffered an MI (primary prevention and treatment) vs. those who have. 
This suggests that disease severity may mediate the interaction between age and 
persistence. Again, this may be due to health perceptions, as younger people 
who suffer an MI may be much more likely to persist than younger patients who 
have not, as this is a much more tangible interaction with ill-health than this age 
group might otherwise be exposed to. Those who are below-55 and are 
asymptomatic (i.e. have high blood pressure or high cholesterol) may choose to 
try to mediate their risk of CVD through diet and exercise in the first instance, 
as lifestyle changes may be easier to implement compared to older adults. 
The association between diabetes and increased adherence in the primary 
prevention and treatment groups may also be mediated through the patient’s 
perception of their health. It could also be related to drug-taking being a regular 
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part of their routine, especially for those with Type 1 diabetes, who will be 
familiar with life-long daily medication taking and the risks of non-adherence or 
non-persistence in this context. For those who have suffered an MI, the different 
interaction with diabetes may be due to poorer health overall, and possible 
confounding from polypharmacy, leading to difficulties in management of 
healthcare. Following literature review, depression may have been expected to 
be associated with a reduction in persistence due to lack of motivation and self-
efficacy. If this were the case, it is not clear why this is observed inconsistently 
across drug-classes. BBs, particularly propranolol, are also prescribed for 
anxiety, and while I attempted to filter these out in the data-cleaning stage, it 
is possible that these prescriptions are still represented in some instances. As 
depression and anxiety often present together[208], this could mean that reduced 
persistence in this class could be due to the BB being prescribed for this 
indication rather than for CV.  
While there is not a clear pattern between SIMD and persistence, it does appear 
that, if anything, persistence is higher in those from more deprived areas. 
Because access to healthcare is one of the factors used to calculate SIMD, these 
patients have less access to such services and may have been predicted to show 
lower levels of persistence. It may be that those who do access these services in 
the first place are more highly motivated. Or, it may be important to consider 
the classes of drugs where we see this interaction. The most common 
antiplatelet drug prescribed in our dataset is aspirin, a drug that can be 
purchased readily and cheaply over-the-counter. Those who appear non-
persistent in the most affluent patient group (here, the referent group) may 
have the means to purchase drugs rather than relying on prescriptions.  
7.9 Chapter Summary 
The epidemiology of adherence and persistence to cardiovascular drugs in 
Scotland largely aligns with findings observed in the literature review, with some 
minor discrepancies. Particularly, adherence appears to be greatest in older, 
male patients, and those with more severe CVD. This suggests that national 
datasets in Scotland can capture population levels of persistence in a reasonably 
reliable way and may be useful to consider in research projects where some 
understanding of such patient mediation-taking behaviors are of interest.  
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8 Results: Outcomes of Non-persistence 
Following the classification of patients in each group as persistent or non-
persistent over the first year of cardiovascular drug therapy, my next aim was to 
investigate whether there were associations between persistence and 
subsequent health outcomes. Here, I look at patients who were classed as 
persistent with TAM at the end of year 1 (for Cox-proportional hazard analyses, 
this is T0) and conducted all-cause mortality over 5-years post-follow-up. To 
investigate some of the results further, a cardiovascular drug-count variable was 
included to account for polypharmacy, and analysis was repeated at 1- and 5- 
years post follow-up, along with additional investigations to exclude patients on 
beta-blockers who may have been prescribed these for anxiety, and then a 
comparison of specific beta-blockers and antiplatelet drugs.   
  
172 
 
8.1 All-Cause Mortality: Over 5-years follow-up 
8.1.1 Primary prevention 
Table 8.1. Mortality 5-years after classed as persistent or not with TAM (T0) in the primary 
group, across four CVD drug-classes. 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 63,946 9,671 - -
Yes 343,409 43,890 0.83 (0.81-0.84, p<0.001) 0.73 (0.71-0.75, p<0.001)
Sex F 200,165 27,563 - -
M 207,190 25,998 0.91 (0.89-0.92, p<0.001) 1.18 (1.16-1.20, p<0.001)
Age group below 55 110,446 2,825 - -
55 to 65 118,314 7,048 2.37 (2.27-2.48, p<0.001) 2.53 (2.42-2.65, p<0.001)
above 65 178,595 43,688
10.83 (10.42-11.25, 
p<0.001) 12.40 (11.91-12.90, p<0.001)
SIMD group high 112,937 12,496 - -
mid 168,295 22,145 1.20 (1.18-1.23, p<0.001) 1.20 (1.17-1.23, p<0.001)
low 125,277 18,772 1.38 (1.35-1.42, p<0.001) 1.45 (1.42-1.49, p<0.001)
Comorbidty Status neither 272,139 32,323 - -
diabetes 59,815 9,268 1.33 (1.30-1.36, p<0.001) 1.29 (1.26-1.32, p<0.001)
depression 40,755 6,264 1.33 (1.29-1.36, p<0.001) 1.67 (1.62-1.71, p<0.001)
both 11,343 2,114 1.63 (1.56-1.71, p<0.001) 2.09 (2.00-2.18, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 75,836 13,871 - -
Yes 275,850 62,322 1.26 (1.23-1.28, p<0.001) 1.04 (1.02-1.06, p<0.001)
Sex F 182,229 41,611 - -
M 169,457 34,582 0.88 (0.87-0.89, p<0.001) 1.07 (1.05-1.08, p<0.001)
Age group below 55 43,050 1,777 - -
55 to 65 85,182 6,894 2.00 (1.90-2.11, p<0.001) 2.16 (2.04-2.28, p<0.001)
above 65 223,454 67,522 8.54 (8.14-8.95, p<0.001) 9.96 (9.48-10.48, p<0.001)
SIMD group high 91,812 18,014 - -
mid 143,694 31,195 1.12 (1.10-1.14, p<0.001) 1.15 (1.13-1.18, p<0.001)
low 115,415 26,763 1.21 (1.18-1.23, p<0.001) 1.33 (1.31-1.36, p<0.001)
Comorbidty Status neither 217,477 46,345 - -
diabetes 56,802 10,134 0.82 (0.80-0.84, p<0.001) 1.00 (0.98-1.02, p=0.972)
depression 42,192 12,102 1.42 (1.40-1.45, p<0.001) 1.71 (1.67-1.74, p<0.001)
both 11,527 2,611 1.07 (1.03-1.12, p<0.001) 1.61 (1.55-1.68, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 101,176 7,489 - -
Yes 257,411 36,765 1.99 (1.94-2.04, p<0.001) 0.92 (0.89-0.94, p<0.001)
Sex F 215,483 24,724 - -
M 143,104 19,530 1.20 (1.18-1.23, p<0.001) 1.24 (1.22-1.26, p<0.001)
Age group below 55 134,562 3,381 - -
55 to 65 83,633 5,590 2.72 (2.60-2.84, p<0.001) 2.92 (2.79-3.06, p<0.001)
above 65 140,392 35,283
11.35 (10.96-11.76, 
p<0.001) 13.17 (12.66-13.69, p<0.001)
SIMD group high 94,921 10,713 - -
mid 143,906 18,207 1.13 (1.10-1.16, p<0.001) 1.18 (1.15-1.21, p<0.001)
low 118,891 15,218 1.14 (1.12-1.17, p<0.001) 1.39 (1.36-1.43, p<0.001)
Comorbidty Status neither 230,409 28,315 - -
diabetes 25,858 5,144 1.69 (1.64-1.74, p<0.001) 1.32 (1.28-1.36, p<0.001)
depression 75,370 6,833 0.73 (0.71-0.75, p<0.001) 1.40 (1.36-1.44, p<0.001)
both 5,850 1,181 1.73 (1.63-1.83, p<0.001) 1.94 (1.83-2.06, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 75,410 10,490 - -
Yes 474,515 63,077 0.94 (0.92-0.96, p<0.001) 0.78 (0.76-0.80, p<0.001)
Sex F 275,171 38,392 - -
M 274,754 35,175 0.91 (0.90-0.93, p<0.001) 1.19 (1.18-1.21, p<0.001)
Age group below 55 107,741 3,035 - -
55 to 65 172,033 10,021 2.10 (2.02-2.19, p<0.001) 2.40 (2.30-2.51, p<0.001)
above 65 270,151 60,511 8.87 (8.56-9.20, p<0.001) 11.22 (10.79-11.66, p<0.001)
SIMD group high 146,080 16,518 - -
mid 223,284 29,665 1.19 (1.17-1.21, p<0.001) 1.20 (1.17-1.22, p<0.001)
low 179,440 27,181 1.37 (1.34-1.40, p<0.001) 1.47 (1.44-1.50, p<0.001)
Comorbidty Status neither 336,824 41,597 - -
diabetes 93,674 12,991 1.13 (1.11-1.15, p<0.001) 1.33 (1.30-1.35, p<0.001)
depression 63,558 10,289 1.35 (1.32-1.38, p<0.001) 1.70 (1.66-1.74, p<0.001)
both 20,374 3,486 1.43 (1.38-1.48, p<0.001) 2.20 (2.13-2.28, p<0.001)
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In the primary prevention group, patients who were persistent at T0 with 
antiplatelets were, counterintuitively, at a higher hazard of death in the next 5 
years, even after adjusting for sex, age, SIMD-group, and comorbidity status. For 
beta-blockers, persistence in the first year of therapy was associated with a 
reduced hazard of mortality when adjusted for the additional risk factors. For 
ACEi’s and lipid-regulatory drugs, persistence is associated with reduced 
mortality in the uni- and multivariate analyses. Risk factors associated with 
poorer survival - male sex, older age, deprived SIMD group, and comorbidities – 
follow the expected pattern for all four drug-classes in the multivariable 
analysis, and this is especially strong for older age (above 65 years), where 
hazard ratios range from 9.96-13.17.  
Figure 8.1 Survival Curves - 5-years after classed as persistent or not with TAM (T0) in the 
primary group, across four CVD drug-classes. 
Survival analysis (Figure 8.1) shows a relatively low number of mortalities over 
5-years following assessment of TAM, as may be expected for the relatively 
younger primary prevention patients. There is little difference in survival rates 
between those who were found to be persistent and those who were not. For 
anti-platelets and beta-blockers, the survival lines cross at around 2-years, 
indicating a failure of the cox-model assumption here. Further analysis of 
Schoenfeld residuals (Appendix F) indicates that these models may indeed be 
flawed.  
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8.1.2 Treatment 
Table 8.2 Mortality 5-years after classed as persistent or not with TAM (T0) in the treatment 
group, across four CVD drug-classes. 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 8,999 2,654 - -
Yes 59,884 13,211 0.70 (0.67-0.73, p<0.001) 0.68 (0.65-0.71, p<0.001)
Sex F 29,131 6,723 - -
M 39,752 9,142 1.00 (0.97-1.03, p=0.861) 1.16 (1.12-1.20, p<0.001)
Age group below 55 7,109 403 - -
55 to 65 17,511 1,869 1.94 (1.74-2.16, p<0.001) 2.00 (1.78-2.24, p<0.001)
above 65 44,263 13,593 6.30 (5.70-6.95, p<0.001) 7.22 (6.51-8.01, p<0.001)
SIMD group high 14,273 3,010 - -
mid 26,722 6,034 1.08 (1.04-1.13, p<0.001) 1.12 (1.07-1.18, p<0.001)
low 27,770 6,786 1.18 (1.13-1.24, p<0.001) 1.33 (1.27-1.39, p<0.001)
Comorbidty Status neither 41,818 8,986 - -
diabetes 10,227 2,721 1.28 (1.22-1.33, p<0.001) 1.29 (1.24-1.35, p<0.001)
depression 8,757 2,111 1.15 (1.10-1.21, p<0.001) 1.41 (1.35-1.48, p<0.001)
both 3,028 820 1.31 (1.22-1.41, p<0.001) 1.75 (1.63-1.88, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 17,507 3,540 - -
Yes 111,052 24,660 1.10 (1.06-1.14, p<0.001) 0.89 (0.86-0.92, p<0.001)
Sex F 61,899 13,538 - -
M 66,660 14,662 1.01 (0.98-1.03, p=0.533) 1.16 (1.13-1.19, p<0.001)
Age group below 55 13,181 698 - -
55 to 65 32,148 2,983 1.79 (1.65-1.94, p<0.001) 1.91 (1.75-2.08, p<0.001)
above 65 83,230 24,519 6.42 (5.95-6.92, p<0.001) 7.64 (7.05-8.28, p<0.001)
SIMD group high 27,319 5,494 - -
mid 49,507 10,756 1.09 (1.06-1.13, p<0.001) 1.14 (1.10-1.18, p<0.001)
low 51,504 11,877 1.17 (1.13-1.20, p<0.001) 1.33 (1.29-1.38, p<0.001)
Comorbidty Status neither 81,104 16,773 - -
diabetes 14,340 3,681 1.28 (1.23-1.32, p<0.001) 1.28 (1.23-1.32, p<0.001)
depression 19,116 4,433 1.14 (1.11-1.18, p<0.001) 1.44 (1.39-1.49, p<0.001)
both 4,449 1,188 1.35 (1.27-1.43, p<0.001) 1.80 (1.70-1.91, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 11,558 2,269 - -
Yes 82,553 17,062 1.04 (1.00-1.09, p=0.053) 0.86 (0.82-0.90, p<0.001)
Sex F 42,855 8,785 - -
M 51,256 10,546 1.01 (0.98-1.03, p=0.692) 1.16 (1.13-1.20, p<0.001)
Age group below 55 10,046 527 - -
55 to 65 24,173 2,096 1.68 (1.53-1.85, p<0.001) 1.72 (1.56-1.90, p<0.001)
above 65 59,892 16,708 6.07 (5.57-6.62, p<0.001) 6.95 (6.35-7.61, p<0.001)
SIMD group high 21,327 4,102 - -
mid 36,723 7,432 1.06 (1.02-1.10, p=0.004) 1.11 (1.07-1.16, p<0.001)
low 35,896 7,754 1.14 (1.09-1.18, p<0.001) 1.31 (1.26-1.37, p<0.001)
Comorbidty Status neither 60,734 11,752 - -
diabetes 11,080 2,785 1.35 (1.29-1.40, p<0.001) 1.33 (1.27-1.38, p<0.001)
depression 12,693 2,606 1.07 (1.03-1.12, p=0.001) 1.35 (1.30-1.41, p<0.001)
both 2,999 800 1.46 (1.36-1.56, p<0.001) 1.91 (1.78-2.06, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 12,632 2,974 - -
Yes 119,088 25,001 0.86 (0.83-0.89, p<0.001) 0.73 (0.70-0.76, p<0.001)
Sex F 62,502 13,061 - -
M 69,218 14,914 1.04 (1.01-1.06, p=0.002) 1.20 (1.17-1.23, p<0.001)
Age group below 55 13,070 669 - -
55 to 65 33,643 3,107 1.84 (1.70-2.00, p<0.001) 2.01 (1.84-2.19, p<0.001)
above 65 85,007 24,199 6.37 (5.90-6.88, p<0.001) 7.76 (7.15-8.42, p<0.001)
SIMD group high 28,084 5,417 - -
mid 50,718 10,556 1.09 (1.05-1.13, p<0.001) 1.13 (1.10-1.17, p<0.001)
low 52,699 11,935 1.20 (1.16-1.24, p<0.001) 1.36 (1.31-1.41, p<0.001)
Comorbidty Status neither 81,940 16,162 - -
diabetes 15,670 4,043 1.35 (1.31-1.40, p<0.001) 1.36 (1.31-1.41, p<0.001)
depression 19,290 4,292 1.15 (1.11-1.19, p<0.001) 1.44 (1.40-1.49, p<0.001)
both 4,895 1,279 1.39 (1.31-1.47, p<0.001) 1.88 (1.77-1.99, p<0.001)
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For the treatment group, the hazard ratio indicates a reduced 5-year risk of 
mortality in patients classed as persistent at T0 across all four drug-classes in 
the multivariate analyses.  
Figure 8.2 Survival Curves - 5-years after classed as persistent or not with TAM (T0) in the 
treatment group, across four CVD drug-classes. 
Survival analyses for the treatment group (Figure 8.2) indicates reduced risk of 
mortality in persistent patients over 5-years for those on ACEi’s and lipid-
regulatory drugs, though little difference between persistent and non-persistent 
patients for those prescribed beta-blockers or antiplatelet drugs, with survival 
curves crossing at the 3.5-year (antiplatelet) and 4-year (beta-blocker) marks. 
This indicates that hazards are not proportional overtime, and the underlying 
assumptions of the Cox proportional hazards model have failed.  
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8.1.3  Secondary prevention  
Table 8.3 Mortality 5-years after classed as persistent or not with TAM (T0) in the secondary 
group, across four CVD drug-classes. 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 434 62 - -
Yes 1,908 235 0.81 (0.61-1.07, p=0.138) 0.80 (0.60-1.07, p=0.134)
Sex F 783 132 - -
M 1,559 165 0.60 (0.48-0.75, p<0.001) 0.81 (0.63-1.03, p=0.089)
Age group below 55 514 10 - -
55 to 65 703 46 3.46 (1.75-6.86, p<0.001) 3.89 (1.89-7.98, p<0.001)
above 65 1,125 241 12.44 (6.61-23.41, p<0.001) 14.00 (7.16-27.35, p<0.001)
SIMD group high 656 75 - -
mid 986 126 1.13 (0.85-1.51, p=0.398) 1.21 (0.90-1.63, p=0.214)
low 694 96 1.24 (0.92-1.68, p=0.156) 1.53 (1.12-2.10, p=0.008)
Comorbidty Status neither 1,658 174 - -
diabetes 252 45 1.79 (1.29-2.49, p<0.001) 1.61 (1.16-2.24, p=0.004)
depression 291 47 1.59 (1.15-2.19, p=0.005) 1.68 (1.21-2.34, p=0.002)
both 44 11 2.65 (1.44-4.87, p=0.002) 3.25 (1.76-5.99, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 279 68 - -
Yes 2,588 372 0.49 (0.38-0.63, p<0.001) 0.54 (0.41-0.71, p<0.001)
Sex F 1,019 206 - -
M 1,848 234 0.59 (0.49-0.72, p<0.001) 0.79 (0.65-0.97, p=0.023)
Age group below 55 582 12 - -
55 to 65 793 55 3.44 (1.84-6.43, p<0.001) 3.62 (1.89-6.96, p<0.001)
above 65 1,492 373 14.06 (7.91-24.97, p<0.001) 14.74 (8.06-26.94, p<0.001)
SIMD group high 815 118 - -
mid 1,205 186 1.08 (0.86-1.36, p=0.516) 1.18 (0.92-1.50, p=0.190)
low 840 136 1.14 (0.89-1.45, p=0.308) 1.41 (1.09-1.83, p=0.009)
Comorbidty Status neither 1,973 245 - -
diabetes 322 68 1.81 (1.38-2.36, p<0.001) 1.62 (1.24-2.12, p<0.001)
depression 367 71 1.62 (1.24-2.11, p<0.001) 1.80 (1.38-2.35, p<0.001)
both 65 20 2.82 (1.79-4.45, p<0.001) 3.27 (2.07-5.16, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 296 52 - -
Yes 2,121 287 0.69 (0.51-0.93, p=0.014) 0.75 (0.55-1.03, p=0.078)
Sex F 841 157 - -
M 1,576 182 0.59 (0.48-0.73, p<0.001) 0.79 (0.63-0.99, p=0.044)
Age group below 55 515 10 - -
55 to 65 694 48 3.67 (1.86-7.26, p<0.001) 4.08 (1.99-8.36, p<0.001)
above 65 1,208 281 13.75 (7.32-25.84, p<0.001) 14.64 (7.50-28.58, p<0.001)
SIMD group high 668 86 - -
mid 1,018 148 1.15 (0.88-1.50, p=0.311) 1.27 (0.95-1.69, p=0.102)
low 726 105 1.15 (0.86-1.53, p=0.346) 1.40 (1.03-1.90, p=0.030)
Comorbidty Status neither 1,673 181 - -
diabetes 286 61 2.09 (1.57-2.80, p<0.001) 1.80 (1.34-2.40, p<0.001)
depression 297 52 1.67 (1.23-2.28, p=0.001) 1.86 (1.36-2.54, p<0.001)
both 50 14 2.89 (1.68-4.97, p<0.001) 3.51 (2.03-6.06, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 250 53 - -
Yes 2,537 346 0.52 (0.39-0.69, p<0.001) 0.57 (0.42-0.77, p<0.001)
Sex F 981 184 - -
M 1,806 215 0.60 (0.49-0.73, p<0.001) 0.80 (0.65-0.99, p=0.037)
Age group below 55 571 11 - -
55 to 65 785 53 3.59 (1.88-6.88, p<0.001) 3.84 (1.94-7.59, p<0.001)
above 65 1,431 335 14.03 (7.69-25.58, p<0.001) 15.00 (7.97-28.24, p<0.001)
SIMD group high 783 103 - -
mid 1,171 174 1.14 (0.90-1.46, p=0.279) 1.28 (0.99-1.66, p=0.058)
low 826 122 1.15 (0.89-1.50, p=0.293) 1.38 (1.04-1.82, p=0.025)
Comorbidty Status neither 1,926 221 - -
diabetes 310 61 1.82 (1.37-2.42, p<0.001) 1.60 (1.20-2.12, p=0.001)
depression 352 65 1.66 (1.26-2.19, p<0.001) 1.82 (1.37-2.40, p<0.001)
both 66 19 2.90 (1.81-4.63, p<0.001) 3.37 (2.11-5.38, p<0.001)
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Patients classed as persistent at T0 in the secondary-prevention group are 
associated with a lower risk of mortality across all four-drug classes. Unlike the 
primary prevention and treatment groups, adjustment for potential confounders 
raises hazard ratios; though these remain below 1 and remain significant for the 
antiplatelets and lipid-regulatory drugs. Generally, traditional risk-factors for 
mortality present with a hazard ratio above one in the univariable and 
multivariable analyses, with the notable exception of male sex, which is 
associated with lower levels of mortality, significant in the adjusted results for 
antiplatelets, beta-blockers, and lipid-regulatory drugs.  
Figure 8.3 Survival Curves - 5-years after classed as persistent or not with TAM (T0) in the 
secondary prevention group, across four CVD drug-classes. 
For all four drug-classes, survival analyses in secondary prevention patients 
(Figure 8.3) indicate an association with better survival in persistent patients 
compared to non-persistent patients, though this is not significant for those 
prescribed ACEi’s (p = 0.14). For antiplatelets, hazards are not directly 
proportional overtime, as the gap between survival for persistent vs non-
persistent patients widens from around 2.5 years onwards.  
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8.1.4 Secondary prevention progressing to treatment 
Table 8.4: Mortality 5-years after classed as persistent or not with TAM (T0) in the 
secondary-with-treatment group, across four CVD drug-classes. 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 607 156 - -
Yes 3,960 629 0.57 (0.48-0.68, p<0.001) 0.67 (0.56-0.81, p<0.001)
Sex F 1,485 337 - -
M 3,082 448 0.61 (0.53-0.70, p<0.001) 0.90 (0.77-1.05, p=0.178)
Age group below 55 1,139 44 - -
55 to 65 1,336 102 2.02 (1.42-2.88, p<0.001) 2.07 (1.43-3.01, p<0.001)
above 65 2,092 639 9.30 (6.85-12.63, p<0.001) 10.15 (7.34-14.03, p<0.001)
SIMD group high 992 151 - -
mid 1,792 290 1.08 (0.89-1.32, p=0.421) 1.15 (0.94-1.41, p=0.177)
low 1,777 343 1.31 (1.08-1.58, p=0.006) 1.55 (1.27-1.89, p<0.001)
Comorbidty Status neither 3,078 427 - -
diabetes 481 141 2.32 (1.92-2.81, p<0.001) 2.12 (1.75-2.56, p<0.001)
depression 643 121 1.41 (1.15-1.72, p=0.001) 1.68 (1.37-2.07, p<0.001)
both 123 34 2.16 (1.52-3.06, p<0.001) 2.21 (1.55-3.15, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 396 120 - -
Yes 5,352 997 0.56 (0.46-0.68, p<0.001) 0.60 (0.49-0.73, p<0.001)
Sex F 2,013 494 - -
M 3,735 623 0.65 (0.58-0.73, p<0.001) 0.95 (0.84-1.08, p=0.425)
Age group below 55 1,320 58 - -
55 to 65 1,600 128 1.86 (1.37-2.54, p<0.001) 1.93 (1.39-2.68, p<0.001)
above 65 2,828 931 8.95 (6.86-11.66, p<0.001) 9.94 (7.51-13.15, p<0.001)
SIMD group high 1,297 227 - -
mid 2,303 436 1.10 (0.94-1.29, p=0.245) 1.18 (0.99-1.39, p=0.058)
low 2,141 452 1.24 (1.06-1.45, p=0.009) 1.48 (1.25-1.75, p<0.001)
Comorbidty Status neither 3,805 599 - -
diabetes 636 201 2.23 (1.90-2.62, p<0.001) 2.01 (1.71-2.36, p<0.001)
depression 813 179 1.47 (1.24-1.74, p<0.001) 1.77 (1.49-2.09, p<0.001)
both 172 54 2.21 (1.67-2.92, p<0.001) 2.27 (1.71-3.00, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 407 91 - -
Yes 4,528 837 0.79 (0.64-0.99, p=0.037) 0.76 (0.61-0.96, p=0.019)
Sex F 1,691 407 - -
M 3,244 521 0.64 (0.56-0.73, p<0.001) 0.94 (0.82-1.08, p=0.413)
Age group below 55 1,182 49 - -
55 to 65 1,385 110 1.96 (1.40-2.75, p<0.001) 1.96 (1.38-2.78, p<0.001)
above 65 2,368 769 9.32 (6.99-12.45, p<0.001) 10.05 (7.44-13.58, p<0.001)
SIMD group high 1,114 188 - -
mid 1,965 360 1.10 (0.93-1.32, p=0.270) 1.15 (0.95-1.38, p=0.142)
low 1,848 378 1.24 (1.04-1.48, p=0.016) 1.48 (1.23-1.77, p<0.001)
Comorbidty Status neither 3,294 499 - -
diabetes 578 182 2.33 (1.96-2.76, p<0.001) 2.06 (1.74-2.45, p<0.001)
depression 664 141 1.46 (1.21-1.77, p<0.001) 1.76 (1.45-2.12, p<0.001)
both 136 40 2.14 (1.55-2.96, p<0.001) 2.25 (1.62-3.12, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 357 103 - -
Yes 5,325 984 0.59 (0.48-0.73, p<0.001) 0.63 (0.51-0.78, p<0.001)
Sex F 1,972 477 - -
M 3,710 610 0.65 (0.58-0.73, p<0.001) 0.96 (0.84-1.09, p=0.512)
Age group below 55 1,310 57 - -
55 to 65 1,583 125 1.86 (1.36-2.54, p<0.001) 1.93 (1.39-2.68, p<0.001)
above 65 2,789 905 8.86 (6.78-11.59, p<0.001) 9.81 (7.39-13.02, p<0.001)
SIMD group high 1,276 211 - -
mid 2,285 431 1.17 (0.99-1.38, p=0.065) 1.28 (1.07-1.52, p=0.006)
low 2,113 444 1.31 (1.11-1.54, p=0.001) 1.57 (1.32-1.86, p<0.001)
Comorbidty Status neither 3,762 583 - -
diabetes 640 204 2.30 (1.96-2.70, p<0.001) 1.99 (1.69-2.33, p<0.001)
depression 791 167 1.42 (1.19-1.68, p<0.001) 1.67 (1.40-1.99, p<0.001)
both 166 49 2.09 (1.56-2.79, p<0.001) 2.08 (1.55-2.79, p<0.001)
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In secondary-with-treatment patients, persistence at T0 is significantly 
associated with reduced mortality over 5-years across all four drug-classes in 
both the univariable and multivariable analyses. Like the secondary group, 
adjusting for other risk factors increases the hazard ratios, except for beta-
blockers where adjustment reduced the hazard ratio from 0.79 to 0.76. 
Figure 8.4 Survival Curves - 5-years after classed as persistent or not with TAM (T0) in the 
secondary-with-treatment group, across four CVD drug-classes. 
Survival analyses for the secondary-with-treatment group indicates a significant 
association between persistence at T0 with 5-year survival across all four drug-
classes. In this instance, hazards are roughly proportional overtime, validating 
the use of Cox proportional hazards models.  
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8.1.5  Summary: 5-year mortality 
 
Figure 8.5: Mortality 5-years after classed as persistent with TAM in each of the four patient 
groups (Primary, Treatment, Secondary, Secondary-with-Treatment): adjusted for sex, age, 
SIMD, and comorbidity. Blue = ACEi, Red = Antiplatelet, Green = BBs, Purple = Lipid-
regulatory. 
Figure 8.5 pools together the multivariable results presented across Tables 8.1, 
8.2., 8.3, and 8.4. From the plot, it appears that the different patient groups 
have similar associations between persistence at T0 and all-cause mortality five-
years on from the observation period, for whom persistence is generally 
associated with reduced mortality. Notably, patients prescribed antiplatelet 
drugs in the primary prevention group are the sole outlier, with an increased risk 
of mortality if they have persisted to medication for their first year of 
prescription. As increased persistence was associated with traditional CVD risk-
factors (in Chapter 7), there could be residual confounding from disease severity 
that is unaccounted for, especially as there may be misclassification of primary 
patients due to: some symptomatic patients never presenting at hospital and so 
being missed, failure to include all the relevant ICD-10 codes in our classification 
of CVD-history, and the possible limit of solely using GTN to identify patients 
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with angina symptoms. This is particularly pertinent for this class of drugs, as 
antiplatelets would not commonly be prescribed to those with mild evidence of 
CVD, and it may be that those who persist to antiplatelet drugs in this group in 
fact have more severe heart disease, while those who do not persist may have 
had a one-off prescription e.g. aspirin for pain-relief.   
For the secondary prevention group, the confidence intervals cross 1 for ACEi 
and beta-blocker drugs, though this may be in-part due to reduced power due to 
the smaller group size (e.g. ACEi’s include 2,342 patients total in the secondary 
group, vs 407,355 in the primary, and 68,663 in the treatment group). 
It is also plausible that this result is nonsignificant due to residual confounding, 
with persistence being higher in those with worse symptoms who are also likely 
to have the most severe disease. In the absence of data on actual disease 
severity, the number of cardiovascular drugs prescribed is used as a proxy 
measure here. The ‘drug-count’ variable was used to indicate the number of 
different CVD drugs a patient was taking during the observation year (up until 
time T0), from the 10 drug-classes initially studied.   
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8.2  All-Cause Mortality: 5-year follow-up including a 
‘drug-count’ variable  
Addition of the drug-count variable (Figure 8.6) did not greatly change the 
associations observed (further tables included in Appendix G). The results also 
showed an inconsistent, and at times unexpected relationship with morality, as 
in some instances, patients with this highest drug count had lower mortality 
compared to those with fewer medications. This indicates that this drug-count 
variable may instead be working as a proxy for disease management, especially 
for secondary prevention patients who require a certain degree of co-prescribing 
for effective disease management; or it may be possible that this measure is not 
very meaningful in the way is has been defined. A more accurate assessment of 
polypharmacy and co-prescribing may be of value in future study. 
Figure 8.6: Mortality 5-years after classed as persistent with TAM in each of the four patient 
groups (Primary, Treatment, Secondary, Secondary-with-Treatment): adjusted for cvd-drug-
count, sex, age, SIMD, and comorbidity. Blue = ACEi, Red = Antiplatelet, Green = BBs, 
Purple = Lipid-regulatory. 
As persistence may have changed over the five-years on from my measurements, 
and as survival curves crossed for several of the drug-classes/ patient groups, 
additional analyses to investigate mortality 1-year on from T0 was conducted 
next.    
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8.3 All-Cause Mortality: 1-year follow-up  
8.3.1 Primary prevention 
Table 8.5: Mortality 1-year after classed as persistent or not with TAM (T0) in the primary 
group, across four CVD drug-classes. Including drug-count  
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 107,759 3,302 - -
Yes 435,403 8,429 0.63 (0.60-0.65, p<0.001) 0.55 (0.53-0.58, p<0.001)
Sex F 267,357 5,897 - -
M 275,805 5,834 0.96 (0.92-0.99, p=0.022) 1.28 (1.23-1.33, p<0.001)
Age group below 55 167,864 721 - -
55 to 65 158,072 1,595 2.36 (2.16-2.57, p<0.001) 2.57 (2.34-2.82, p<0.001)
above 65 217,226 9,415 10.29 (9.54-11.10, p<0.001) 12.23 (11.30-13.24, p<0.001)
SIMD group high 150,732 2,731 - -
mid 223,917 4,851 1.20 (1.14-1.26, p<0.001) 1.21 (1.15-1.27, p<0.001)
low 167,399 4,107 1.36 (1.29-1.43, p<0.001) 1.44 (1.37-1.52, p<0.001)
Comorbidty Status neither 367,220 6,925 - -
diabetes 72,027 1,850 1.37 (1.30-1.44, p<0.001) 1.34 (1.27-1.41, p<0.001)
depression 58,526 1,639 1.49 (1.41-1.58, p<0.001) 1.92 (1.82-2.03, p<0.001)
both 14,008 486 1.85 (1.69-2.03, p<0.001) 2.37 (2.16-2.60, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 111,889 4,577 - -
Yes 325,412 14,029 1.05 (1.02-1.09, p=0.003) 0.80 (0.78-0.83, p<0.001)
Sex F 229,865 10,014 - -
M 207,436 8,592 0.95 (0.92-0.98, p<0.001) 1.13 (1.10-1.17, p<0.001)
Age group below 55 70,235 533 - -
55 to 65 108,385 1,712 2.09 (1.90-2.30, p<0.001) 2.31 (2.08-2.56, p<0.001)
above 65 258,681 16,361 8.58 (7.87-9.35, p<0.001) 10.62 (9.69-11.64, p<0.001)
SIMD group high 114,570 4,395 - -
mid 178,072 7,609 1.12 (1.08-1.16, p<0.001) 1.15 (1.11-1.20, p<0.001)
low 143,677 6,540 1.19 (1.15-1.24, p<0.001) 1.32 (1.27-1.38, p<0.001)
Comorbidty Status neither 277,210 11,181 - -
diabetes 62,781 2,132 0.84 (0.80-0.88, p<0.001) 0.98 (0.94-1.03, p=0.422)
depression 55,220 3,438 1.56 (1.50-1.62, p<0.001) 1.88 (1.81-1.96, p<0.001)
both 12,932 652 1.26 (1.16-1.36, p<0.001) 1.80 (1.67-1.95, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 192,457 2,868 - -
Yes 327,018 8,471 1.75 (1.67-1.82, p<0.001) 0.78 (0.74-0.81, p<0.001)
Sex F 316,658 6,081 - -
M 202,817 5,258 1.35 (1.31-1.41, p<0.001) 1.37 (1.32-1.43, p<0.001)
Age group below 55 237,903 1,188 - -
55 to 65 110,746 1,491 2.71 (2.51-2.92, p<0.001) 3.08 (2.83-3.34, p<0.001)
above 65 170,826 8,660 10.39 (9.78-11.04, p<0.001) 13.22 (12.35-14.15, p<0.001)
SIMD group high 135,328 2,692 - -
mid 206,745 4,666 1.14 (1.08-1.19, p<0.001) 1.21 (1.15-1.27, p<0.001)
low 176,013 3,953 1.13 (1.08-1.19, p<0.001) 1.43 (1.36-1.50, p<0.001)
Comorbidty Status neither 320,793 7,027 - -
diabetes 31,812 1,201 1.74 (1.63-1.85, p<0.001) 1.29 (1.21-1.37, p<0.001)
depression 128,437 2,017 0.71 (0.68-0.75, p<0.001) 1.43 (1.36-1.51, p<0.001)
both 7,841 319 1.88 (1.68-2.10, p<0.001) 2.09 (1.87-2.34, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 112,741 3,557 - -
Yes 584,480 11,699 0.63 (0.61-0.65, p<0.001) 0.52 (0.50-0.54, p<0.001)
Sex F 347,262 7,697 - -
M 349,959 7,559 0.97 (0.94-1.01, p=0.108) 1.30 (1.25-1.34, p<0.001)
Age group below 55 152,749 773 - -
55 to 65 224,012 2,174 1.92 (1.77-2.09, p<0.001) 2.32 (2.13-2.53, p<0.001)
above 65 320,460 12,309 7.72 (7.18-8.30, p<0.001) 10.60 (9.81-11.45, p<0.001)
SIMD group high 185,127 3,303 - -
mid 281,948 6,219 1.24 (1.19-1.29, p<0.001) 1.24 (1.19-1.30, p<0.001)
low 228,717 5,685 1.40 (1.34-1.46, p<0.001) 1.51 (1.45-1.58, p<0.001)
Comorbidty Status neither 434,463 8,374 - -
diabetes 107,862 2,451 1.18 (1.13-1.23, p<0.001) 1.41 (1.34-1.47, p<0.001)
depression 86,051 2,512 1.52 (1.46-1.59, p<0.001) 1.96 (1.88-2.06, p<0.001)
both 23,822 765 1.68 (1.56-1.81, p<0.001) 2.63 (2.44-2.83, p<0.001)
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 In the primary prevention group, persistence to ACEi’s and lipid-regulatory 
drugs at T0 is associated with significantly lower mortality over the following 
year in both the adjusted and unadjusted analyses. For antiplatelet and beta-
blockers, persistence appears to be associated with higher mortality in the 
unadjusted analyses, but adjusting for sex, age, drug-count, SIMD, and 
comorbidity, reduces the hazard ratio below 1. This indicates reduced mortality 
for those who persist compared to those who do not across all four drugs. 
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8.3.2 Treatment 
Table 8.6: Mortality 1-year after classed as persistent or not with TAM (T0) in the treatment 
group, across four CVD drug-classes, Including drug-count 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 16,461 1,129 - -
Yes 86,141 3,144 0.52 (0.49-0.56, p<0.001) 0.51 (0.48-0.55, p<0.001)
Sex F 43,811 1,785 - -
M 58,791 2,488 1.04 (0.98-1.11, p=0.202) 1.26 (1.18-1.34, p<0.001)
Age group below 55 12,693 97 - -
55 to 65 27,196 468 2.26 (1.82-2.82, p<0.001) 2.42 (1.92-3.06, p<0.001)
above 65 62,713 3,708 7.94 (6.49-9.72, p<0.001) 9.75 (7.86-12.10, p<0.001)
SIMD group high 22,475 848 - -
mid 40,278 1,636 1.08 (0.99-1.17, p=0.076) 1.09 (1.00-1.19, p=0.040)
low 39,687 1,781 1.19 (1.10-1.30, p<0.001) 1.34 (1.23-1.46, p<0.001)
Comorbidty Status neither 62,425 2,328 - -
diabetes 14,475 706 1.32 (1.21-1.43, p<0.001) 1.33 (1.22-1.44, p<0.001)
depression 13,631 669 1.32 (1.21-1.44, p<0.001) 1.66 (1.52-1.81, p<0.001)
both 4,384 225 1.39 (1.21-1.59, p<0.001) 1.85 (1.61-2.12, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 31,732 1,438 - -
Yes 149,998 6,091 0.89 (0.84-0.94, p<0.001) 0.69 (0.65-0.74, p<0.001)
Sex F 86,593 3,545 - -
M 95,137 3,984 1.02 (0.98-1.07, p=0.304) 1.20 (1.14-1.26, p<0.001)
Age group below 55 22,547 180 - -
55 to 65 47,831 742 1.95 (1.66-2.29, p<0.001) 2.21 (1.86-2.63, p<0.001)
above 65 111,352 6,607 7.63 (6.58-8.85, p<0.001) 10.01 (8.54-11.73, p<0.001)
SIMD group high 40,838 1,548 - -
mid 70,722 2,892 1.08 (1.02-1.15, p=0.013) 1.12 (1.05-1.19, p=0.001)
low 69,850 3,068 1.16 (1.09-1.24, p<0.001) 1.33 (1.25-1.42, p<0.001)
Comorbidty Status neither 113,868 4,283 - -
diabetes 19,583 942 1.29 (1.20-1.38, p<0.001) 1.27 (1.18-1.36, p<0.001)
depression 28,215 1,388 1.32 (1.24-1.40, p<0.001) 1.67 (1.57-1.77, p<0.001)
both 6,385 358 1.51 (1.36-1.68, p<0.001) 1.99 (1.78-2.21, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 22,811 971 - -
Yes 116,983 4,362 0.87 (0.81-0.93, p<0.001) 0.72 (0.67-0.78, p<0.001)
Sex F 64,142 2,389 - -
M 75,652 2,944 1.05 (0.99-1.10, p=0.103) 1.24 (1.17-1.31, p<0.001)
Age group below 55 18,213 159 - -
55 to 65 37,123 545 1.69 (1.41-2.01, p<0.001) 1.85 (1.53-2.24, p<0.001)
above 65 84,458 4,629 6.43 (5.49-7.53, p<0.001) 8.18 (6.91-9.70, p<0.001)
SIMD group high 33,156 1,179 - -
mid 55,146 2,104 1.07 (1.00-1.15, p=0.048) 1.12 (1.04-1.21, p=0.002)
low 51,256 2,037 1.12 (1.04-1.20, p=0.002) 1.29 (1.19-1.39, p<0.001)
Comorbidty Status neither 89,056 3,019 - -
diabetes 15,754 749 1.41 (1.30-1.53, p<0.001) 1.37 (1.27-1.49, p<0.001)
depression 20,296 863 1.26 (1.17-1.36, p<0.001) 1.62 (1.50-1.75, p<0.001)
both 4,568 264 1.73 (1.53-1.96, p<0.001) 2.24 (1.98-2.55, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 21,693 1,218 - -
Yes 163,070 5,763 0.62 (0.58-0.66, p<0.001) 0.51 (0.48-0.54, p<0.001)
Sex F 86,684 3,134 - -
M 98,079 3,847 1.09 (1.04-1.14, p=0.001) 1.30 (1.23-1.36, p<0.001)
Age group below 55 22,093 167 - -
55 to 65 49,643 752 2.01 (1.70-2.38, p<0.001) 2.37 (1.98-2.83, p<0.001)
above 65 113,027 6,062 7.27 (6.23-8.47, p<0.001) 9.92 (8.40-11.72, p<0.001)
SIMD group high 41,584 1,428 - -
mid 71,802 2,686 1.09 (1.02-1.16, p=0.008) 1.12 (1.05-1.20, p=0.001)
low 71,073 2,851 1.17 (1.10-1.25, p<0.001) 1.32 (1.24-1.41, p<0.001)
Comorbidty Status neither 114,097 3,803 - -
diabetes 21,331 981 1.39 (1.30-1.49, p<0.001) 1.40 (1.30-1.50, p<0.001)
depression 28,181 1,269 1.36 (1.28-1.45, p<0.001) 1.74 (1.63-1.86, p<0.001)
both 7,037 379 1.64 (1.47-1.82, p<0.001) 2.24 (2.01-2.49, p<0.001)
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Persistence at T0 is associated with lower mortality 1-year on in adjusted and 
unadjusted analysis for all four drug-classes (Table 8.6), with HRs ranging from 
0.51-0.72 for the multivariate analyses.   
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8.3.3 Secondary prevention 
Table 8.7: Mortality 1-year after classed as persistent or not with TAM (T0) in the secondary 
group, across four CVD drug-classes. Including drug-count 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 913 21 - -
Yes 3,753 37 0.40 (0.23-0.68, p=0.001) 0.44 (0.25-0.78, p=0.004)
Sex F 1,570 33 - -
M 3,096 25 0.38 (0.23-0.64, p<0.001) 0.64 (0.37-1.12, p=0.119)
Age group below 55 929 < 5 - -
55 to 65 1,365 < 5 2.72 (0.30-24.37, p=0.370) 1.49 (0.13-16.42, p=0.746)
above 65 2,372 53
21.26 (2.94-153.74, 
p=0.002) 21.59 (2.96-157.25, p=0.002)
SIMD group high 1,291 13 - -
mid 1,937 23 1.18 (0.60-2.32, p=0.641) 1.15 (0.56-2.36, p=0.713)
low 1,430 22 1.55 (0.78-3.07, p=0.213) 1.89 (0.93-3.84, p=0.080)
Comorbidty Status neither 3,242 28 - -
diabetes 504 7 1.62 (0.71-3.72, p=0.251) 1.41 (0.61-3.24, p=0.417)
depression 570 13 2.65 (1.37-5.12, p=0.004) 2.64 (1.35-5.16, p=0.005)
both 123 5 4.82 (1.86-12.48, p=0.001) 4.85 (1.86-12.66, p=0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 617 24 - -
Yes 5,229 75 0.30 (0.19-0.48, p<0.001) 0.33 (0.20-0.54, p<0.001)
Sex F 2,116 52 - -
M 3,730 47 0.51 (0.34-0.75, p=0.001) 0.69 (0.45-1.06, p=0.088)
Age group below 55 1,060 < 5 - -
55 to 65 1,576 6 4.03 (0.48-33.44, p=0.197) 2.19 (0.23-21.06, p=0.497)
above 65 3,210 92
31.34 (4.37-224.90, 
p=0.001) 29.60 (4.11-213.27, p=0.001)
SIMD group high 1,619 20 - -
mid 2,445 43 1.43 (0.84-2.43, p=0.188) 1.50 (0.86-2.63, p=0.157)
low 1,774 36 1.66 (0.96-2.87, p=0.068) 1.96 (1.10-3.49, p=0.022)
Comorbidty Status neither 3,962 48 - -
diabetes 662 17 2.17 (1.25-3.77, p=0.006) 1.89 (1.09-3.29, p=0.024)
depression 744 18 2.00 (1.17-3.44, p=0.012) 1.95 (1.12-3.38, p=0.017)
both 169 6 3.02 (1.29-7.06, p=0.011) 3.66 (1.56-8.58, p=0.003)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 602 19 - -
Yes 4,424 69 0.43 (0.26-0.71, p=0.001) 0.45 (0.26-0.77, p=0.003)
Sex F 1,765 41 - -
M 3,261 47 0.62 (0.40-0.93, p=0.023) 0.90 (0.58-1.42, p=0.661)
Age group below 55 954 0 - -
55 to 65 1,382 5
18877916.22 (0.00-Inf, 
p=0.994)
13945918.14 (0.00-Inf, 
p=0.995)
above 65 2,690 83
166150525.31 (0.00-Inf, 
p=0.994)
192166658.44 (0.00-Inf, 
p=0.994)
SIMD group high 1,384 18 - -
mid 2,112 38 1.38 (0.79-2.42, p=0.259) 1.39 (0.77-2.49, p=0.270)
low 1,524 32 1.63 (0.92-2.91, p=0.096) 1.88 (1.03-3.43, p=0.039)
Comorbidty Status neither 3,448 44 - -
diabetes 577 17 2.33 (1.33-4.09, p=0.003) 1.98 (1.13-3.46, p=0.017)
depression 608 14 1.81 (0.99-3.30, p=0.054) 1.93 (1.05-3.55, p=0.034)
both 134 5 3.00 (1.19-7.57, p=0.020) 3.64 (1.44-9.20, p=0.006)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 548 23 - -
Yes 5,131 68 0.26 (0.16-0.42, p<0.001) 0.28 (0.17-0.46, p<0.001)
Sex F 2,020 45 - -
M 3,659 46 0.56 (0.37-0.84, p=0.005) 0.84 (0.54-1.30, p=0.430)
Age group below 55 1,043 < 5 - -
55 to 65 1,556 6 4.02 (0.48-33.35, p=0.198) 2.27 (0.24-21.82, p=0.478)
above 65 3,080 84
29.36 (4.09-210.88, 
p=0.001) 29.56 (4.10-213.20, p=0.001)
SIMD group high 1,562 18 - -
mid 2,373 40 1.46 (0.84-2.55, p=0.180) 1.50 (0.83-2.72, p=0.178)
low 1,735 33 1.68 (0.94-2.98, p=0.078) 2.03 (1.10-3.72, p=0.023)
Comorbidty Status neither 3,861 47 - -
diabetes 633 14 1.84 (1.01-3.34, p=0.045) 1.52 (0.84-2.77, p=0.170)
depression 717 14 1.61 (0.88-2.92, p=0.119) 1.56 (0.85-2.86, p=0.154)
both 169 7 3.58 (1.62-7.91, p=0.002) 3.88 (1.75-8.61, p=0.001)
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In the secondary prevention patient group, persistence is strongly associated 
with lower mortality in adjusted and unadjusted analysis for all drug classes. 
While adjustment for known risk-factors increases HRs toward 1, the association 
between persistence and reduced mortality remains stark, with HRs ranging from 
0.28-0.45.  
The association observed between mortality and various demographic variables 
differs from the results seen in primary and treatment groups. In the unadjusted 
analysis, male sex is associated with better survival – though in multivariate 
analysis this is not significant.  
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8.3.4 Secondary prevention progressing to treatment 
Table 8.8: Mortality 1-year after classed as persistent or not with TAM (T0) in the secondary-
with-treatment group, across four CVD drug-classes. Including drug-count. 
ACEI All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 1,867 106 - -
Yes 12,204 345 0.49 (0.39-0.61, p<0.001) 0.58 (0.46-0.73, p<0.001)
Sex F 4,400 200 - -
M 9,671 251 0.57 (0.47-0.68, p<0.001) 0.80 (0.66-0.98, p=0.030)
Age group below 55 3,343 23 - -
55 to 65 4,156 44 1.54 (0.93-2.55, p=0.093) 1.83 (1.07-3.11, p=0.027)
above 65 6,572 384 8.71 (5.72-13.27, p<0.001) 9.88 (6.27-15.57, p<0.001)
SIMD group high 3,221 75 - -
mid 5,658 192 1.46 (1.12-1.91, p=0.005) 1.51 (1.15-1.99, p=0.003)
low 5,177 183 1.53 (1.17-2.00, p=0.002) 1.71 (1.30-2.27, p<0.001)
Comorbidty Status neither 9,287 230 - -
diabetes 1,540 84 2.24 (1.74-2.87, p<0.001) 1.97 (1.54-2.54, p<0.001)
depression 2,025 80 1.61 (1.25-2.08, p<0.001) 1.89 (1.45-2.45, p<0.001)
both 408 25 2.52 (1.66-3.80, p<0.001) 2.47 (1.63-3.74, p<0.001)
Antiplatelets All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 1,333 120 - -
Yes 16,753 613 0.39 (0.32-0.48, p<0.001) 0.45 (0.37-0.55, p<0.001)
Sex F 6,204 331 - -
M 11,882 402 0.63 (0.54-0.73, p<0.001) 0.90 (0.77-1.05, p=0.174)
Age group below 55 3,898 21 - -
55 to 65 5,018 66 2.45 (1.50-4.01, p<0.001) 2.84 (1.68-4.81, p<0.001)
above 65 9,170 646 13.51 (8.75-20.86, p<0.001) 16.06 (10.03-25.73, p<0.001)
SIMD group high 4,274 130 - -
mid 7,367 328 1.47 (1.20-1.81, p<0.001) 1.65 (1.34-2.04, p<0.001)
low 6,426 274 1.41 (1.14-1.74, p=0.001) 1.67 (1.34-2.08, p<0.001)
Comorbidty Status neither 11,757 380 - -
diabetes 2,018 117 1.82 (1.48-2.24, p<0.001) 1.58 (1.28-1.95, p<0.001)
depression 2,666 145 1.71 (1.41-2.07, p<0.001) 2.00 (1.65-2.43, p<0.001)
both 563 41 2.30 (1.67-3.18, p<0.001) 2.39 (1.73-3.30, p<0.001)
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 1,314 79 - -
Yes 14,446 539 0.61 (0.48-0.77, p<0.001) 0.66 (0.52-0.85, p=0.001)
Sex F 5,289 258 - -
M 10,471 360 0.70 (0.60-0.82, p<0.001) 1.00 (0.85-1.19, p=0.975)
Age group below 55 3,458 22 - -
55 to 65 4,424 48 1.71 (1.03-2.83, p=0.037) 2.01 (1.16-3.49, p=0.013)
above 65 7,878 548 11.29 (7.37-17.28, p<0.001) 14.62 (9.11-23.46, p<0.001)
SIMD group high 3,713 112 - -
mid 6,420 265 1.38 (1.10-1.72, p=0.005) 1.50 (1.19-1.89, p=0.001)
low 5,610 240 1.43 (1.14-1.79, p=0.002) 1.68 (1.33-2.13, p<0.001)
Comorbidty Status neither 10,282 322 - -
diabetes 1,850 105 1.84 (1.47-2.29, p<0.001) 1.58 (1.27-1.97, p<0.001)
depression 2,229 109 1.58 (1.27-1.96, p<0.001) 1.91 (1.53-2.39, p<0.001)
both 477 34 2.33 (1.64-3.32, p<0.001) 2.46 (1.72-3.51, p<0.001)
Lipid-regulators All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 1,329 89 - -
Yes 16,560 595 0.52 (0.42-0.65, p<0.001) 0.55 (0.44-0.70, p<0.001)
Sex F 6,013 304 - -
M 11,876 380 0.63 (0.54-0.73, p<0.001) 0.88 (0.75-1.03, p=0.121)
Age group below 55 3,868 24 - -
55 to 65 4,979 61 1.98 (1.24-3.18, p=0.005) 2.37 (1.42-3.96, p=0.001)
above 65 9,042 599 11.00 (7.32-16.55, p<0.001) 13.45 (8.59-21.06, p<0.001)
SIMD group high 4,244 125 - -
mid 7,274 306 1.44 (1.17-1.77, p=0.001) 1.57 (1.26-1.94, p<0.001)
low 6,353 253 1.36 (1.10-1.68, p=0.005) 1.56 (1.25-1.95, p<0.001)
Comorbidty Status neither 11,635 349 - -
diabetes 2,030 120 2.00 (1.63-2.47, p<0.001) 1.72 (1.40-2.12, p<0.001)
depression 2,603 126 1.63 (1.33-2.00, p<0.001) 1.91 (1.56-2.35, p<0.001)
both 557 42 2.57 (1.87-3.54, p<0.001) 2.64 (1.91-3.64, p<0.001)
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In the treatment following secondary prevention group, persistence at T0 is 
associated with higher 1yr-survival across all drug-classes in uni- and 
multivariate analysis, with HRs ranging from 0.45-0.66. Unlike the primary 
prevention and treatment groups, adjusting for other risk factors increases HRs 
toward 1, indicating an increased risk of mortality once factoring these in.  
Counterintuitively, for ACEi’s male sex is significantly associated with better 
survival in multivariate analysis, while other variables such as age, SIMD, and 
comorbidity status are more in line with expectations. 
8.3.5 Summary: 1-year mortality with CVD drug-count  
 
Figure 8.7: Mortality 1-year after classed as persistent with TAM in each of the four patient 
groups (Primary, Treatment, Secondary, Secondary-with-Treatment): adjusted for cvd-drug-
count, sex, age, SIMD, and comorbidity. Blue = ACEi, Red = Antiplatelet, Green = BBs, 
Purple = Lipid-regulatory. 
Compared to the 5-year mortality summary, hazard ratios after 1-year shift left, 
indicating reduced mortality is associated with persistent patients compared to 
non-persistent patients. In the primary prevention group, and to a lesser-extent 
in the treatment group, there seems to be a split between the HRs for ACEi’s 
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and lipid-regulatory drugs, which are approximately 0.25 lower than the HRs for 
antiplatelets and beta-blockers. This further implies a difference in the patients 
making-up these groups, and suggests that those thought as having “milder” 
CVD, and thus classified as primary prevention or treatment, may be being 
prescribed these drugs for different reasons.  
8.4 Further investigating confounding 
8.4.1  Beta-blockers 
Sensitivity analysis was performed on beta-blockers, as it was suspected that 
some of these patients had been prescribed beta-blockers for anxiety and not for 
a CVD indication, despite excluding records that stated ‘anxiety’ in the dosage 
information line during data-cleaning steps. This seemed especially pertinent to 
the primary prevention group, as patients in this group are most likely to be 
asymptomatic; for example, hypertension is estimated to affect 28-40% of adults 
in Scotland (according to the 2017 Scottish Health Survey[209]) and this rarely 
presents with symptoms[210].  Using guidance from a clinician, it was suggested 
that for a CVD indication, beta-blockers would usually be prescribed alongside 
an ACEi or a CCB drug, so all patients with either of these drugs prescribed in 
their first year of beta-blocker therapy were identified, and analysis was 
repeated on this subgroup.   
 
Table 8.9. Mortality 5-years after classed as persistent or not with TAM (T0) in the primary 
prevention group, for beta-blockers; limited to only include patients with a concurrent 
prescription of either ACEi’s or CCB’s during the observation period.   
Beta-blockers All (n) Deaths (n) HR (univariable) HR (multivariable)
Persist No 22,249 3,474 - -
Yes 121,508 20,752 1.01 (1.00-1.03, p=0.054) 0.97 (0.96-0.98, p<0.001)
Sex F 74,973 12,926 - -
M 68,784 11,300 0.99 (0.98-1.00, p=0.102) 1.02 (1.01-1.04, p<0.001)
Age group below 55 25,881 989 - -
55 to 65 38,479 2,911 1.04 (1.02-1.05, p<0.001) 1.05 (1.03-1.06, p<0.001)
above 65 79,397 20,326 1.26 (1.25-1.28, p<0.001) 1.29 (1.27-1.31, p<0.001)
SIMD group high 38,635 5,826 - -
mid 59,301 10,218 1.02 (1.01-1.04, p<0.001) 1.03 (1.01-1.04, p<0.001)
low 45,556 8,122 1.03 (1.02-1.04, p<0.001) 1.05 (1.03-1.06, p<0.001)
Comorbidty neither 97,204 15,426 - -
diab 18,644 3,798 1.05 (1.04-1.07, p<0.001) 1.05 (1.03-1.06, p<0.001)
dep 15,836 2,700 1.01 (1.00-1.03, p=0.102) 1.06 (1.04-1.08, p<0.001)
both 3,498 766 1.07 (1.04-1.11, p<0.001) 1.11 (1.07-1.15, p<0.001)
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Compared to the previous analysis, removing patients who cannot be confirmed 
as having been prescribed beta-blockers for CVD attenuates the level of risk 
observed, from 1.99 down to 1.01 in the univariable analysis, though raises the 
risk for the multivariate model from 0.92 to 0.97 (Tables 8.1 and 8.9). This 
indicates that misclassification of patients who received medication for other 
non-cardiac interactions does not appear to have a significant impact on 
associations observed between persistent patients and survival.   
 
 
Figure 8.8: Mortality 5-years (top) and 1-year (bottom) after classed as persistent with TAM 
to three different beta-blocker drugs, in the Primary (green) and Treatment (dark green) 
patient groups: adjusted for CVD-drug-count, sex, age, SIMD, and comorbidity.  
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Persistence to atenolol and bisoprolol at T0 was associated with a reduced risk 
of mortality after 1- and 5-years (Figure 8.8), for patients in both the primary 
prevention, though for bisoprolol this is not significant in the treatment group 
after 5 years.  
The opposite is true of propranolol: persistence to this beta-blocker drug is 
associated with increased mortality 1 and 5-years on from T0, significant in the 
primary prevention group. This may be related to residual confounding for 
propranolol due to its use for several other non-cardiac indications (including 
migraine, anxiety, cirrhosis, and portal hypertension[211]). This may explain the 
differential findings for this drug compared with the other beta-blockers, as 
these non-CVD indications may still be included in the analyses. Bisoprolol is 
licensed for heart failure[22] and its use in primary prevention patients may 
indicate misclassification, due to failure to include the relevant ICD-10 code 
(I50) when categorising patient groups. Atenolol is more limited to its use as an 
antihypertensive agent, so is likely to be prescribed for this indication. 
8.4.2 Anti-platelets 
Persistence to aspirin at T0 is associated with increased 5-year mortality rate in 
the primary prevention group, though for treatment patients, aspirin persistence 
is associated with reduced mortality (Figure 8.9). For clopidogrel, the hazard 
ratios show the opposite effect: as primary preventions are associated with 
lower levels of mortality while treatment patients are non-significantly 
associated with higher mortality. There is a non-significant relationship between 
dipyridamole and 5-year mortality for primary prevention patients, though a 
protective association is observed for those classed as treatment. For all the 1-
year analyses, persistence was associated with better survival. The difference in 
findings between the 1- and 5-year analyses may indicate failure of the cox 
proportional hazards models, as risk appears to change with time. 
Some of these Cox analyses present with very wide confidence intervals. This is 
due to very small patient numbers, as we may expect for the primary prevention 
and treatment groups, as antiplatelets are usually recommended for prescription 
following an MI, and evidence of an MI would exclude patients from being 
eligible for inclusion in these groups. 
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Figure 8.9: Mortality 5-years (top) and 1-year (bottom) after classed as persistent with TAM 
to four different antiplatelet drugs, in the Primary prevention (red) and Treatment (dark red) 
patient groups: adjusted for CVD-drug-count, sex, age, SIMD, and comorbidity. 
8.5 Discussion 
8.5.1 Overall conclusions 
Adjusting for traditional CVD risk factors has a differential effect on HR 
depending on whether patients have suffered an MI previously: in the primary 
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and treatment groups, adjusting for these risk factors reduced mortality risk 
observed, while in the secondary and secondary-with-treatment groups, 
adjustment increased the risk.  
However, in almost all instances, persistence with medications was found to 
correlate with a decreased risk of mortality. While this finding may be line with 
expectations for this study, it is important to acknowledge the flaw in using Cox 
models here when the model assumptions failed, due to survival lines crossing 
overtime (Figures 8.1-8.4) and results from plotting Schoenfeld Residuals 
(Appendix F). A revision of these methods must be considered for these results 
to be taken as legitimate.  
8.5.2 Cardiovascular polypharmacy  
Polypharmacy has previously been associated with increased mortality[212, 213], so 
a drug-count variable was added to the analyses to ascertain CVD drug 
polypharmacy and to create a proxy of disease severity. However, addition of 
this variable did not have a clear effect on HRs, and direct associations between 
the number of CVD drugs prescribed and mortality was often counterintuitive. 
This may be due to the broad approach taken here: some CVD polypharmacy may 
be acceptable and indeed important in preventing or treating disease and 
therefore may be indicative of good disease management. Identifying 
‘acceptable polypharmacy’ for each patient may provide deeper insights and use 
of a drug-count variable as a proxy for good CVD management could be 
considered/ validated for future studies.  
 
8.5.3 Comparing specific CVD drugs  
In the primary and treatment groups, persistence to antiplatelet and beta-
blocker drugs tended to be associated with higher HRs compared to ACEi’s and 
lipid-regulatory drugs, so further investigation was carried out for these classes. 
It was expected that persistence may differ by specific drug; for example, 
persistence to aspirin may not be as important as persistence to other 
antiplatelet drugs, due to the availability of this as an over-the-counter 
medicine which could mean patients who appear non-persistent here are in fact 
purchasing aspirin themselves; or, due to propranolol being commonly 
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prescribed as an anxiolytic and for other non-CVD indications, that there may be 
important differences between specific drugs within these classes.  
These analyses showed there were different drug-specific interactions to 
observe. For beta-blockers, persistence to atenolol and bisoprolol was associated 
with reduced mortality while persistence to propranolol was associated with 
increased mortality for primary prevention patients (NS for treatment patients). 
Here, persistence may act as a proxy for disease severity: for example, for 
propranolol, patients who are non-persistent may not be true CVD patients. This 
confounding is not observed for atenolol persistence, as this drug is only used for 
management of hypertension, hence the reduced risk of mortality for those who 
persist.  
To break down drug-classes into their individual drugs to study persistence 
differences in depth could be a valuable follow-up but would require further 
clinical information to define different drug indications, identify and validate 
allowed gap-lengths, and to define acceptable drug-switches for each.   
8.6 Chapter Summary  
Secondary databases can have value for estimating population level adherence 
and persistence, and to some extent can be used for estimating the outcomes 
associated with good persistence. These results, while intuitive, should be 
considered with a degree of caution due to issues in fulfilling the assumptions 
that underpin Cox proportional hazards models, and the influence of known and 
unknown confounders. Residual confounding presents a limitation in using 
secondary data for such analyses, as all CVD risk factors cannot be accounted for 
with the data available.  
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9 Discussion 
9.1 Study context 
In Scotland, morbidity and mortality related to CVD exceeds the levels observed 
in the rest of the UK and other similar European countries. There are already a 
host of interventions with proven efficacy against CVD, including pharmaceutical 
prevention and treatment. Improving management of such interventions could 
be crucial in addressing excess CVD burden in Scotland. Adherence, whether it is 
the initiation, implementation, or persistence to a therapy, is an important 
aspect of chronic disease management and understanding the epidemiology of 
this in Scotland may be a key feature of future public health interventions. 
However, previous studies have found that adherence and persistence can be 
challenging to assess, and both have been inconsistently defined in the 
literature. The different ways of measuring and recording adherence, different 
assumptions made about the data, and different analyses run can all lead to 
different findings, highlighting the importance in clearly and accurately 
reporting on the methods used and the justifications for these, within the limits 
of the available data.  
Scotland has access to anonymised, population-level pharmacy data, which can 
be readily linked to hospitalisation and death data, and therefore provides a 
valuable tool for adherence research. When using secondary data, it is important 
to be aware of its limitations for defining a behavioural trait such as adherence 
and the lack of granularity when compared to methods such as electronic-
monitoring, while also highlighting the potential value secondary data can have 
for identifying general trends across the population.  
9.1.1 What was previously known: cardiovascular adherence 
A 2003 report by The World Health Organisation suggested that adherence to 
long-term therapy was particularly problematic for chronic diseases, with 
adherence estimated at 50% for patients in developed countries[214]. This trend 
was replicated in a 2008 study of patients prescribed antihypertensive drugs, 
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which found that half had discontinued their drug within 1 year[215]. Studies in 
LMICs have found that adherence levels are suboptimal here too[216]. 
Different risk factors have previously been identified as being associated with 
adherence in cardiovascular disease, and these are defined across five key 
domains: disease factors, therapy factors, healthcare factors, patient factors, 
and social factors[76, 214]. From systematic review (Chapter 2), higher levels of 
adherence in cardiovascular disease were associated with secondary prevention 
(compared with primary prevention), diabetes comorbidity (compared to no 
comorbidity), ARBs (compared to other drug-classes), higher SES, male sex, and 
lower dosing frequencies. Mixed findings were associated with ACEi’s and CCBs, 
complex dosing regimens, and age, which had a ‘u’ shaped relationship with 
nonadherence. Younger patients, below the age of 50, are generally less-
adherent than older adults; however, over the age of 80 adherence once again 
decreases in prevalence[217]. 
My review of systematic reviews also indicated that adherence was associated 
with improved clinical and economic outcomes in the majority of reviews; 
however, there was some mixed evidence across the primary studies. Good 
adherence was generally associated with a reduction in CVD risk and all-cause 
mortality[11, 123], as well as a reduction in overall healthcare costs[118, 124]. 
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9.2 Main findings 
Table 9.1: Comparison of the associations between different risk factors and levels of 
adherence, observed in systematic review vs findings in this thesis 
The epidemiology of adherence to cardiovascular drugs in Scotland is largely 
similar to that observed in my literature review (Table 9.1). Notably, the 
systematic review conducted included studies which used a range of methods for 
measuring adherence (self-report, EMS, secondary databases), as well as across 
many different countries and contexts. This helps validate the potential utility 
of using PIS as a tool for estimating adherence at the population level. It also 
suggests that the epidemiology of adherence to cardiovascular drugs in Scotland 
is not especially different to other countries and contexts previously studied.  
This broad summary table does not provide granular information that may be 
important. Patients over 65 years are more adherent than those aged below 55 
or aged 55-65 years in my cohort, but in my literature review it was found that 
patients over the age of 85 years tend to be less adherent. It may be important 
for future studies to further subdivide older age groups to investigate this, as 
geriatric care for people living in residential nursing homes or assisted living 
facilities, and with increased comorbidities and polypharmacy, may have very 
different interactions with adherence. Around 60% of people living in care-homes 
are aged over 85 years[218], highlighting the heterogeneity of people included in 
our over-65-year group. Relevant to this, the secondary prevention group is the 
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one patient group where 55-65-year-olds are more likely to be adherent or 
persistent than over-65s. 
Table 9.2 Summary of levels of persistence and implementation observed across different 
drug-classes and patient groups. (Adapted from Table 7.7). 
My analyses comparing the primary prevention, treatment, secondary 
prevention, and secondary-prevention-with-treatment provided valuable insights 
into how adherence may vary by drug class. Adherence is best for lipid-
regulatory drugs and ARBs across all four patient groups, while adherence to 
ACEi’s and beta-blockers is high across treatment, secondary, and secondary-
with-treatment only. Conversely, the drug to which primary prevention patients 
are least adherent to are beta-blockers, and this may be due to a higher rate of 
prescriptions with an anxiolytic indication in this group, despite efforts to 
minimise this through data-cleaning. Similarly, antiplatelet adherence is higher 
for those patients who have suffered an MI compared to those who have not. 
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Adherence is consistently lowest across alpha-blockers, anti-anginal drugs, and 
nitrates. Despite excluding records with ‘as required’ in the dosage instructions, 
it is likely that many prescriptions of nitrates are for symptom management of 
angina, and therefore adherence cannot be ascertained.  
Notably, implementation and persistence were associated with traditional CVD 
risk-factors in the primary and treatment groups, but this effect was attenuated 
in the secondary prevention group (Chapter 7, Figure 7.1 and Table 7.7) – 
possibly due to the fact that all patients had a clear CVD risk which was tangible 
to the patient.    
Table 9.3 Summary of associations between persistence and outcomes, across different 
drug-classes and patient groups (adapted from 5-year and 1-year Cox survival analyses, 
Chapter 8). 
Results observed for the associations between persistence and survival (Table 
9.3) showed that, generally, persistence was associated with reduced mortality. 
There were several exceptions to this: in the primary prevention group, patients 
found to be persistent to antiplatelet drugs were associated with increased 
mortality over 5-years of follow-up compared to those who did not persist, 
though this was not replicated in the 1-year follow-up analyses. In the secondary 
prevention group, association with persistence and reduced mortality were non-
significant for ACEi and beta-blocker drugs, though this may be in part due to 
the smaller sample size of this group. Follow-up time was very limited in the 
secondary prevention group, and many patients will have been excluded from 
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investigations into levels of persistence (Chapter 7) if they did not fulfil the 
eligibility criteria for inclusion in this group for the entire year. This may 
introduce bias as it could be possible that the least adherent patients have the 
poorest outcomes and may have already suffered a subsequent MI or death 
within this timeframe. It is important to note also that this reduced time is due 
to limitations in the definition of secondary prevention patients, which ought to 
be revised for future study.  
The assumptions of the Cox proportional hazards models, namely that risk is 
proportional for the duration of follow-up, was not met for all of these analyses, 
and therefore the results may need to be considered with caution. There are 
also certain limitations in study design (discussed further in section 9.3.3) which 
may allow for residual confounding that has not been accounted for.  
Another dimension of adherence that was not considered was a comparison of 
initiators from non-initiators. Patients who suffered an MI but did not collect a 
prescription within the defined time period were excluded from analyses, as the 
PIS data provided here does not include non-initiators who were prescribed drugs 
but who did not collect their first script. It is also important to note that 
persistence tends to change overtime. An adherence study which is more 
detailed may benefit from a longer follow-up period, comparing different 
outcomes for patients who persist after 6-months, 1-year, 2-years, and so on. 
Future analysis may benefit from additionally investigating the association 
between persistence with subsequent MI for primary or treatment patients. 
9.2.1 What this study adds 
This is the first study to provide a population-level perspective of adherence 
across a range of CVD drug-classes in Scotland. Previous studies using these 
Scottish datasets have provided an in depth analysis of individual classes, 
including statins[219] and anticoagulants[199], whereas this study provided a much 
broader epidemiological approach across ten different CVD drug-classes. 
It also highlights the possibilities of using PIS as a tool for estimating population-
level adherence. Findings here tend to replicate those observed in literature 
review: traditional CVD risk factors were associated with higher levels of 
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adherence. This suggests that PIS is comparable to other validated databases as 
a tool for conducting adherence research, whilst suggesting that there may be 
potential confounding issues that require further study.  
As much time in this project was spent identifying the data cleaning steps 
needed to be taken, and deciding on adherence and persistence measures that 
were possible with the data available, a paper to lay out the framework used 
here to estimate adherence with PIS, SMR, and NRS records could be of 
methodological value for future studies, as it would allow for adherence 
measures to be included more readily.  
9.2.2 Future research 
A longitudinal follow-up of adherence and persistence over time, beyond the 
first year of therapy, would provide interesting insights, particularly as 
adherence tends to decline overtime[39, 88, 91]. This was limited here due to the 
secondary prevention group having very short follow-up time, less than 4 
months. Further analysis of this in patients taking medications for primary 
prevention or treatment, especially as these patients may receive CVD 
medication for many years before suffering an MI, may provide valuable insights 
into the long-term management of CVD. This is pertinent as patients who 
discontinue statins are at an elevated risk, with one study citing a 33% increase 
in CVD hospital admissions in patients over the age of 75 who did not persist with 
statins for primary prevention[220].   
Additionally, studying adherence at specific points in time could be a valuable 
follow-up study, particularly in response to changes in policy: for example, 
introduction of new drugs (as has been previously studied when DOACs were first 
licensed in Scotland[206]), changes to guidelines, or introduction of new 
interventions to improve adherence. This would be particularly valuable as a 
longitudinal study, to observe changes in behaviours in response to public health 
policy. Some of the more beneficial and cost-effective interventions to improve 
management of adherence include the introduction of combination pills/ 
therapies[221, 222], especially for secondary-prevention patients who have a higher 
pill burden, and automated phone-call reminders[221]. As electronic-pill-bottles 
and blister-packs come off patent, these could also to useful to help patients to 
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monitor their own medication-use in real-time and is also relatively cost-
effective, and in one study improved adherence by 27%[222]. As health services 
are under particular strain in the context of the global coronavirus pandemic, 
the opportunity to invest in options such as increased consultations with 
clinicians and pharmacists and developing disease co-management plans (which 
has been found to be effective[221]) may be limited, but should be considered as 
a future goal.  
Due to the scale of this study, comparing across various drug-classes and patient 
groups, a general adherence and persistence measure was used. For more 
nuanced study, adherence measures and acceptable gaps between prescriptions 
ought to be validated for specific drugs, for example, based on the specific 
pharmacokinetics.  
This study also used narrow age-bands of age groups and comorbidity status, and 
a future project looking at this in more detail would be valuable. Grouping age 
into further categories and/ or including it as a continuous variable could 
provide useful insights, and particularly subdividing the over-65s age group to 
explore adherence patterns in geriatric patients could be pertinent. Exploring 
patient pathways into care facilities and interactions with CVD adherence may 
be insightful, especially considering how adherence may change due to onset of 
cognitive decline and other diseases of ageing. There is also a great loss of 
information in the way comorbidity is assessed here, as study of comorbidities 
was limited to diabetes and depression. While these comorbidities were deemed 
relevant from findings in literature review (Chapter 2) it does not negate the 
impact of other comorbidities that could have important implications: for 
example, a patient diagnosed with cancer may be briefly prescribed an 
antiplatelet drug due to clotting as a side-effect of chemotherapy, and may be 
classed as nonadherent to CVD drugs when it has been discontinued for 
legitimate clinical reasons; a patient diagnosed with a stomach ulcer may cease 
therapy with aspirin due to contraindication; or a patient with Alzheimer’s 
disease may require additional support to maintain their medication regimen. 
Analyses including use of a multimorbidity measure, such as the Charlson 
Index[223] or the Elixhauser score[224], would be a valuable follow-up.   
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A complementary study to this, including a qualitative dimension conducted in a 
sub-group of patients, could add value in order to more fully understand patient 
adherence behaviours and the factors that influence them. 
There could be relevance here to COVID-19, the disease caused by the novel 
coronavirus SARS-CoV-2. Patients with pre-existing conditions such as CVD and 
diabetes are at a particular risk from the virus, though the exact mechanism is 
unknown[225]. Respiratory viruses are known to put added strain on the 
cardiovascular system so this could explain the increased risk, or a systemic 
immune response could affect organs such as the heart and kidneys. Another 
theory involves the ACE2 receptor, by which the virus enters the cells. Notably 
the ACE2 receptor interacts with drugs studied here; specifically, ACEi’s and 
ARBs[225]. Using PIS, identifying patients prescribed these drugs, and estimating 
their adherence using the methods within this thesis could be an interesting way 
of seeing a population level picture. Comparing adherent patients to 
nonadherent patients, and comparing patients prescribed ACEi’s and ARBs to 
patients prescribed other CVD drugs, and then linking this to records of patients 
with positive tests, ICU admissions, and deaths from COVID-19 could present a 
worthwhile exploratory analysis of any possible relationship between this and 
the virus. It may also be important to consider how adherence behaviours 
changed during national lockdown, particularly as shielding individuals may have 
had new barriers to accessing medications.  
9.3 Challenges and limitations 
9.3.1 Using secondary records 
Access to secondary data in Scotland depends on application through eDRIS, and 
approval via Public Benefit and Privacy Panel. While this can be a time-
consuming process, it is important in ensuring safe and proper use of patient 
data. For conducting this PhD project, the benefit of this process was that it 
forced an early focus on deciding key aims and developing the basis and value of 
such research early on. From the date of PBPP approval to receiving the majority 
of the data output took 6 months, though with some added delay to dosage 
instruction information arriving.  
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As per the PBPP request, all prescriptions for each drug listed in the whole of 
Scotland between the years of 2009-early 2017 were included in the data 
output. This produced a considerable sized dataset and created a need for 
efficient data management in order to reduce burden on computer memory. 
However, these challenges are outweighed by the value in having access to a 
population-level dataset for epidemiological study. 
At a fundamental level, all routinely collected data will carry inherent flaws, 
and quality assessment is vitally important in any research project which 
attempts to use it, as understanding where these flaws occur and how to counter 
them is an important aspect of study design. In Chapter 4, quality assessment of 
the PIS dataset highlighted issues with the dispensed date variable, where 55% of 
records defaulted to the end of the month (Figure 4.1). This led to selection of 
the prescribed date variable instead, which was more complete. However, this 
variable continues to be imperfect as 11% of records defaulted to the end of the 
month. Communicating such issues back to data providers is crucial, as it allows 
steps to be taken to improve these datasets, and for details of such issues to be 
communicated to future users of these data.  
There were some other issues with data quality observed at the data-cleaning 
steps. While some of these issues were clearly erroneous (for example, patients 
who attended hospitals following their registered date of death; prescriptions of 
tablets with dosing quantities of mg/ml, etc.) it leaves the possibility of other, 
less obvious, errors being present that cannot be identified in the data.  
9.3.2 Defining Patient Groups 
Using hospitalisation and prescribing data to characterise patient groups depends 
on certain assumptions being made about patient characteristics. Here, despite 
certain flaws, it seems that the definitions used to separate primary prevention 
patients from the treatment group and secondary prevention groups did work 
reasonably well, as the resulting groups did differ in ways we may expect; for 
example, with the average age being lower in the primary group and higher 
levels of polypharmacy in the treatment and secondary groups. CVD is a disease 
that lends itself reasonably well to secondary database study, due to clear 
clinical endpoints such as MI. While previous studies have validated ICD10 codes 
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as having high sensitivity and specificity for identifying MIs[226], this is still 
imperfect. The ICD disease code R074 indicates the diagnosis of ‘unspecified 
chest pain,’ and this was seen to be a common cause of hospitalisation in our 
cohort (Chapter 6). This could relate to angina or even an MI, especially as there 
is increasing evidence that female patients present with atypical symptoms and 
are often misdiagnosed or delayed in treatment[227]; however, the R074 code 
may not relate to any CVD indication at all and cannot be presumed as such. 
Studies using secondary data to observe CVD clinical endpoints may need to 
consider this in sensitivity analysis, and to investigate if there is a sex bias in MI 
reporting.  
However, there remains further potential for classification bias due to 
researcher error, particularly if selection of ICD-10 codes is flawed. Here, 
patients with atrial fibrillation (I48), heart failure (I50), and peripheral vascular 
disease (I73) may have erroneously been classified as primary prevention, due to 
the omission of these codes when characterising key groups. Additionally, those 
with angina may not always present at hospital and therefore may not be 
captured, also allowing for misclassification as primary prevention patients. GTN 
was used here instead to separate symptomatic from non-symptomatic CVD 
patients, but this may be misleading, particularly for those who have suffered an 
MI (secondary, secondary-with-treatment) as these patients are advised to 
collect GTN spray as a precautionary measure, even in the absence of symptoms. 
These flaws likely explain the high number of “primary” prevention patients 
prescribed nitrate drugs, and the very short follow up times observed in the 
secondary group, due to the majority going on to collect their recommended 
GTN spray, and is an error that ought to be rectified for any future publications.  
9.3.3 Reflecting on study design  
The challenge of taking on a vast dataset and attempting to carry out analyses 
across a series of risk factors has led to some oversights in study design, 
particularly in grouping of key variables. Despite overall demographics of the 
patient groups falling somewhat in line with expectations, there is clear 
evidence that some misclassification occurred, particularly with the secondary 
prevention group. While some degree of misclassification is unavoidable when 
using secondary data, further discussions with clinicians – particularly with 
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General Practitioner’s and Cardiologist’s - would have been invaluable in 
improving these analyses and could have given greater credibility to this 
research.   
Other important factors to improve the study design here include rethinking the 
age bands, as the very narrow bands (effectively 18-55, 55-65, and 65-100) will 
obscure some of the rich epidemiological insights that this dataset could have 
provided. Equally, limiting comorbidity to diabetes and depression will have 
failed to make full use of the information available.  
A missed opportunity in the original data request to PBPP was the exclusion of 
anticoagulants, particularly as the novel DOACS were introduced during the 
years of the study period. While these have been included in other high quality 
research studies using Scottish datasets[199, 206], it does not negate the relevance 
it would have had for this project. 
It is also important to note that co-prescribing was not included in the models 
here. Instead of taking such a vast, big picture, attempt at describing 
adherence, a more meaningful project of CVD adherence may have looked at 
this in a more refined approach. For example, assessing patient pathways, e.g. 
patients moving from ACEi’s to ARBs and adherence levels between switchers 
and non-switchers, could have provided more clinically interesting analyses than 
a range of adherence levels between classes. Importantly, effective 
management of cardiovascular disease often requires a regimen of multiple 
drugs, such as ACD prescribing (ACEi/ ARB, CCB, Diuretic) for management of 
hypertension, or a combination therapy which is standard care following an MI. 
While a goal of this project was to consider if there were differences in 
adherence between specific drug-classes, it is important to note that differences 
are most likely to occur between individuals rather than between different 
drugs. Understanding which questions are most clinically relevant and likely to 
provide the most epidemiologically insightful findings should be considered when 
designing a research study.   
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9.3.4 Prescribing data 
Prescribing data has value for defining CVD patients, as many of the drugs here 
have a clear indication and are not used regularly for other indications. This 
could be a challenge for other drug classes; for example, when attempting to 
define patients with depression as a comorbidity, it was important to look at 
other prescriptions received by the patient and to curate a list of medications 
which allowed a patient to be classed as having suspected depression vs. those 
who did not. Some patients (those prescribed only <75mg amitriptyline, 
duloxetine, flupentixol, moclobemide, reboxetine, agomelatine, phenelzine, 
tranylcypromine, and tryptophan) were omitted from the analysis, due to the 
fact their comorbidity status could not be confidently defined. Some of these 
drugs are used in management of pain, and patients should not be incorrectly 
classified in the analysis if this is the indication for which drugs were prescribed. 
While this may minimise some misclassification, it may also miss some people 
who were prescribed these drugs for a depression indication, reducing the 
sample size and leading to a loss of information.  
It is also not true that all CVD medications have one clear indication. Beta-
blockers were an issue here, as propranolol is commonly prescribed for anxiety. 
Results observed in the levels of implementation and persistence in the primary 
prevention group are likely to have been confounded by this, despite attempts 
to remove prescriptions for anxiety at the data-cleaning stage. 
Similarly, GTN, used to define our treatment group, may also be prescribed for 
another indication; management of anal fissures. In this instance, it is dispensed 
as a cream rather than as a spray formulation. Understanding this allowed a 
distinction to be made between patients who did not have GTN prescribed for 
angina from those who did.  
All of this underpins the importance in thoroughly understanding the drugs 
included in such analyses. Understanding different drug-indications, and how 
these can possibly be teased out, is crucial to improve the reliability of the 
assumptions made. For some medications, it may not be possible to make these 
distinctions, and without additional clinical information, this type of study may 
not be possible. 
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9.3.5 Adherence research 
Adherence is one of the more complicated drug-utilisation interactions to study, 
and this has led to numerous guidelines in assessing and reporting on it[43, 142] 
being developed. Even within these frameworks, there is not a clear gold-
standard, and there is much room for variation in measures, dependent on the 
data available[44] and specific study aims. When using PIS for this project, 
considerable data-cleaning was required to estimate the ‘days-coverage’ value 
from the dosage information variable, and from this, to estimate adherence. 
Here, simple implementation and persistence measures were used as these are 
more readily assessed, but further validation of adherence measures could add 
value for future study.  
Furthermore, adherence is a complex behaviour, which can be difficult to 
quantify as there are many unexpected and potentially unmeasurable 
confounders. An anecdote given by a leading adherence researcher during their 
presentation at the European Drug Utilisation Research Group (EuroDURG) 
Conference in 2017 summed this up nicely: using EMS monitoring, a patient 
consistently took their medication at the same time every evening and then 
suddenly stopped. Upon patient interview, it was determined that this change in 
behaviour was related to their television-set breaking, as they had previously 
used the start of the evening news as a reminder to take their medication. To 
truly understand patient interactions with their medications, qualitative 
research gives much greater depth; however, individual quirks such as this could 
never feasibly considered in any epidemiological study.  
However, there are other interactions with adherence that could be more 
broadly considered. Clinicians, district nurses, and social workers have many 
anecdotes of arriving at a patient’s house to find that, while they have been 
collecting their medication regularly, they have stockpiled these extensively. 
Additionally, there are more recent social events that may lead to stockpiling 
and may create challenges in measurements: news around potential drug 
shortages after the UK left the European Union, and concerns around access to 
pharmacies in the midst of the COVID-19 pandemic are two notable recent 
events that led to increased demand seen in pharmacies[228]. Conversely, public 
perceptions of drugs could also lead to changes in adherence. There is some 
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debate about statin use in primary prevention of CVD[229], especially for those in 
low-risk groups, due to the benefit: cost ratio for the associated side-effects 
such as myopathy[229]. Similarly, confusion around the interaction between SARS-
CoV-2 with ACEi’s and ARB’s could lead to patients choosing to stop taking these 
drugs without consulting a doctor or pharmacist if they have not been clearly 
informed on this, particularly as research is on-going.      
To study this nuance at a population level could create substantial noise in the 
data. An understanding of general levels of adherence in a population, such as 
those identified within this PhD study, could be valuable in order to allow future 
investigation into the impact of such changes in response to current affairs. 
9.3.6 Unexpected challenges  
This PhD was a sideways step from my previous study in virology and medical 
genetics, but I choose this project as I was keen to learn transferable data-
analysis skills and to dip my toe into public health research. This was harder 
than I had expected, and I had a steep learning curve with R. On reflection, 
starting out with such a large dataset certainly did not help as I found myself 
constantly crashing R in the early days of data-cleaning. Working out what to 
look for during data-cleaning while learning to implement the code at the same 
time was challenging and I was lucky to receive help from Kevin Ross, a 
researcher with previous experience of PIS data, and to have my supervisor’s 
expertise throughout. A valuable resource could be developed by data 
controllers and researchers using secondary datasets such as PIS, SMR, and NRS 
in the form of a ‘living document’, which can be updated regularly to highlight 
quirks of the datasets to look out for.  
The years of my PhD were strange times, bookended by the Brexit referendum 
the summer before I started and a global pandemic to round things off. There 
were two general elections during my study, and I found myself easily distracted 
by the political turbulence that characterised the UK in these years. Losing my 
flat toward the end of my PhD and moving back in with my parents to complete 
my write-up in the midst of COVID-19 presented other unexpected challenges, 
not least because the dogs want me to let them in and out of the garden every 
five minutes. It is worth noting that, while inconvenient, getting up and down 
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from my seat constantly must have a cardioprotective effect for me and I should 
be grateful.  
9.4 Conclusions  
Scottish datasets offer great potential for studying drug use at the population 
level, but there are important considerations in the data cleaning steps and 
assumptions made when conducting such study. The epidemiology of 
cardiovascular drug adherence in Scotland is largely related to traditional 
cardiovascular risk-factors, as has been observed previously, and therefore it is 
hard to use this data to make any conclusions about the long-term outcomes 
that may be related to adherence compared to nonadherence.  
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13 studies 
(2672) 
MEDLINE, 
Cochrane, 
reference 
lists of 
articles 
identified; 
until 2016 
Not 
specified 
Cochran
e ROB 
tool 
No significant 
change in 
adherence 
associated with 
telemedicine (in 
one trial- more 
research 
needed?) 
Not 
specified (++) 
Kristina 
and 
Wulanda
ri (2020)  
Assess self-
reported 
adherence in 
chronic 
disease 
Not 
geographi
cally 
restricted. 
16 papers 
in total, 
range of 
diseases. 
6 HTN, 1 
angina. 
PubMed, 
Science 
Direct, 
Google 
Scholar; 
2008-18; 
English 
language 
Mostly self-
repot/ 
MMAS 
GRADE 
approac
h 
SES, personal 
factors 
(confidence/ 
behaviour), 
healthcare 
factors(staff 
knowledge) all 
impacted  
Not 
specified (-) 
Lemstra, 
(2018) 
Analyse 
primary 
nonadherenc
e/ non-
initiation in 
chronic 
disease 
N. 
America 
and 
Europe 
24 papers 
(relates to 
a pooled 
550,485 
prescripti
ons) 
CINAHL, 
Cochrane,E
mbase, 
MEDLINE, 
ProQuest, 
PsycINFO, 
PubMed, 
Scopus 
Mostly 
prescriptio
n 
fills/admini
strative 
records. 
Cochran
e ROB, 
Newcast
le-
Ottawa 
Scale 
Evidence of 
considerable 
burden on non-
initiation in 
chronic disease; 
highest in lipid-
regulatory 
drugs (20.8%). 
Lack of social 
support 
associated with 
reduced adhere 
Initiator 
yes/no (++) 
Miguel-
Cruz et al 
(2019)  
Assess 
evidence for 
use of 
electronic-pill 
boxes 
Not 
specified 
22 studies 
included; 
3 HTN, 1 
HF 
Scopus, 
Pubmed, 
Embase, 
Medline-
Ovid, 
Medline-
Ebsco, IEEE 
Explore, ISI 
Web of 
Sciences, 
Ebsco Host 
Electronic 
pillboxes 
(range of 
designs) 
Physioth
erapy 
Evidenc
e 
Databas
e 
(PeDro) 
Scale  
Weak evidence 
that pill-boxes 
may be 
associated with 
improved 
adherence in 
hypertension/ 
chronic disease 
Range; 
includes 
80% cut-
off, 
persistence
, timing 
adherence 
(+) 
Ofori-
Asenso 
et al 
(2018)a 
To review 
risk-factors 
for statin-
nonadherenc
e in people 
aged 65 or 
over 
13 
countries 
45 
articles, 
(1.8M) 
Medline, 
Embase, 
CINAHL, 
PsycINFO, 
NHSEED, 
DARE and 
Cochrane; 
Published 
up until 
Dec 2016; 
English 
language 
Not 
specified 
NIH 
Quality 
Assessm
ent tool 
for 
observa
tional 
studies; 
Joanna 
Briggs 
Institute
’s 
checklist 
for RCT 
Factors 
associated with 
nonadherence: 
black/non-
white race; 
female gender; 
current smoker; 
higher co-
payments; new 
user; lower 
number of 
concurrent 
cardiovascular 
medications; 
primary 
prevention; 
comorbidity of 
respiratory 
disorders, 
depression, 
cancer, 
dementia; not 
having; lower 
income status; 
higher number 
of medications;  
and not having 
hypertension, 
renal disease, 
or diabetes  
Majority 
(80%) of 
adherence 
studies 
used PDC; 
Majority of 
persistence 
studies 
used gap 
methods. 
(+) 
Ofori-
Asenso, 
R., et al. 
(2018)b 
To review 
patterns of 
statin-
nonadherenc
e in people 
aged 65 or 
over 
40 
countries 
82 studies 
(>3M) 
Medline, 
Embase, 
PsycINFO, 
CINAHL, 
DARE, 
NHSEED, 
CENTRAL; 
Published 
up until 
Dec 2016; 
English 
language 
Studied 
adherence 
and 
persistence  
NIH 
Quality 
Assessm
ent tool 
for 
observa
tional 
studies 
At 1 year, 
47.9% of 
primary 
prevention 
group & 62.3% 
secondary 
prevention. 
Adherence 
reduced 
in >75yrs 
compared to 
65-75yrs. At 3 
years, adhere 
drops to 55%; 
at 10 years, 
28 %  
Adherence: 
MPR and 
PDC; 
Persistence
: most used 
permissible 
gap 
(+) 
Oori, et 
al (2019) 
Identify rates 
of statin 
adherence in 
Iran 
Iran 17 studies (7941) 
MagIran, 
Barakat 
Knowledge 
Network 
System, 
Scientific 
Informatio
n Database 
(SID), Web 
of Sciences, 
PubMed, 
Science 
Direct, 
Google 
Scholar; 
Years 2000-
2018; 
English and 
Persian 
Self-report: 
MMAS-8, 
HBMA; 
researcher 
tools; self-
care tools 
Develop
ed a 15-
item 
scale  
Overall 
prevalence of 
adherence = 
33%.Highest 
adherence rates 
observed in 
older, married 
people (vs. 
younger/ single) 
Score high/ 
moderate/ 
low 
(++) 
Schneide
r et al. 
(2018) 
Investigate 
relationship 
between 
aspects of 
drug-therapy 
and non-
adherence 
Not 
geographi
cally 
restricted. 
31 studies 
(27,441) 
PubMed, 
LILACS, 
Academic 
Search and 
CINAHL; 
Jan 1960-
Dec2015 
Mostly self-
repot/ 
MMAS 
Strobe 
criteria 
Non adherence 
associated with 
lack of access to 
insurance/ 
medication 
coverage and 
dosing freq 2 or 
more per day 
Cut-off 
score/ 
adherent 
yes or no 
(++) 
Shahin et 
al 
(2019)   
Investigate 
effect of 
personal/ 
cultural 
beliefs on 
adherence in 
chronic 
conditions 
(including 
HTN) 
Majority 
US, 
though 
not 
geographi
cally 
restricted 
25 
studies, 
majority 
looked at 
HTN and 
DM 
PubMed, 
CINAHL, 
EMBASE 
and 
PsychINFO 
Mostly self-
repot/ 
MMAS/ 
MARS 
(some with 
language 
adaptations
) 
None 
specifie
d  
Factors studied: 
perception of 
illness, health 
literacy, cultural 
beliefs, self-
efficacy, 
spiritual and 
religious beliefs, 
and illness 
knowledge. 
80% of studies 
found 
significance but 
direction of 
association 
inconsistent 
Not 
specified (+) 
Van Der 
Laan et al 
(2017) 
Identify risk-
factors 
associated 
with non-
adherence to 
antihyperten
sives 
Majority 
US 44 studies 
MEDLINE, 
EMBASE, 
PsycINFO, 
Cochrane; 
Jan 1960-
Jul 2016 
Half of the 
studies 
used 
pharmacy 
refill 
Quality 
assessm
ent tool 
based 
on that 
of 
Effective 
Public 
Health 
Practice 
Project 
Higher co-
payment, side 
effects and 
poor patient-
provider 
relationship 
were associated 
with 
nonadherence 
MPR most 
commonly 
used/ 80% 
cut-off 
(-) 
 
Papers included here were identified in updated search, Feb 2020. Papers identified in original 
search can be downloaded as Supplementary Table 1 from: 10.1093/pubmed/fdy088 
 
Supplementary Table 2: Data Extraction for outcomes associated 
with non-adherence 
Review 
Author 
(year) 
Aim Setting 
No. of studies 
included 
(participants) 
Search Strategy 
Adherence 
Measurem
ent 
Quality tool 
used 
Outcomes (and factors if 
included) 
Adherence 
operational measure 
Quality 
Score 
(from 
AMSTAR 
tool) 
Martin-Ruiz 
et al 
(2018)   
Assess risk of 
nonadherence to 
statins in primary 
prevention of CVD 
events/ mortality 
Predomina
ntly 
Europe 
and US 
17 studies 
MEDLINE, Trip 
database; 
articles 
published up 
until Dec 2016; 
limited to 
English and 
Spanish 
language 
Mix; tablets 
received/ 
treatment 
visits/ 
pharmacy 
refills 
Newcastle-
Ottawa 
Scale 
Pooled across studies: 18% 
reduced risk associated 
with CVD outcome and 
49% reduced risk of 
mortality adherence vs 
nonadherence. 
Two methods: split 
into adherence levels/ 
compare relative risk 
against ref (worst 
adherers); arbitrary 
80% cut-off/ compare 
'good' to 'bad 
(++) 
Murali et al 
(2017)  
Evaluate how 
adherence/persistenc
e assessed in trials, 
and their association 
with CVD outcomes/ 
mortality for dialysis 
patients 
Not 
specified 
22 trials 
(19,322); 5 
measured 
adherence 
MEDLINE, 
EMBASE and 
Cochrane 
CENTRAL; 
searched RCTs 
published 2005-
2015; English 
Not 
specified 
None 
specified  
Inconclusive; in five trials 
which studied this, 
appears that outcomes for 
these patients are 
negatively associated with 
poor adherence. More 
research needed. 
Only defined in one 
trial; used 80% cut-off (+) 
Xu, et al 
(2017). 
Identify association 
between adherence 
and stroke risk 
Majority 
US or 
Europe 
15 studies MEDLINE, EMBASE 
Not 
specified 
Newcastle-
Ottawa 
Scale 
Increased adherence 
associated with reduced 
stroke risk, significant in 
12 of 15 studies. Pooled 
RR of 0.77. 
PDC and MPR (++)  
 
Papers included here were identified in updated search, Feb 2020. Papers identified in original 
search can be downloaded as Supplementary Table 2 from: 10.1093/pubmed/fdy088 
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Appendix C: PBPP Form 
 
Public Benefit and Privacy Panel for Health and Social Care 
Application Form 
 
Application Control 
Applicants should not fill out this section 
Application Coordinator David Bailey 
Application Number 1617-0221 Submitted Date  
Applicant Name Kirstin Leslie 
Proposal Name Scotland-wide study of adherence with cardiovascular 
medication 
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Note to Applicants 
 
Prior to completing your application form you should: 
 Contact the eDRIS Team, who will assist you - Nss.edris@nhs.net or by phone on 0131 
275 7333 
 Read and understand the separate Guidance for Applicants 
 
Your application should be typed, not handwritten. Your eDRIS application coordinator will 
inform you how to submit your application form and any supporting evidence. Before 
submitting your completed application, you should ensure that: 
 All relevant sections of the application are complete 
 Relevant supporting evidence is attached 
 Individuals named on the form have read and approved its submission 
 
Please note that submitted applications may be circulated to panel members, administrative 
colleagues, NHSScotland information governance and information security colleagues, 
Caldicott Guardians, the CHI Advisory Group and, where appropriate, non-NHS Scotland 
colleagues from a variety of participating partner bodies, in the course of processing. You 
must make your eDRIS application coordinator aware of any confidential or sensitive 
information contained in your application which you would consider inappropriate for 
circulation in such a manner. Your application could be subject to disclosure or partial 
disclosure under the Freedom of Information (Scotland) Act, and will be retained in line with 
NHSScotland information policy. 
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Section 1 – People 
1.1 Applicant Please read section 1.1 of the guidance 
1.1.01 Full Name:  Kirstin Leslie 
1.1.02 Title: Ms 
1.1.03 Position: PhD student 
1.1.04 Professional Registration No.: If applicable 
1.1.05 Organisation Name: University of Glasgow 
1.1.06 Address: Institute of Health and Wellbeing, 1 Lilybank Gardens, 
Glasgow 
1.1.07 Postcode: G12 8RZ 
1.1.08 Telephone Number: 0141 330 4072 
1.1.09 Email: k.leslie.1@research.gla.ac.uk 
1.1.10 Do you have an NHS 
contract/honorary contract? 
No 
1.1.11 Provide details of the most recent information governance training undertaken - a list of 
training courses is included at Appendix A, and you should particularly indicate if you 
have undertaken any of those listed 
 Name of course: MRC Research Data and Confidentiality e-learning 
 Link to course content: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
 Institution: Medical Research Council 
 Date completed: 30/11/2016 
 
1.2 Clinical Sponsor/Lead Please read section 1.2 of the guidance  
1.2.01 Full Name:  Jill Pell 
1.2.02 Title: Professor & Doctor 
1.2.03 Position: Director of the Institute of Health and Wellbeing 
1.2.04 Professional Registration No.: 3259687 
1.2.05 Organisation Name: University of Glasgow 
1.2.06 Address: 1 Lilybank Gardens, Glasgow 
1.2.07 Postcode: G12 8RZ 
1.2.08 Telephone Number: 0141 330 3239 
1.2.09 Email: Jill.pell@glasgow.ac.uk 
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1.2.10 Does this person have an NHS 
contract/honorary contract? 
Honorary Consultant in Public Health  NHS Greater 
Glasgow and Clyde 
1.2.11 Provide details of the most recent information governance training undertaken - a list of 
training courses is included at Appendix A, and you should particularly indicate if this 
person has undertaken any of those listed 
 Name of course: MRC Research Data and Confidentiality e-learning 
 Link to course content: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
 Institution: Medical Research Council 
 Date completed: 15/05/2015 
 
1.3 Information/Data Custodian Please read section 1.3 of the guidance 
1.3.01 Full Name: Jill Pell 
1.3.02 Title: Professor & Doctor 
1.3.03 Position: Director of the Institute of Health and Wellbeing 
1.3.04 Professional Registration No.: 3259687 
1.3.05 Organisation Name: University of Glasgow 
1.3.06 Address: 1 Lilybank Gardens, Glasgow 
1.3.07 Postcode: G12 8RZ 
1.3.08 Telephone Number: 0141 330 3239 
1.3.09 Email: Jill.pell@glasgow.ac.uk 
1.3.10 Does this person have an 
NHS contract/honorary 
contract? 
Honorary Consultant in Public Health 
NHS Greater Glasgow and Clyde 
1.3.11 Provide details of the most recent information governance training undertaken - a list of 
training courses is included at Appendix A, and you should particularly indicate if this 
person has undertaken any of those listed 
 Name of course: MRC Research Data and Confidentiality e-learning 
 Link to course content: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
 Institution: Medical Research Council 
 Date completed: 15/05/2015 
 
1.4 Others with access to identifiable or potentially identifiable data Please read section 1.4 
of the guidance  
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Complete this section if applicable – for each additional person 
Full Name: Alex Marshall Telephone/ Email: a.marshall.1@research.gla.ac.uk 
Organisation: Robertson Centre for 
Biostatistics (RCB), 
University of Glasgow 
Position: PhD Research Student 
Professional 
Registration 
No: 
n/a NHS contract/ 
honorary 
contract? 
No  
IG Training - Name of 
course: 
MRC Research Data and Confidentiality e-learning 
IG Training - Link to course: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
IG Training - Institution: Medical Research Council Date completed: 26/09/2016 
 
1.4 Others with access to identifiable or potentially identifiable data Please read section 1.4 
of the guidance  
Complete this section if applicable – for each additional person 
Full Name: Professor Jill Pell Telephone/ Email: 0141 330 3239 
Jill.Pell@glasgow.ac.uk 
Organisation: University of Glasgow Position: Director of Institute of Health 
and Wellbeing 
Professional 
Registration 
No: 
3259687 NHS contract/ 
honorary 
contract? 
Honorary Consultant in Public 
Health – NHS Greater Glasgow 
and Clyde 
IG Training - Name of 
course: 
 MRC Research Data and Confidentiality e-learning 
IG Training - Link to course: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
IG Training - Institution: Medical Research Council Date completed: 15/05/2015 
 
1.4 Others with access to identifiable or potentially identifiable data Please read section 1.4 
of the guidance  
Complete this section if applicable – for each additional person 
Full Name: Colin McCowan  Telephone/ Email: 0141 330 3319 
Colin.McCowan@Glasgow.ac.uk 
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Organisation: RCB, University of 
Glasgow 
Position: Professor of Health Informatics 
Professional 
Registration 
No: 
 NHS contract/ 
honorary 
contract? 
Yes Honorary Contract with NHS 
GGC HB 
IG Training - Name of 
course: 
MRC Research Data and Confidentiality e-learning 
IG Training - Link to course: http://www.byglearning.co.uk/mrcrsc-lms/login/index.php 
IG Training - Institution: Medical Research Council Date completed: 05/01/2015 
 
1.4 Others with access to identifiable or potentially identifiable data Please read section 1.4 
of the guidance  
Complete this section if applicable – for each additional person 
Full Name: Kevin Ross Telephone/ Email: 0141 330 5188 
Organisation: University of Glasgow Position: Data Analyst 
Professional 
Registration  
No NHS contract/ 
honorary 
contract? 
No 
IG Training - Name of 
course: 
MRC Research Data and Confidentiality e-learning course 
IG Training - Link to course: https://byglearning.com/mrcrsc-
lms/course/index.php?categoryid=1 
IG Training - Institution: Medical Research Council Date completed: 18/02/2016 
 
1.5 Others Please read section 1.5 of the guidance 
Complete this section if applicable – for each additional person 
Full Name:  Involvement in 
Proposal: 
 
Organisation:  Position:  
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Section 2 – Organisations & Bodies 
2.1 Organisation or Body Leading Proposal Please read section 2.1 of the guidance  
2.1.01 Organisation or Body Name: University of Glasgow 
2.1.02 Is this organisation or body a registered data controller? 
If ‘Yes’, provide Data Protection Registration Number: 
Yes  Z6723578 
2.1.03 Is this a commercial organisation or body?  No  
2.1.03a If ‘Yes’, please provide a full explanation of the 
organisation or body’s activity and industry sector, 
including any previous experience of using 
NHSScotland data  - append supporting documentation 
as appropriate 
If applicable 
2.1.04 Is this organisation or body wholly funding or paying for 
the costs of conducting the proposal? 
No  
 
2.2 Organisation or Body Funding Proposal Please read section 2.2 of the guidance  
Complete the following section if you answered ‘No’ to question 2.1.4 
2.2.01 Organisation or Body Name: University of Glasgow 
Joint MRC Doctoral Training 
Programme (with Edinburgh 
University) 
2.2.02 Is this organisation or body a registered data 
controller? If ‘Yes’, provide Data Protection Registration 
Number: 
Yes  Z6723578 
2.2.03 Is this organisation or body a commercial organisation? No  
2.2.03a If ‘Yes’, please provide a full explanation of the 
organisation or body’s activity and industry sector, 
including any previous experience of using 
NHSScotland data - append supporting documentation 
as appropriate 
N/A 
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2.3 Other Relevant Organisations or Bodies Please read section 2.3 of the guidance  
Complete this section if applicable 
Organisation Name Nature of Business/Sector Nature of interest in proposal 
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Section 3 – Overview 
3.1 Proposal Essentials Please read section 3.1 of the guidance  
3.1.01 Proposal title/name: Scotland-wide study of adherence 
with cardiovascular medication 
3.1.02 Is this proposal an extension or renewal of an 
existing approval (for example to conduct a study 
over a wider geographic area or for a longer 
period of time)? Please provide details, include 
the reference number of the original approval, 
and summarise the changes requested 
No 
3.1.03 Is this new proposal related to a previous 
application (approved or not)? Please give 
details, indicate if this is a resubmission, including 
the reference number of the original submission 
No 
3.1.04 What is(are) the substantive purpose(s) of the proposal? (tick all that apply) 
   Patient Care   Research 
   Audit   Performance Monitoring/Management 
   Service Planning/Improvement   Health/Social Care Administration 
   Systems Implementation/Testing   Training/Education 
   Quality (Clinical, Educational, etc)  
 If other clearly defined purpose, please give details: 
 
3.1.05 Does the proposal require the use of information 
which can identify or potentially identify 
individuals?  
No  
3.1.06 Access is being requested to data from which sources? (tick as many as are relevant) 
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     A single NHS Scotland Board (excluding NSS)  
    NHS National Services Scotland  
    More than one NHS Scotland Board 
    A national NHS Scotland system/database 
    More than one NHS Scotland system/database 
    Community Health Index (CHI) database 
   NHS Central Registry 
 
 If other, please give details: 
3.1.07 Provide a full, clear concise outline of the proposal background – describe why it is 
needed, aims and objectives and envisaged benefits to the public and/or patients: 
also referred to as compliance, is defined by World Health Organization as “the extent to which a person’s 
–
” There have been recent efforts to move away 
from the use of the term “compliance” as this implies a lack of patient autonomy, though both terms are 
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Despite the known risks, there are many reasons patients fail to comply with a drug regimen: forgetfulness, 
side-effects, complex dosage regimens, a perception that the drug is not working, and a lack of 
understanding. Complex dosing may be difficult to avoid in particular classes of medication, especially if 
they are fast-acting drugs. It has also been found that
 Furthermore, some sub-groups of patients are more likely to struggle with adherence 
than others. Adherence generally improves with age, and adolescents are notoriously poor compliers. 
However, elderly patients may also struggle to adhere, for example if they have a co-morbid disorder 
affecting their cognition, making it difficult for them to understand instructions. Social demographics, such 
as level of deprivation may also have an impact. 
 
Need for Study: Despite advances, there is still a lack of quality research in this field; a 2014 Cochrane 
Review of 182 studies found that only 17 had an acceptably low risk of bias (Nieuwlaat et al 2014). For 
years research into medical adherence has been plagued by a lack of standardized methodology and 
failure of researchers to clearly define the terms ‘adherence’ or ‘compliance,’ as well as the different 
metrics used to study this, making it difficult for comparison in meta-analyses. This is the first study of its 
kind: A longitudinal, Scotland-wide, retrospective study of adherence in anti-hypertensive therapy, covering 
all ages and socioeconomic classes, giving greater insight into potential risk factors, and allowing us to 
identify unmodifiable risk factors, or particular patient groups requiring extra support. We will also consider 
other key patient and disease factors, and whether different drug classes (e.g. lipid-lowering drugs, beta-
blockers, etc.) has a major impact on adherence.  
 
Aim: To study the epidemiology of non-adherence to cardiovascular medication in Scotland and its 
subsequent effect on outcomes 
 
Objectives: 
- To determine the level of adherence with cardiovascular medication within Scotland 
- To determine the factors associated with adherence, including drug group, dosage and 
prescribing regimen, sociodemographic factors, type of usage (treatment vs primary 
prevention vs secondary prevention), as well as co-morbidity and polypharmacy. 
- To determine the outcomes of poor adherence by linking prescription data to medical records
 to assess future hospitalisations and deaths 
 
Benefits to public: Failure to adhere to medication can contribute to reduced clinical effectiveness, 
reduced cost effectiveness, poorer overall health and health inequalities. Identifying  national levels of 
adherence as well as identifying sub-groups of the population who do not comply and why is fundamental 
to developing interventions to improve adherence and, thereby, population health.  
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3.1.08 Provide a full, clear and concise outline of the proposal design, listing: data sources; 
sample size ; inclusion/exclusion criteria (eg involvement in trial/survey; health event, 
etc); relevant date range; need for identifiable or potentially identifiable data; requirement 
for a matched control cohort etc. 
 
Data Sources: 
 PIS (2009-most recent) – for prescribing information; PIS data for all items prescribed to members 
of our cohort will be used to identify polypharmacy 
 SMR01 (1999-most recent) – record of admissions to acute hospitals 
 SMR04 (1999-most recent) – record of admissions to psychiatric hospitals 
 Death Certificates (NRS Deaths) (2009-most recent) 
 
PIS will be used to identify all individuals prescribed one or more of the following medications from January 
2009 onwards (including individuals who did not collect  some/all of the prescriptions):  
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For these individuals we require linkage to all SMR01, SMR04 and death data for the time periods listed 
above.  
 
SMR01 data will be used to categorise use of these medications into secondary prevention (commencement 
within 30 days of acute myocardial infarction), treatment (commencement of anti-anginal medication within 
10 years of ischaemic heart disease code) and primary prevention (neither).  
 
SMR01, SMR04 and death data will be used to derive outcomes: 
 All-cause hospitalisations 
 Cause-specific hospitalisations 
 All-cause mortality 
 Cause-specific mortality  
  
SMR01 and SMR04 records in the 10 years prior to prescription of the listed drugs will be used to ascertain 
comorbidities based on the ICD-10 coding as this is likely to be an important factor for levels of adherence.  
 
PIS data will be used to identify polypharmacy in terms of the number and types of additional drugs 
prescribed at the same time as the drug of interest.  
 
We will investigate whether adherence varies by the following and undertake sub-group analyses where 
relevant.   
 
• age,  
• sex,  
• socioeconomic deprivation,  
 drug category 
 prescribing regimen 
• use of medication for primary versus secondary prevention treatment 
• presence / absence and level of comorbidity / multimorbidity 
• presence / absence and level of polypharmacy    
 
3.1.09 Does the proposal have implications for, or target, sensitive groups or vulnerable 
populations? Please give details 
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  No 
 
3.1.10 Does the proposal seek to use information exclusively about deceased persons? Please 
give details 
 No 
3.1.11 Have any members of the public/lay representatives been involved in the proposal 
design? Please give details 
 No 
 
 
3.1.12 Has any peer review of the proposal been undertaken? Please give details (for example 
formal review by a peer organisation or funding body, informal internal review, review by 
a third party) 
 Yes the project was subjected to internal peer review as part of the MRC Doctoral 
Training Programme – all proposals were reviewed, ranked and shortlisted. 
 
3.1.13 Is there any commercial aspect or dimension to the proposal or its outcomes? Please 
give details 
 No 
 
 
 
 
 
 
 
 
 
3.2 Proposal Geography Please read section 3.2 of the guidance 
   Local/Regional (relating to one or more specific areas within Scotland) 
   National (relating to the whole of Scotland) 
   UK-wide (relating to the whole of the UK, or to UK regions outside Scotland) 
   International (relating to areas within the EEA) 
                                                                                                                         
  
Public Benefit and Privacy Panel for Health and Social Care – Application Form v 1.1                     Page 15 
 
   International (relating to areas beyond the EEA) 
 
3.3 Proposal Duration and Frequency Please read section 3.3 of the guidance  
3.3.01 What is the proposed duration of the proposal? 4 years 
3.3.02 Does the proposal require updates of information 
at regular intervals? Please give details 
No 
3.3.03 Are you seeking approval to iterate the proposal 
(ie the whole project, audit or study) at regular 
intervals? Please give details 
No 
 
3.4 Statutory and Regulatory Context Please read section 3.4 of the guidance  
3.4.01 Does your proposal have a statutory or 
regulatory justification - is the proposal 
responding to a statutory or regulatory 
instruction, duty or order? Please give details 
No 
3.4.02 Which Data Protection Act schedule 2 and 
schedule 3 conditions are relevant? (a list of 
conditions can be found at Appendix B) 
Schedule 2:(6) “legitimate interests 
pursued by the Data Controller or the 
third party.” 
 
Schedule 3: (8), “processing is 
necessary for “medical 
purposes”…includes the purposes of 
medical research…” 
3.4.03 Are there any relevant information sharing 
agreements, protocols or contracts in place 
which support your proposal? Please give 
details and attach as supporting documentation 
if available 
No – all datasets are held by ISD 
3.4.04 Has a Privacy Impact Assessment been carried 
out which supports your proposal? Please give 
details and attach as supporting documentation 
if available 
Not applicable – see attached 
document which applies screening 
criteria to the need for an application 
3.4.05 Has local Caldicott approval been given for your 
proposal at a local level? Please give details 
Not applicable 
                                                                                                                         
  
Public Benefit and Privacy Panel for Health and Social Care – Application Form v 1.1                     Page 16 
 
3.4.06 Are approvals from Caldicott Guardians outside 
Scotland pending or received? Please give 
details 
Not applicable 
 
3.5 Research and Ethics Governance Please read section 3.5 of the guidance 
3.5.01 Has your proposal sought research/ethics 
approval? 
No –not applicable as the project 
would fall under the pre-arranged 
Ethics Approval for eDRIS studies 
analysed within the National Safe 
Haven   
3.5.01a If yes, please provide committee details  and 
status of approval (ie pending, approved, etc). 
Please attach as supporting documentation if 
available 
If applicable 
 
 
 
3.5.01b If no, please explain why research/ethics 
approval is not sought: 
If applicable 
 
 
3.6 Safe Havens Please read section 3.6 of the guidance 
3.6.01 Do you intend to access the data requested 
exclusively through a safe haven listed at 
Appendix A? Please provide details of which safe 
haven/s 
Yes 
 
If you have answered ‘Yes’ you do not 
need to complete sections 5.2 or 5.3 
3.6.02 If you applying to use NHS NSS data and you do 
not intend to do this through the National Safe 
Haven, please explain why 
If applicable 
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Section 4 – Data & Data Subjects 
4.1 Data yet to be collected  Please read section 4.1 of the guidance 
 
Dataset/source 
Name 
Collection by 
(whom)? 
Explicit consent sought? If Yes, describe how 
explicit consent being sought – provide copies of 
participant consent/registration forms, etc. If No, 
explain why consent is not being sought (eg 
impractical, risk associated with seeking consent, 
etc) 
N/A   
   
   
 
4.2 All Other Datasets / sources Please read section 4.2 of the guidance 
Dataset/source 
Name 
Data Controller (Organisation) Original purpose compatible with 
proposal? 
SMR 01 NSS  Outcomes (cause specific and all 
cause hospitalisations) 
 Differentiate between primary or 
secondary prevention and 
treatment 
 Identify comorbid conditions 
SMR 04 NSS  Outcomes (all-cause 
hospitalisations) 
 Identify comorbid conditions 
Deaths NRS  Outcomes 
PIS NSS  Exposure (adherence to 
medication) 
 Modifying factors (drug category, 
polypharmacy, doseage regiment) 
 Comorbidity 
 Confirmation of date of first usage 
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How were individuals originally informed of the use of their data? (if known) 
We are requesting a download of data collected and collated by NHS Scotland. Patients attending / 
accessing NHS healthcare services are provided with leaflets informing them that data will be 
collected and the uses to which they they will be put. No written consent is obtained. We are not 
involved in this process 
For existing dataset/sources for which the data controller is not an NHSScotland board, please 
append evidence of the data controllers permission to use the data 
 
We are using an anonymised extract of data collected by the NHS and already collated and held 
by ISD. 
 
4.3 Data Variables Please read section 4.3 of the guidance  
Dataset/source 
Name 
Variable Time 
Period/Range 
Processing only? 
SMR 01 Unique Patient ID 
Full admission date 
Full discharge date 
Continuous Inpatient Stay 
(CIS) marker (including 
GLS) 
Location 
Health Board of Treatment 
Specialty 
Significant Facility 
Admission Type 
Admission Reason 
Admission transfer from 
Admission transfer from 
desc 
Discharge type 
Discharge transfer to 
Discharge transfer to desc 
main_condition 
other_condition_1 
Jan 1999 onwards Yes 
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other_condition_2 
other_condition_3 
other_condition_4 
other_condition_5 
main_operation_date 
main_operation_a 
main_operation_b 
other_operation_1_a 
other_operation_1_b 
other_operation_2_a 
other_operation_2_b 
other_operation_3_a 
other_operation_3_b 
Inpatient/Day Case 
MarkerSIMD  Scotland 
Quintile (2012) 
 SIMD  Scotland Decile 
(2012) 
D.O.B (mm/yyyy)  
Length of Stay 
SMR 04 Unique Patient ID 
Full admission date 
Full discharge date 
Continuous Inpatient Stay 
(CIS) marker (including 
GLS) 
Location 
Health Board of Treatment 
Specialty 
Significant Facility 
Admission Type 
Admission Reason 
Admission transfer from 
Admission transfer from 
desc 
Discharge type 
2009 Onwards Yes 
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Discharge transfer to 
Discharge transfer to desc 
main_condition 
other_condition_1 
other_condition_2 
other_condition_3 
other_condition_4 
other_condition_5 
main_operation_date 
main_operation_a 
main_operation_b 
other_operation_1_a 
other_operation_1_b 
other_operation_2_a 
other_operation_2_b 
other_operation_3_a 
other_operation_3_b 
Inpatient/Day Case Marker 
SIMD  Scotland Quintile 
(2012) 
SIMD  Scotland Decile 
(2012) 
Age in years 
Length of Stay 
NRS Death 
Registrations 
Unique Patient ID  
Age at Death 
Date of Death 
Underlying Cause of Death 
Code 
Cause of Death Code 0 
Cause of Death Code 1 
Cause of Death Code 2 
Cause of Death Code 3 
Cause of Death Code 4 
Cause of Death Code 5 
2009 Onwards Yes 
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Cause of Death Code 6 
Cause of Death Code 7 
Cause of Death Code 8 
Cause of Death Code 9 
Place of Occurrence Code 
PIS Unique Patient ID 
Gender 
Age D.O.B (mm/yyyy) 
Patient Postcode Sector (5 
digit) 
SIMD  Scotland Quintile 
(2012) 
SIMD  Scotland Decile 
(2012) 
Patient Health Board 
Patient CHP 
Patient Local Authority 
 
Anonymised Prescribing 
GP practice code 
 
Prescribing Health Board 
 
Paid date (full date)  
Dispensed date (full date) 
Prescribed Date (full date)) 
 
PI Drug approved name 
PI Item Description 
PI Product Description 
PI Drug Formulation  
PI Strength/UOM 
BNF Item 
BNF root drug 
 
2009 Onwards  
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Number of Items 
Dispensed/ Paid 
Quantity dispensed/ paid 
Number of Defined Daily 
Doses dispensed for all 
prescribed drugs listed in 
3.1.8 
ePR native dose 
instructions for drugs listed 
in 3.1.8. (Dose variable 
information extracted from 
Dose Instructions using 
NLP) 
    
Please justify your need for identifiable or potentially identifiable variables: 
 
Full dates of death, admission and discharge are requested to allow for accurate modelling of 
clinical and economic outcomes. 
GP Practice code and Patient Postcode Sector have been requested to group patients by these 
categories and examine whether practice or location are associated with different outcomes.   
 
4.4 NRS/NHSCR Data Sources Please read section 4.4 of the guidance  
Complete this section if access to NHSCR is required, or if there is any National Records of 
Scotland involvement 
4.4.01 Does the proposal require access to NHS Central Registry 
as a sampling frame for cohorts? 
No  
4.4.02 Does the proposal involve flagging of individuals on the 
NHSCR for long term follow up? 
No  
4.4.03 If yes, is flagging necessary: 
   To trace and contact individuals throughout the UK?  
   To be informed of fact and cause of death?  
   To be informed of the incidence of on-going cancers?  
   To be informed of emigrations prospectively and retrospectively?  
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4.4.04 Is any other NRS involvement required? 
Please provide details 
No 
 
4.5 Making Contact with Individuals Please read section 4.5 of the guidance  
4.5.01 Is any direct contact with any group of individuals required? If 
Yes, please provide details below 
No  
 Contact Group and Method of contact Contact by (whom) 
   Hospital Consultants  
 
 Letter   Phone   Other 
(specify) : 
 
 
  Other NHSS Staff  Letter   Phone   Other 
(specify) : 
 
 
  General Practitioners  Letter   Phone   Other 
(specify) : 
 
 
  Patients/Public  Letter   Phone   Other 
(specify) : 
 
 
  Relatives of 
participants 
 Letter   Phone   Other 
(specify): 
  
 
  Others (please 
specify): 
 
 Letter   Phone   Other 
(specify) : 
 
 
4.5.02 Please explain why contact is being made – append copies of relevant 
correspondence as supporting evidence 
 
 If applicable 
 
4.6 Community Health Index (CHI) Database Please read section 4.6 of the guidance 
Complete this section if access to CHI Database is required 
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4.6.01 What monitoring and audit of the use of 
CHI is planned? Please provide details 
 
4.6.02 What technical method will be used to 
access CHI (online read-only, download, 
other extract, anonymised extract, etc)? 
Please provide details 
 
4.6.03 Have any risks been identified in the 
proposal which relate specifically to 
CHI? 
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Section 5 – Methodology & Data Processing  
5.1 Methodology Please read section 5.1 of the guidance 
5.1.01 Does the proposal require any of the following: 
  Data matching/linking 
   Use of matched 
controls 
  Single anonymised data extract  
 
Other (please specify): 
 
5.1.02 Who is carrying out any indexing/ 
linkage/anonymisation, and where? 
ISD Indexing team 
5.1.03 Which data sources listed at section 4.1 and 4.2  will 
NSS/NRS receive identifiers for linkage purposes? 
If applicable 
5.1.04 What variables will be provided for linkage?  
 
  CHI Number   Forename   Surname 
  Date of Birth   Address or Postcode   NHS Number 
Other Please Specify: N/A 
 
 
5.2 Access Please read section 5.2 of the guidance 
Complete the following section if you answered ‘No’ to question 3.6.1 
5.2.01 At what location is identifiable or potentially identifiable  
data being accessed? 
N/A 
5.2.02 Please provide details of security policy/procedure  
governing access to this physical and technical 
environment – append supporting documentation  
N/A 
5.2.03 Does this policy/procedure cover password policy in 
detail? Please provide details/ append supporting 
documentation 
N/A 
5.2.04 Does this policy/procedure cover user account 
management, including review or removal of access to 
N/A 
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sensitive/personal data, in detail? Please provide details/ 
append supporting documentation  
5.2.05 Will individuals with access to data have individual or 
shared accounts? 
N/A 
5.2.06 Will the data be accessed by staff working off site eg staff 
working from home at any time during the duration of the 
proposal?  
Choose an item.  
5.2.06b If yes, are policies/procedures in place to facilitate, 
monitor and audit this access? Please provide details/ 
append supporting documentation 
If applicable 
5.2.07 Provide any additional detail of how data is protected  
from unauthorised access 
If applicable 
 
5.3 Store & Use Please read section 5.3 of the guidance 
Complete the following section if you answered ‘No’ to question 3.6.1 
5.3.01 Where is data being stored and used? (location, 
organisation,  address – refer to addresses in previous 
sections if appropriate) 
N/A 
5.3.02 Data Protection Registration Number If applicable 
5.3.03 ISO 27001 Cert. No. If applicable 
5.3.04 Please provide details of security policy/procedure  
governing storage and use of data within this physical and 
technical environment – append supporting 
documentation 
N/A 
5.3.05 Does this policy/procedure cover the implementation of 
up-to-date controls for the detection and prevention of 
malware? Please provide details/ append supporting 
documentation 
N/A 
5.3.06 Does this policy/procedure cover access control and 
auditing of system administrator activity? Please provide 
details/ append supporting documentation 
N/A 
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5.3.07 Does this policy/procedure cover the production of 
backups and the controls in place around these? Please 
provide details/ append supporting documentation 
N/A 
5.3.08 Does this policy/procedure describe the controls in place 
to prohibit unauthorised copying of data? Please provide 
details/ append supporting documentation 
N/A 
5.3.09 Does this policy/procedure describe physical and site 
controls? Please provide details/ append supporting 
documentation 
N/A 
5.3.10 Does this policy/procedure cover hardware repair, 
replacement or disposal and protection of data from 
inappropriate access during such procedures? Please 
provide details/ append supporting documentation 
N/A 
5.3.11 Describe the systems, software and security used to store 
and use data - please provide details/ append supporting 
documentation 
N/A 
5.3.12 Is outsourced IT in use? Please give details N/A 
Please repeat section 5.3 above for each relevant location in the proposal – see guidance 
  
 
5.4 Transfer Please read section 5.4 of the guidance 
5.4.01 Please provide details of security policy/procedure to 
ensure that data will be transferred in such a way that it is 
protected from inappropriate or unauthorised access 
(mention email encryption, secure file transfer protocols 
SFTP, device encryption, physical controls, etc, as 
appropriate) - append supporting documentation 
All data transfers will only 
be required within  eDRIS 
procedures including 
hosting on National Safe 
Haven 
5.4.02 At what intervals/ trigger points will data transfer take 
place? 
Single transfer 
5.4.03 Will any identifiable or potentially identifiable data be 
transferred outside of the UK? 
No  
5.4.03b If yes, please provide details of the country of destination, 
the method of transfer, the proposed location and method 
If applicable 
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of storage outside of the UK, and details of any further 
onward transfer 
5.4.04 Other than initial transfers from source systems, is there 
any copying of data required within the proposal? Please 
give details 
No 
 
5.5 Dissemination  Please read section 5.5 of the guidance 
5.5.01 Will proposal findings be published or disseminated 
beyond the proposal team? 
Yes 
 If you have answered ‘No’, 
go directly to section 5.6 
5.5.01a If yes, how will proposal findings be published or 
disseminated, to what audience and in what format? 
Please give details 
Dissemination to 
researchers through high 
quality, peer reviewed 
journals, conference 
presentations, and 
publication in PhD Thesis.  
 
To general audiences, 
accessible summary 
articles will be presented.  
5.5.01b If yes, what steps will be taken to ensure that persons 
cannot be identified in published findings (eg disclosure 
control procedures (safe haven), use of aliases, 
numbers, avoidance of small geographical areas, 
avoidance of small numbers , etc)? Please give details 
Only aggregated data 
presented  
5.5.01c If yes,  are there any circumstances where a living or 
dead individual would be cited? (eg where a person 
consented to their data being used as a case study)? 
Please give details 
No 
5.5.01d If yes, were any permissions to publish data required or 
sought (for example from data controllers)? Please 
provide details 
No 
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5.6 Retain/Dispose Please read section 5.6 of the guidance  
5.6.01 Which information/data/records retention policy will you be 
applying to the proposal data (details of the policy and the 
organisation to which it belongs)? 
NHS NSS Retention Policy 
5.6.02 How long do you intend to retain identifiable or potentially 
identifiable data after the conclusion of the proposal 
(including archive/backup copies)? 
2 years 
5.6.03 Who will retain the data and where? As per NSS Safe Haven 
Pol 
5.6.04 What is the purpose for retaining the data for the specified 
time? 
To re-visit analysis/ make 
amendments, write up of 
papers, answer journal 
questions and write-up of 
and Thesis 
5.6.05 What method of disposal or destruction will be used when 
this period has expired (including archive/backup copies)? 
As per eDRIS User 
Agreement. 
5.6.06 What evidence will be obtained that destruction has 
occurred (eg IT supplier certificate of destruction, etc)? 
As per eDRIS User 
Agreement. 
 
5.7 Review Please read section 5.7 of the guidance 
5.7.01 Describe how the mechanisms which safeguard data 
security will be audited and reviewed at regular intervals to 
ensure their continued efficacy 
As per eDRIS User 
Agreement. 
5.7.02 Describe any resource implications to any of the proposed 
measures for the protection of  physical or technical 
security of information which are unresolved at the time of 
this application? (for example encryption of devices is an 
intention not yet fulfilled, training is not yet undertaken, 
etc) 
As per eDRIS User 
Agreement. 
5.7.03 Describe the breach reporting mechanisms to be invoked 
in the event of any inappropriate access to data or other 
information security incident 
As per eDRIS User 
Agreement. 
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Section 6 – Declaration 
 
 I DECLARE THAT this application is accurate, and that, should it be successful, any health 
data made accessible will be used for no other purpose, and in no other way, than as 
described above.  
 I UNDERTAKE TO notify the Public Benefit and Privacy Panel of any future changes to 
the purpose or manner in which data is processed in accordance with this application. 
 I UNDERSTAND THAT any future applications by me, or my employing or sponsoring 
organisation, may be refused should any health data made accessible be used for any 
other purpose or in any other way than that described above.   
 I CERTIFY THAT all those who have access to health data in this proposal are aware of 
the requirements of confidentiality and understand that any breach (eg disclosure of 
confidential information to a person not authorised to receive it) will be reported to the data 
controller, and in the case of NHS Scotland originated data to Scottish Government 
eHealth division. 
 I GUARANTEE THAT no publication will appear in any form in which an individual may be 
identified without the written permission of that individual, and that I will  apply appropriate 
disclosure control when planning publications involving the data requested. 
 I UNDERSTAND THAT the Data Controller, and agents acting on its behalf, reserves the 
right to inspect the data on the sites where it is being processed. 
 
To be signified by the APPLICANT 
Name (in Capitals): KIRSTIN LESLIE Date: 22/12/2016 
 
 I DECLARE THAT (the applicant named above) is a bona fide worker engaged in a 
reputable project and that the data he/she asks for can be entrusted to him/her in the 
knowledge that he/she will conscientiously discharge his/her obligations, including in 
regard to confidentiality of the data, as stated in the declaration above. 
 
To be signified by the INFORMATION CUSTODIAN named in Section 1.3  above (where the 
Information Custodian is not the applicant). 
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Name (in Capitals): JILL PELL Date: 22/12/2016 
 
Section 7 - Supporting Evidence  
 
Supporting Evidence Please read section 7 of the guidance  
Please list each piece of supporting evidence which you have included with your 
application in the box below – the name of each should clearly indicate what the 
document/file/reference is about 
1617-0221 - Privacy Impact Assessment – comparison of application against the 
criteria listed in the ICO Code of Practice Report 
1617-0221 – Certificate of Completion - MRC Research Data and Confidentiality e-
learning – Kirstin Leslie 
1617-0221 – Certificate of Completion - MRC Research Data and Confidentiality e-
learning – Alex Marshall 
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Appendix A – Reference lists for applicants 
1. Examples of Existing Datasets and Data Sources 
SMR 00 Outpatients SMR 04 Mental Health 
SMR 01 Inpatients and Day Cases SMR 06 Cancer Registration 
SMR 02 Maternity SMR 11/SBR Neonatal/Scottish Birth 
Records 
Scottish Drugs Misuse Database (SDMD) Birth Registrations 
A&E – Accident & Emergency Stillbirth Registrations 
PIS Prescribing Information Death Registrations 
CHSP-PS/CHSP-S/SIRS – Child Health 
Surveillance and Immunisation 
SCI-DC 
NHS National Service Scotland’s Information Services Division (ISD) maintains a National 
Dataset Catalogue (NDC) containing details of all health and health related datasets that are 
held by ISD. The Administrative Data Liaison Service (ADLS) publishes further information 
on key NHSScotland datasets 
 
2. Common Identifiable Variables 
Forename Middle Name Surname 
CHI Number Date of Birth UK NHS Birth Registration Number 
Gender Postcode  
 
3. Recognised Safe Havens  
NHS NSS ISD Electronic Data Research Innovation Service (@Farr Institute) 
NHS Research Scotland South East (ACCORD) 
NHS Research Scotland East (TASC) 
NHS Research Scotland North (DaSH) 
NHS Research Scotland West 
University of Dundee Health Informatics Centre (HIC) 
National Records Scotland Scottish Longitudinal Study (SLS) 
Robertson Centre @ Glasgow University 
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4. Research and Information Governance Training 
MRC Research Data and Confidentiality online module 
University of Edinburgh SHIP Information Governance training 
NHS Health and Social Care Information Centre On-line Information Governance training 
NHSScotland Information Governance eLearning: 
 Safe Information Handling (Foundation Level) 
 Information Handling in Practice (Intermediate Level) 
 
5. Sensitive Data Categories    
Abortion Mental health Contraception 
Pregnancy in age < 16 years Drugs and alcohol misuse Crime related statistics 
Sexually transmitted disease Suicide Ethnicity 
Assisted conception   
 
6. Vulnerable Populations 
Adults with Incapacity Drugs users 
Minority ethnic groups Specific religious affiliation 
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Appendix B –The Caldicott Principles & the Data Protection Principles (& Schedules) 
1. Caldicott Principles 
1. Justify the purpose(s) 
Every single proposed use or transfer of patient identifiable information within or from an 
organization should be clearly defined and scrutinized, with continuing uses regularly 
reviewed, by an appropriate guardian. 
2. Don't use patient identifiable information unless it is necessary 
Patient identifiable information items should not be included unless it is essential for the 
specified purpose(s) of that flow. The need for patients to be identified should be considered 
at each stage of satisfying the purpose(s). 
3. Use the minimum necessary patient-identifiable information 
Where use of patient identifiable information is considered to be essential, the inclusion of 
each individual item of information should be considered and justified so that the minimum 
amount of identifiable information is transferred or accessible as is necessary for a given 
function to be carried out. 
4. Access to patient identifiable information should be on a strict need-to-know basis 
Only those individuals who need access to patient identifiable information should have 
access to it, and they should only have access to the information items that they need to see. 
This may mean introducing access controls or splitting information flows where one 
information flow is used for several purposes. 
5. Everyone with access to patient identifiable information should be aware of their 
responsibilities 
Action should be taken to ensure that those handling patient identifiable information - both 
clinical and non-clinical staff - are made fully aware of their responsibilities and obligations to 
respect patient confidentiality. 
6. Understand and comply with the law 
Every use of patient identifiable information must be lawful. Someone in each organization 
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handling patient information should be responsible for ensuring that the organization 
complies with legal requirements. 
7. The duty to share information can be as important as the duty to protect patient 
confidentiality 
Health and social care professionals should have the confidence to share information in the 
best interests of their patients within the framework set out by these principles. They should 
be supported by the policies of their employers, regulators and professional bodies. 
 
2. Data Protection Principles 
1. Personal data shall be processed fairly and lawfully and, in particular, shall not be 
processed unless – 
(a) at least one of the conditions in Schedule 2 is met, and 
(b) in the case of sensitive personal data, at least one of the conditions in Schedule 3 is 
also met 
2. Personal data shall be obtained only for one or more specified and lawful purposes, and 
shall not be further processed in any manner incompatible with that purpose or those 
purposes 
3. Personal data shall be adequate, relevant and not excessive in relation to the purpose or 
purposes for which they are processed 
4. Personal data shall be accurate and, where necessary, kept up to date 
5. Personal data processed for any purpose or purposes shall not be kept for longer than is 
necessary for that purpose or those purposes 
6. Personal data shall be processed in accordance with the rights of data subjects under this 
Act 
7. Appropriate technical and organizational measures shall be taken against unauthorized or 
unlawful processing of personal data and against accidental loss or destruction of, or 
damage to, personal data 
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8. Personal data shall not be transferred to a country or territory outside the European 
Economic Area unless that country or territory ensures an adequate level of protection for 
the rights and freedoms of data subjects in relation to the processing of personal data 
 
3. Data Protection Schedule 2 & 3 Conditions 
Schedule 2 – Conditions for Processing any Personal Data 
1. The data subject has given his consent to the processing 
2. The processing is necessary— 
(a) for the performance of a contract to which the data subject is a party, or 
(b) for the taking of steps at the request of the data subject with a view to entering into a 
contract 
3. The processing is necessary for compliance with any legal obligation to which the data 
controller is subject, other than an obligation imposed by contract 
4. The processing is necessary in order to protect the vital interests of the data subject 
5. The processing is necessary— 
(a) for the administration of justice, 
(aa) for the exercise of any functions of either House of Parliament, 
(b) for the exercise of any functions conferred on any person by or under any enactment, 
(c) for the exercise of any functions of the Crown, a Minister of the Crown or a 
government department, or 
(d) for the exercise of any other functions of a public nature exercised in the public 
interest by any person 
6. (1) The processing is necessary for the purposes of legitimate interests pursued by the data 
controller or by the third party or parties to whom the data are disclosed, except where the 
processing is unwarranted in any particular case by reason of prejudice to the rights and 
freedoms or legitimate interests of the data subject. 
(2) The Secretary of State may by order specify particular circumstances in which this condition 
is, or is not, to be taken to be satisfied 
Schedule 3 – Conditions for Processing any Sensitive Personal Data 
1. The data subject has given his explicit consent to the processing of the personal data 
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2. (1) The processing is necessary for the purposes of exercising or performing any right or 
obligation which is conferred or imposed by law on the data controller in connection with 
employment 
3. The processing is necessary— 
(a) in order to protect the vital interests of the data subject or another person, in a case 
where— 
(i) consent cannot be given by or on behalf of the data subject, or 
(ii) the data controller cannot reasonably be expected to obtain the consent of the 
data subject, or 
(b) in order to protect the vital interests of another person, in a case where consent by or 
on behalf of the data subject has been unreasonably withheld 
4. The processing— 
(a) is carried out in the course of its legitimate activities by any body or association which— 
(i) is not established or conducted for profit, and 
(ii) exists for political, philosophical, religious or trade-union purposes, 
(b) is carried out with appropriate safeguards for the rights and freedoms of data subjects, 
(c) relates only to individuals who either are members of the body or association or have 
regular contact with it in connection with its purposes, and 
(d) does not involve disclosure of the personal data to a third party without the consent of 
the data subject 
5. The information contained in the personal data has been made public as a result of steps 
deliberately taken by the data subject 
6. The processing— 
(a) is necessary for the purpose of, or in connection with, any legal proceedings (including 
prospective legal proceedings), 
(b) is necessary for the purpose of obtaining legal advice, or 
(c) is otherwise necessary for the purposes of establishing, exercising or defending legal 
rights 
7. (1) The processing is necessary— 
(a) for the administration of justice, 
(aa) for the exercise of any functions of either House of Parliament, 
(b) for the exercise of any functions conferred on any person by or under an enactment, or 
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(c) for the exercise of any functions of the Crown, a Minister of the Crown or a 
government department 
(2)The Secretary of State may by order— 
(a) exclude the application of sub-paragraph (1) in such cases as may be specified, or 
(b) provide that, in such cases as may be specified, the condition in sub-paragraph (1) is not 
to be regarded as satisfied unless such further conditions as may be specified in the order 
are also satisfied 
7A.  (1) The processing— 
(a) is either— 
(i) the disclosure of sensitive personal data by a person as a member of an anti-fraud 
organisation or otherwise in accordance with any arrangements made by such an 
organisation; or 
(ii) any other processing by that person or another person of sensitive personal data 
so disclosed; and 
(b) is necessary for the purposes of preventing fraud or a particular kind of fraud 
(2) In this paragraph “an anti-fraud organisation” means any unincorporated association, body 
corporate or other person which enables or facilitates any sharing of information to prevent fraud 
or a particular kind of fraud or which has any of these functions as its purpose or one of its purposes 
8. (1) The processing is necessary for medical purposes and is undertaken by— 
(a) a health professional, or 
(b) a person who in the circumstances owes a duty of confidentiality which is equivalent to 
that which would arise if that person were a health professional 
(2) In this paragraph “medical purposes” includes the purposes of preventative medicine, medical 
diagnosis, medical research, the provision of care and treatment and the management of 
healthcare services 
9. (1) The processing— 
(a) is of sensitive personal data consisting of information as to racial or ethnic origin, 
(b) is necessary for the purpose of identifying or keeping under review the existence or 
absence of equality of opportunity or treatment between persons of different racial or 
ethnic origins, with a view to enabling such equality to be promoted or maintained, and 
(c) is carried out with appropriate safeguards for the rights and freedoms of data subjects 
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(2) The Secretary of State may by order specify circumstances in which processing falling within 
sub-paragraph (1)(a) and (b) is, or is not, to be taken for the purposes of sub-paragraph (1)(c) to 
be carried out with appropriate safeguards for the rights and freedoms of data subjects 
10. The personal data are processed in circumstances specified in an order made by the Secretary 
of State for the purposes of this paragraph 
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Appendix E: Multivariable Models Odds Ratios of 
persistance 
       
 

      
 

      
 

      
 





Appendix G: All-Cause Mortality: 5-year follow-up 
including a ‘drug-count’ variable 
1.1.1 Primary  
Table G1: Mortality 5-
years after classed as 
persistent or not with 
TAM (T0) in the primary 
group, across four CVD 
drug-classes. Including 
drug-count.  
  
1.1.2 Treatment 
Table G2: 
Mortality 5-years 
after classed as 
persistent or not 
with TAM (T0) in 
the treatment 
group, across four 
CVD drug-classes. 
Including drug 
count. 
1.1.3 Secondary 
Table G3: 
Mortality 5-years 
after classed as 
persistent or not 
with TAM (T0) in 
the secondary 
group, across four 
CVD drug-classes. 
Including drug 
count. 
1.1.4 Secondary-treatment 
 Table G4: Mortality 
5-years after 
classed as 
persistent or not 
with TAM (T0) in the 
secondary-
treatment group, 
across four CVD 
drug-classes. 
Including drug-
count.  
